PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086; subfamily A and B; Ec o l i ])
B1971057Final Protocol Amendment 2, 09 July 2019
PFIZER CONFIDENTIAL
Page 1A PHASE 3, RANDOMIZED, ACTIVE-CONTROLLED, OBSERVER-BLINDED 
STUDY TO ASSESS THE IMMUNOGENICITY, SAFETY, AND TOLERABILITY 
OF BIVALENT rLP2086 WHEN ADMINISTERED AS A 2-DOSE REGIMEN AND A 
FIRST-IN-HUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY, SAFETY,
AND TOLERABILITY OF A BIVALENT rLP2086–CONTAINING PENTAVALENT 
VACCINE (MenABCWY) IN HEALTHY SUBJECTS ≥≥10 TO <26 YEARS OF AGE
Investigational Product Number: PF-05212366
Investigational Product Name: Neisseria meningitidis Serogroup B Bivalent 
Recombinant Lipoprotein 2086 Vaccine(Bivalent rLP2086)
United States (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:2016-004421-17
Protocol Number: B1971057
Phase: 3
This document and accompanying materials contain confidential information belonging to Pfizer.  Except as 
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this information in 
confidence and not copy or disclose it to others (except where required by applicable law) or use it for unauthorized purposes.  In the event of any actual or suspected breach of this obligation, Pfizer must be promptly notified.
CCI
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 2Document History
Document Version Date Summary of Changes and Rationale
Amendment 2 09July 2019 Added edits included in the administrative letter sdated 
13July 2018, 18 February 2019, and29March 2019 .
Open edenrol lment in Stage 2 to ACWY -experienced 
subjects in addition to ACWY -naïve subjects . This is based 
on the recommendation from the Centers for Disease 
Control and Prevention ( CDC ) Advisory Committee on 
Immunization Practices ( ACIP )to obtain data on the 
persistence of the immune response after 2 doses of 
MenABCWY as well as on the safety and immunogenicity 
of the booster response in individuals who had previously 
received an ACWY -containing vaccine .
Moved the b ooster dose safety endpoints from secondary to 
primary safety endpoints . These changes were made in 
consideration of a potential schedule that would include a 
booster for adolescents Safety of the booster dose w as,
therefore ,reprioritized to a primary safety endpoint.
Moved s ome immunogenicity endpoints (related to 
persistence evaluation) from secondary to exploratory 
endpoints . As booster responses were not previously 
assessed for MenABCWY, certain secondary 
immunogenicity endpoints for persistence and booster 
response were reconsidered and deemed more appropriate as 
exploratory endpoints .
Removed the 1:4 endpoint for ACWY strains for the 
persistence and booster endpoints . As the ACWY assay 
qualification had established that the lower limit of 
quantitation (LLOQ )could not be qualified at the start of the 
study, but subsequently qualified pri or to unblinding with 
the LLOQ ≥1:8 for all 4 serogroups, the 1:4 titer w as 
uninterpretable and therefore removed from analysis.
Added LLOQs for the ACWY strains. This was added 
because the LLOQ was established during assay 
qualification .
Updated the gradi ng for redness and swelling in the mild and 
moderate categories in Table 7 to be consisten twith the 
analyses performed in Stage 1.
Amendment 1 23 August 2017 Addition of edits included in the adm inistrative letter dated 
24February 2017.
Increase in Visit 6 and 7 w indow s to allow additional time 
for unblinding of all subjects prior to Visit 6 completion.
Increase in the volume of the subset blood draw s at Visits 1, 
2,and 4 from 50 to 100 mL to support assay development .  
The volume of blo od draw n will depend on the consent 
obtained.
Addition of a subset of subjects having a 100-mL blood 
draw  at Visit 11 rather than 20 mL.
Correction in Section 3.1 of the 
duration of Stage 1 
participation for subjects in the ACWY- naive strat um.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 3Document Version Date Summary of Changes and Rationale
Clarification of laboratory testing personnel blinding status 
in Section 5.3 .
Clarification added to Sections 9.5.2 and 9.6 as to what the 
primary analysis population is for MnB and M enA/C/W/ Y 
responses.
Addition of an optional blood draw  of 50 mL of whole blood 
at Visit 4 at designated sites. Several changes were made 
throughout this protocol amendment to adjust blood volumes 
collected at Visit 4 and to modify language in order to allow  
whole blood sample testing fo r exploratory purposes. 
Additional exploratory analyses will be performed on study 
samples to augment vaccine assay development.
Original Protocol 16January 2017 N/A
This amendment incorporates all revisions to date, including amendments made at the 
request of country  health authorities and institutional review boards (I RBs)/ethics committees 
(
ECs).  
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 4TABLE OF CONTENTS
LIST OF TABLES .....................................................................................................................9
PROTOCOL  SUMMARY .......................................................................................................10
Objectives and Endpoints ...............................................................................................11
Study  Design ..................................................................................................................15
Investigational Products .................................................................................................17
Statistical Methods .........................................................................................................17
SCHEDUL E OF ACTIVITI ES................................................................................................19
1. INTRODUCTION ...............................................................................................................24
1.1. Mechanism of Acti on/Indication .............................................................................24
1.2. Background and Rationale
......................................................................................24
1.2.1. Background of Disease and Medical Need .................................................24
1.2.2. Prior Clinical Experience ............................................................................26
1.2.2.1. Bivalent rLP2086 (Trumenba) ..................................................26
1.2.2.2. Nimenrix (MenACWY -TT)......................................................27
1.2.3. MenA, MenC, MenW, and MenY Functional Antibody  Assay s as a 
Surrogate of Efficacy .......................................................................................28
1.2.4. Study  Rationale ...........................................................................................29
2. STUDY OBJECTIVES AND ENDPOINTS .......................................................................29
3. STUDY DESIGN .................................................................................................................37
3.1. Approximate Duration of Subject P articipation ......................................................40
3.2. Approximate Duration of Study ..............................................................................40
3.3. Approximate Number of Subjects ................................ ................................ ........... 40
4. SUBJECT ELIGIBILI TY CRI TERIA ................................ ................................ ................. 40
4.1. I nclusion Criteria .....................................................................................................41
4.2. Exclusion Criteria ....................................................................................................41
4.3. Criteria for Temporarily  Delay ing Vaccine Administration ...................................43
4.4. Criteria for Temporarily  Delay ing Blood Collection ..............................................43
4.5. L ifesty le Requirements ...........................................................................................43
4.5.1. Contraception ..............................................................................................43
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 54.6. Sponsor’s Qualified Medical Personnel ..................................................................44
5. INVESTIGAT IONAL P RODUCTS ...................................................................................45
5.1. Allocation to I nvestigational Product ......................................................................45
5.2. Blinding of Site Personnel .......................................................................................46
5.3. B linding of the Sponsor ...........................................................................................46
5.4. Blinding of the Pilot Cohort ....................................................................................46
5.5. Breaking the Blind ..................................................................................................47
5.5.1. Planned Unblinding ....................................................................................47
5.6. Subject Compliance .................................................................................................47
5.7. I nvestiga tional Product Supplies .............................................................................47
5.7.1. Dosage Form(s) and Packaging ..................................................................47
5.7.2. Preparation and Dispensing ........................................................................48
5.8. Administration .........................................................................................................48
5.9. I nvestigation al Product Storage ..............................................................................49
5.10. I nvestigational Product Accountabilit y
.................................................................50
5.10.1. Destruction of Investigational Product Supplies
......................................50
5.11. Concomitant Treatment(s) .....................................................................................51
5.11.1. Prohibited During the Stud y .....................................................................51
5.11.2. Permitted During the Study ......................................................................51
5.11.3. Prior Treatment .........................................................................................52
5.11.4. Prohibited Prior Treatments ......................................................................52
6.
STUDY PROCEDURES .....................................................................................................52
6.1. I nformed Consent Process .......................................................................................52
6.2. Stage 1 .....................................................................................................................53
6.2.1. Visit 1 (Day  1): Vaccination 1 ....................................................................53
6.2.2. Visit 2 (28 to 42 Day s After Visit 1), Post –Vaccination 1 Blood 
Draw ................................ ................................ ................................ ................. 56
6.2.3. Visit 3 (173 to 194 Day s After Visit 1): Vaccination 2 .............................. 57
6.2.4. Visit 4 (28 to 42 Day s After Visit 3), Post –Vaccination 2 Blood 
Draw .................................................................................................................59
6.2.5. Visit 5 (168 to 196 D
ays After Last Vaccination), Telephone Contact ......61
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 66.2.6. Visit 6 (After Study Unblinding and Prior to Transition to Stage 2) 
Telephone Contact ...........................................................................................61
6.3. Stage 2 .....................................................................................................................62
6.3.1. Visit 7 (336 to 694 Day
s After Visit 3), Antibody  Persistence Blood 
Draw 1 ..............................................................................................................62
6.3.2. Visit 8 (700 to 756 Day s After Visit 3), Antibody  Persistence Blood 
Draw 2 ..............................................................................................................63
6.3.3. Visit 9 (1064 to 1120 Day s After Visit 3), Antibody  Persistence 
Blood Draw 3 ...................................................................................................63
6.3.4. Visit 10 (1428 to 1484 Day s After Visit 3): Booster Vaccination .............64
6.3.5. Visit 11 (28 to 42 Day s After Visit 10), Postbooster Blood Draw
.............66
6.3.6. Visit 12 (168 to 196 Day s After Booster Vaccination), Final 
Telephone Contact ...........................................................................................67
6.4. Unscheduled Visits ..................................................................................................68
6.5. Subject Withdrawal .................................................................................................68
7. ASSESSMENTS ..................................................................................................................70
7.1. Pregnancy  Testing ...................................................................................................70
7.2. Biologica l Samples ..................................................................................................70
7.2.1. I mmunogenicit
y..........................................................................................71
7.2.2. Serum Bactericidal Assay s
.........................................................................71
7.2.2.1. MenB Serum Bactericidal Assay s ................................ ............. 72
7.2.2.2. MenA, MenC, MenW, and MenY Serum Bactericidal 
Assay s................................................................................................73
7.2.3. Exploratory  Assays .....................................................................................73
7.3. Safet y
.......................................................................................................................74
7.4. Electronic Diary ......................................................................................................75
7.4.1. L ocal Reactions ................................ ................................ .......................... 76
7.4.1.1. Redness and Swelling ................................................................76
7.4.1.2. Pain ............................................................................................76
7.4.2. Sy stemic Events ..........................................................................................77
7.4.2.1. Tempe rature ..............................................................................77
7.4.2.2. Other Sy stemic Events ..............................................................77
7.4.3. Use of Antip yretic Medication ...................................................................78
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 77.5. Pilot Cohort Safety  Assessments .............................................................................78
8. ADVERSE EVENT REP ORTI NG......................................................................................78
8.1. Requirements ...........................................................................................................78
8.1.1. Additional Details on Recording Adverse Events on the CRF ...................79
8.1.2. Eliciting Adverse Event Information ..........................................................80
8.1.3. Withdrawal From the Study  Due to Adverse Events (See A lso the 
Subject Withdrawal Section)
...........................................................................80
8.1.4. Time Period for Collecting AE/SAE Information
......................................80
8.1.4.1. Reporting SAEs to Pfizer Safety ...............................................81
8.1.4.2. Recording Nonserious AEs and SAEs on the CRF
...................81
8.1.5. Causality  Assessment .................................................................................82
8.1.6. Sponsor’s Reporting Requirements to Regulatory  Authorities ..................82
8.2. Definitions
...............................................................................................................82
8.2.1. Adverse Events ...........................................................................................82
8.2.2. Abnormal Test Findings .............................................................................83
8.2.3. Serious Adverse Events ..............................................................................83
8.2.4. Research -Related Injury .............................................................................84
8.2.5. Hospitalization ............................................................................................85
8.3. Severity  Assessment ................................................................................................86
8.4. Special Situations ....................................................................................................87
8.4.1. Protocol
-Specified Serious Adverse Events ...............................................87
8.4.2. Potential Cases of Drug -
Induced Liver Injury............................................87
8.4.3. Exposure to the I nvestigational Product During Pregnancy  or 
Breastfeeding, and Occupational Exposure ................................ ..................... 89
8.4.3.1. Exposure During Pregnancy ......................................................89
8.4.3.2. Exposure During Breastfeeding ................................................90
8.4.3.3. Occupational Exposure .............................................................90
8.4.4. Medication Errors and Lack of Efficacy ................................ .................... 91
8.4.4.1. Medication Errors ......................................................................91
8.4.4.2. Lack of Efficacy ........................................................................92
8.5. Medical Device Complaint Reporting Requirements ................................ ............. 92
9. DATA ANALYSI S/STA TISTICAL  METHODS ................................ ............................... 92
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 89.1. Sample Size Determination .....................................................................................92
9.2. I mmunogenicit y Analyses .......................................................................................94
9.2.1. A nalysis of the Primary  Immunogenicit y Objective ..................................94
9.2.2. Analy ses of the Secondary  Objectives .......................................................95
9.2.3. Analy ses of Exploratory  Objectives ...........................................................99
9.3. Demographic and Baseline Characteristics ................................ ........................... 101
9.4. Safet y Anal yses.....................................................................................................101
9.4.1. Analy sis for Safet y and Reactogenicity ....................................................101
9.5. Analy
sis Populations .............................................................................................101
9.5.1. Full Anal ysis Set .......................................................................................101
9.5.2. Per
-Protocol Analy sis Set .........................................................................101
9.6.Modified Intent -to-Treat (mITT) Population ........................................................102
9.7. Safet y Anal ysis Set ................................................................................................103
9.8. Analy sis Timing ....................................................................................................104
9.9. Data Monitoring Committee .................................................................................104
10. QU ALITY CONTROL  AND QU ALITY ASSURANCE ...............................................104
11. DATA HANDLING AN
D RECORD KEEPING ...........................................................105
11.1. Case Report Forms/Electronic Data Record .......................................................105
11.2. Record Retention .................................................................................................105
12. ETHI CS............................................................................................................................106
12.1. I nstitutional Review Board/Ethics Committee ....................................................106
12.2. Ethical Conduct of the Study ..............................................................................106
12.3. Subject I nformation and Consent ................................ ................................ ........ 106
12.4. Reporting of Safet y Issues and Serious Breaches of the Protocol or ICH 
GCP .........................................................................................................................108
13. DEFINITION OF EN D OF TRIAL ................................ ................................ ................. 108
13.1. End of Trial in a Member State...........................................................................108
13.2. End of Trial in All Other Participating Countries ...............................................108
14. SPONSOR DI SCONTI NUATION CRITERIA ..............................................................108
15. PUBLICATION OF S TUDY RESUL TS........................................................................108
15.1. Communication of Results by  Pfizer ..................................................................108
15.2. Publications by  Investigators ..............................................................................109
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 916. REFERENCES ................................................................................................................111
LIST OF TABLES
Table 1. Stage 1 Stud y Design ................................................................................38
Table 2. Stage 2 Stud y Design ................................................................................39
Table 3.
Investigational Product Administration Schedule ....................................49
Table 4. Validated hSBA LODs and LLOQs for the 4 Primary  MenB Strains ......72
Table 5. Qualified hSBA LODs and LLOQs for the 10 Secondary  MenB 
Strains .......................................................................................................73
Table 6.
Qualified hSBA LODs and LLOQs for the ACWY Strains.....................73
Table 7. Grading of Redness and Swelling .............................................................76
Table 8. Grading of Pain .........................................................................................77
Table 9. Severity  Scale for Fever ............................................................................77
Table
10. Grading of Other Sy stemic Events ...........................................................77
Table 11. Summary  of Adverse Event Collection ....................................................81
Table 12. Overall Power to Meet the Primary  Objectives ........................................93
Table 13.
Probabilities of Detecting AEs at Specified Incidences ...........................94
Table 14. Highlights of the Anal yses for the Sec ondary  Immunogenicit y 
Objectives –Stage 1 .................................................................................96
Table 15. Highlights of the Anal yses for the Secondary  Immunogenicit y 
Objectives –Persistence ................................ ................................ ............ 98
Table 16. Highlights of the Anal yses for the Secondary  Immunogenicit y 
Objectives –Booster .................................................................................98
Table 17. Analy ses for the Exploratory  Immunogenicity  Objectives 
–Stages 
1 and 2 .......................................................................................................99
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 10PROTOCOL SUMMARY
Background and Rationale
Neisseria meningitidis is an obligate human pathogen that colonizes the upper respiratory  
tract and in some individuals can cause se rious, life -threatening disease .  Under certain 
instances that are not well understood, N meningitidis is capable of invading the human host, 
leading to bacteremia ,which then manifests as life -threaten ing invasive meningococcal 
disease (IMD).  Five (5) N meningitidis serogroups (groups A, B, C, W, and Y) currently  
cause virtuall y all IMD globally.  In the United States, meningococcal disease is primaril y 
caused b y groups B, C,and Y, which are responsible for approximately  64% of disease 
across all ages.
Temporal variations in IMD incidence occur naturally .  In industrialized countries, disease 
rates range from 0.1 cases per 100,000 individuals during endemic periods to 5 to 15 or more 
cases per 100,000 individuals during prolonged epidemics.  In the U nited States, prevention 
of meningococcal disease through vaccination has been focused on routine immunization of 
adolescents and also individuals identified at increased risk of disease due to either 
medical 
or situational factors. 
Results from Phase 2 S tudy B1971012, a randomized, single -blind, multicenter trial 
conducted in Europe comparing the safet y and immunogenicit y of bivalent recombinant 
lipoprotein 2086 vaccine ( bivalent rL P2086 )administered using various 2 -and 3 -dose 
schedules ,demonstrated the sa fety and immunogenicity  of bivalent rL P2086 administered on 
a 2-dose 0 -and 6 -month schedule ; these results supported the licensure of b ivalent rL P2086
(Trumenba)in the United States under Accelerated Approval (AA) regulations.   As part of 
the AA approva l
, a Phase 3 postmarketing commitment is required to confirm the data 
observed in Phase 2.  T his study  will fulfill the Food and Drug Administration ( FDA )
postapproval requirement (PAR) to verify  and describe the clinical benefit of a 2-dose 
schedule for the use of bivalent rL P2086 administered at Months 
0 and 6 in healthy  subjects 
10years to < 26 years of age.
In the United States , it is recommended to routinely  immunize 11 -to 12 -year-olds with a 
meningococcal group A, C, W, and Y con jugate vaccine (MenACWY )(as a single dose), 
followed by the addition of a booster vaccination at 16 years of age. The recommendation 
and use of meningococcal vaccines differ in other regions. Monovalent meningococcal 
group C vaccines have been used in a number of ex -US countries and continue to be 
administered in response to increases in disease (eg, Italy).In the United Kingdom ,there has 
been an increase in group W disease , and a campaign has started to vaccinate adolescents 
with quadrivalent meningoc occal conjugate vaccines ( ie, MenACWY ). France has also seen 
recent group B outbreaks and has responded with local (as opposed to national) vaccination 
campaigns to manage the outbreaks.
Recommendations remain complicated for preventive immunization again st IMD due to the 
different age groups targeted for MenACWY and N meningitidis group B ( MnB ) vaccination, 
the dosing regimens for the different vaccines , and regional differences. Currentl y, no 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 11combination pentavalent ( containing groups A, B, C, W , and Y)meni ngococcal vaccine is 
available.
Development and licensure of a pentavalent vaccine for the prevention of IMD due to groups
A, B, C, W, andY would allow for optimization of the current schedules , offer the possibility  
of using a single vaccine to meet the current recommendations , and offer acomprehensive
approach toprevent meningococcal disease against all5 disease -causing N meningitid is 
groups (A, B, C, W
,and Y).
Pfizer intends to develop a pentavalent meningococcal vaccine (N meningitidis group A, B, 
C, W, and Y vaccine [ MenABCWY ]) by combining bivalent rL P2086 and Nimenrix®
(meningococcal polysaccharide group sA, C, W -135, and Y tetanus toxoid conjugate vaccine 
[MenACWY -TT]).  This study  is primaril y designed to fulfill the FDA PA Rto ver ify the 
clinical benefit of a 2-dose schedule for the use of bivalent rL P2086 administered at 
Months 0 and 6 in healthy subjects 10 years to 
<26 years of age.  This study  will also 
describe the safet y, tolerability , and immunogenicity  of MenABCWY, and describe the 
immune response to groups A, C, W , and Y following administration of MenABCWY, or 
bivalent rL P2086 and a meningococcal group A, C, W -135, and Y conjugate vaccine
(MenACWY -CRM )
.
Objectives and E ndpoints
Prim ary Immunogenicity Objective: Prim aryImmunogenicity Endpoints:
Toassess the immune response induced by 
bivalent rLP2086 as measured by serum 
bactericid al assay using human complement 
(hSBA )performed w ith 4 primary MnB test 
strains, 2 expressing a lipoprotein 2086 ( LP2086 )
subfamily A protein and 2 expressing an LP2086 
subfamily B protein, measured 1 month after the 
second vaccination, in the bivalent rLP2086 arms 
(Group 2 and 4 subjects) combined. Five (5) coprimary endpoints are defined for the 
primary objective; they ar e defined for hSBA 
performed with each of the 4 primary test strains: 
PMB80 (A22), PMB2001 (A56), PMB2948 (B24), 
and PMB2707 (B44).
One (1)of the 5 coprimary endpoints is the 
composite endpoint defined as the proportion of 
subjects achieving an hSBA titer lower limit of 
quantitation (LLOQ; 1:16 for A22 and 1:8 for 
A56, B24 ,and B44 ) for all 4 primary test strains 
combined, 1 month after the second vaccination 
in the bivalent rLP2086 arms (Group 2 and 4 
subjects) combined. 
Four (4)of the coprimary endpo ints are defined 
as the proportion of subjects achieving at least a 
4-fold increase in hSBA titer from baseline to 
1month after the second vaccination in the 
bivalent rLP2086 arms (Group 2 and 4 subjects) 
combined for each of the 4 primary test strains.
 For subjects w ith a baseline hSBA titer below 
the limit of detection (LOD ,or an hSBA titer of 
<1:4), a 4 -fold response is defined as an hSBA 
titer of 1:16 or the LLOQ (whichever titer is 
higher).
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 12 For subjects w ith a baseline hSBA titer of 
LOD (ie, hS BA titer of 1:4) and < LLOQ, a 
4-fold response is defined as an hSBA titer of 
4 times the LLOQ.
 For subjects w ith a baseline hSBA titer of 
LLOQ, a 4 -fold response is defined as an 
hSBA titer of 4 times the baseline titer.
Prim ary Safety Objective s: Prim ary Safety Endpoints :
To describe the safety profile of bivalent rLP2086, 
as measured by local reactions, systemic events, 
adverse events ( AEs) , serious adverse events 
(SAEs ), newly diagnosed chronic medical 
conditions, medically attended AEs, and 
immediate AEs, following Vaccinations 1 and 2 in 
the bivalent rLP2086 arms (Group 2 and 4 
subjects) combined.The follow ing endpoints will be described after 
Vaccinations 1 and 2 in
the bivalent rLP2086 arms 
(Group 2 and 4 subjects) combined.
Percentage of subjects reporting local reactions 
(pain, redness ,and swelling) and by severity 
within 7 days after each vaccination visit.
Percentage of subjects reporting systemic events 
(fever , vomiting, diarrhea, headache, fatigue, 
chills, muscle pain other than muscle pain at any 
injection site, and joint pain) and by severity 
within 7 days after each vaccination visit. 
Percentage of subjects reporting the use of 
antipyretic medication withi n 7 days after each 
vaccination visit. 
Percentage of subjects w ith at least 1SAE during 
the following time periods:
30 Days after each vaccination .
30 Days after any vaccination .
During the Stage 1 vaccination phase (from 
the first study vaccination [ Visit 1 ]through 
1month after the second study vaccination 
[Visit 4 ]).
During the Stage 1 follow -up phase (from 
1month after the second study vaccination 
[Visit 4]through 6 months after the second 
study vaccination [Visit 5 ]).
Throughout Stage 1 (from t he first study 
vaccination [Visit 1 ]through 6 months after 
the second study vaccination [Visit 5] ).
Percentage of subjects w ith at least 1medically 
attended AEoccurring during the following time 
periods:
30 Days after each vaccination .
30 Days after any vaccination .
During the Stage 1 vaccination phase (from 
the first study vaccination [ Visit 1 ]through 
1month after the second study vaccination 
[Visit 4] ).
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 13During the Stage 1 follow -up phase (from 
1month after the second study vaccination 
[Visit 4] through 6 months after the second 
study vaccination [Visit 5]).
Throughout Stage 1 (from the first study 
vaccination [Visit 1] through 6 months after 
the second study vaccination [Visit 5]).
Percentage of subjects w ith at least 1 newly 
diagnosed chronic me dical condition occurring 
during the following time periods:
30 Days after each vaccination.
30 Days after any vaccination.
During the Stage 1 vaccination phase (from 
the first study vaccination [Visit 1] through 
1month after the second study vaccination 
[Visit 4]).
During the Stage 1 follow -up phase (from 
1month after the second study vaccination 
[Visit 4] through 6 months after the second 
study vaccination [Visit 5]).
Throughout Stage 1 (from the first study 
vaccination [Visit 1] through 6 months after 
the second study vaccination [Visit 5]).
Percentage of subjects w ith at least 1 AE 
occurring during the following time periods:
30 Days after each vaccination.
30 Days after any vaccination.
During the Stage 1 vaccination phase (from 
the first study vaccin ation [Visit 1] through 
1month after the second study vaccination 
[Visit 4]).
Percentage of subjects reporting at least 1 
immediate AE after each vaccination.
Subject days missing school or w ork because of 
AEs during the Stage 1 vaccination phase (Visit 1
though Visit 4).
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 14To describe the safety profile of MenABCWY, as 
measured by local reactions, systemic events, 
AEs, SAEs, ne wly diagnosed chronic medical 
conditions, medically attended AEs, and 
immediate AEs, after the booster vaccination. 
To describe the safety profile of bivalent rLP2086, 
as measured by local reactions, systemic events, 
AEs, SAEs, ne wly diagnosed chronic medical 
conditions, medically attended AEs, and 
immediate AEs, after the booster vaccination.The follow ing endpoints will be descri bed after the 
booster vaccination in Groups 1 through 4:
Percentage of subjects reporting local reactions 
(pain, redness, and swelling) and by severity 
within 7 days after the booster vaccination.
Percentage of subjects reporting systemic events 
(fever, vo miting, diarrhea, headache, fatigue, 
chills, muscle pain other than muscle pain at any 
injection site, and joint pain) and by severity 
within 7 days after the booster vaccination. 
Percentage of subjects reporting the use of 
antipyretic medication within 7 days after the 
booster vaccination. 
Percentage of subjects w ith at least 1 SAE during 
the following time periods:
During the booster vaccination phase (from 
the booster vaccination [Visit 10] through 
1month after the booster vaccination [Visit 
11]). 
During the booster follow -up phase (from 
1month after the booster vaccination 
[Visit 11] through 6 months after the booster 
vaccination [Visit 12]).
From  the booster vaccination (Visit 10) 
through 6 months after the booster vaccination 
(Visit 12).
Percent age of subjects w ith at least 1 medically 
attended AE occurring during the following time 
periods:
During the booster vaccination phase (from 
the booster vaccination [Visit 10] through 
1month after the booster vaccination [Visit 
11]).
During the booster f ollow -up phase (from 
1month after the booster vaccination [Visit 
11] through 6 months after the booster 
vaccination [Visit 12]).
From  the booster vaccination (Visit 10) 
through 6 months after the booster vaccination 
(Visit 12).
Percentage of subjects w ithat least 1 newly 
diagnosed chronic medical condition occurring 
during the following time periods:
During the booster vaccination phase (from 
the booster vaccination [Visit 10] through 1 
month after the booster vaccination [Visit 11]).
During the booster follow -up phase (from 
1month after the booster vaccination [Visit 
11] through 6 months after the booster 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 15vaccination [Visit 12]).
From  the booster vaccination (Visit 10) 
through 6 months after the booster vaccination 
(Visit 12).
Percent age of subjects w ith at least 1 AE 
occurring during the following time periods:
During the booster vaccination phase (from 
the booster vaccination [Visit 10] through 1 
month after the booster vaccination [Visit 11]).
Percentage of subjects reporting at least 1 
immediate AE after the booster vaccination.
Subject days missing school or w ork because of 
AEs.
Study Design
This is a P hase 3, randomized, active -controlled, observer -blinded multicenter trial in which 
approximately  1590 subjects will be randoml y assigned to receive either MenABCWY and 
placebo ( saline )
,or bivalent rL P2086 andMenACWY -CRM .  All subjects will be na ive to 
any meningococcal group B vaccine prior to enrollment. Randomization will be stratified by  
prior vaccination history ; approximate ly 795 ACWY - nai ve subjects and 795 
ACWY -experienced (having received 1 prior dose of a vaccine containing 1or more ACWY 
groups 4 years prior to the date of randomization) subjects will be enrolled.
Randomization will also be stratified b y geographic regi on.  Approximately  1320 subjects 
from US investigative sites and 270 subjects from ex
-US countries will be randomized.  
Regional stratification will ensure sufficient population representation. 
The study  will be conducted in 2stages as shown below.  In order to support assay  
development, a subset of upto approximately  600 subjects 18 to 25 years of age will have up 
to 10 0 mL ,rather than 20 mL ,of blood drawn at Visits 1, 2
,and 4.  Additionally , at 
designated sites, an addit ional optional whole blood sample of approximately  50 mL will be 
obtained at Visit 4 from up to approximately  30 subjects 18 to 25 y ears of age.  This sample 
will be used for exploratory purposes .
Subjects from both ACWY -naïve and ACWY -experienced strata will participate in Stage 2
(approximately 132subjects from each of Group s 1and 3and approximately 65subjects
from each of Group s 2and 4).  Stage 1 will be observer -blinded and Stage 2 will be 
open -label.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 16Stage 1 Study Design
Vaccination 1 Post –
Vaccination 
1 Blood 
DrawVaccination 
2Post–
Vaccination 
2 Blood 
DrawSafety 
Telephone 
CallTelephone 
Call
Approximate 
Month0 1 6 7 12
Visit Number 1 2 3 4 5 6
ACWY-
Naive 
SubjectsGroup 1a
(n=265)MenABCWY + 
salineMenABCWY
Group 2 
(n=530)Bivalent rLP2086 + 
MenACWY -CRMBivalent 
rLP2086
Blood Draw
for serum 
collection20 mL
(or up to 100 mL in 
subset)20 mL
(or up to 
100mL in 
subset)20 mL 20 mL
(or up 
to100 mL in 
subset)
ACWY-
Experienced 
SubjectsGroup 3a
(n=265)MenABCWY + 
salineMenABCWY
Group 4 
(n=530)Bivalent rLP2086 + 
MenACWY -CRMBivalent 
rLP2086
Blood Draw
for Ser um
Collection20 mL
(or up to 100 mL in 
subset)20 mL
(or up to 
100mL in 
subset)20 mL 20 mL
(or up to 
100mL in 
subset)
Subjects 18 
to 25 years 
of age (naïve 
or 
experienced)Optional 
Blood Draw 
for Whole 
Blood 
Collection50 mL
a. Pilot cohort subjects will be assigned to either Group 1 or 3, but will receive only MenABCWY at Vaccination 1. Pilot 
cohort subjects will not receive saline at Vaccination 1.
Stage 2 Study Design
Antibody 
PersistenceBooster Vaccination Postbooster Blood 
DrawSafety 
Telephone 
Call
Approximate Month 18-42 54 55 60
Visit Number 7-9 10 11 12
ACWY-
Naive 
SubjectsGroup 1 (n ~132 ) MenABCWY
Group 2 (n~65) Bivalent rLP2086 + 
MenACWY -CRM
ACWY-
Experienced 
SubjectsGroup 3 ( n ~132 ) MenABCWY
Group 4 ( n ~65) Bivalent rLP2086 + 
MenACWY -CRM
Blood Draw for 
SerumCollection20 mL × 3 20 mL 20 mL
(or up to 100 mL in 
subset)
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 17Investigational Products
For this study , the investigational products are bivalent rLP2086 (Trumenba), MenABCWY
(consisting of MenACWY -TT [Nimenrix ]and bivalent rL P2086 [Trumenba ]), 
MenACWY -CRM (Menveo) , and placebo.  An y reference to normal saline or placebo refers 
to a solution containing 0.85% sodium chloride and water for injection. The placebo solution 
is also referred to as “saline” throughout the protocol.
Statistical Method s
Both h ypothesis testing and estimation will be performed.  The h ypothesis -testing component 
will address the need to confirm the immunogenicity  ofbivalent rL P2086 administered at 
Months 
0 and 6 in all subjects 10 through 25 years of age, using pre specified criteria for the 
primary  MnB immunogenicity  endpoints. Safet y of bivalent rL P2086 administered at 
Months 0 and 6 will also be described. Immunogenicity  and safet y information f or the 
MenABCWY arms will be described.
Hypothesis testing will be performed on the 5 coprimary MnB endpoints in all subjects ,
which include sa 4-fold rise from baseline in hSBA titers for each of the 4 primary  strains 
and the composite response (hSBA tite r LLOQ for all 4 primary  strains combined) 1 month 
after the second vaccination.  If the l ower limit of the 2-sided 95% confidence interval 
exceed
seach of the target lower limit of theconfidence interval (LCI) values , the study ’s
primary  objective willbemet.
The study sample size is mainly  based on h ypothesis -testing criteria to verify  the clinical 
benefit of a 2 -dose schedule for the use of bivalent rL P2086 administered at Months 0 and 6 
in healthy  subjects 10 y ears to <26 y ears of age. With 900 eval uable subjects in Group 2 and 
Group 4, 
the primary  objective s (based on all 5 primary  endpoints) will be met with a power 
of 95.2% as shown in the table below.
Overall Power to Meet the Primary Objectives
Prim ary Endpoint 
Test Strain 
(Variant)LCI Criteria Study B1971012 0 -
and 6 -Month 
Responses With 95% 
Confidence Interval 
(%)aNumber of 
Evaluable 
SubjectsPower
hSBA titer fold rise 4 
from baselinePMB80
(A22)LL of 95%
CI >75%82.3
(76.3, 87.3)900 99.97%
PMB2001 (A56) LL of 95%
CI >8590.1
(85.1, 93.8)900 99.60%
PMB2948 (B24) LL of 95%
CI >5564.5
(57.4, 71.1)900 99.99%
PMB2707 (B44) LL of 95%
CI >6066.0
(58.9, 72.6)900 95.7%
Com posite response
(hSBA titer LLOQ 
for all of 4 primary 
strains combined)LL of 95%
CI >6572.9
(65.9, 79.1)900 99.92%
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 18Overall Power to Meet the Primary Objectives
Prim ary Endpoint 
Test Strain 
(Variant)LCI Criteria Study B1971012 0 -
and 6 -Month 
Responses With 95% 
Confidence Interval 
(%)aNumber of 
Evaluable 
SubjectsPower
Overall pow er 95.2%
Abbreviations: hSBA = serum bactericidal assay using human complement; LCI = low er limit of the confidence 
interval; LL = lower limit; LLOQ = low er limit of quantitation.
a.The pow er calculation was based on Study B1971012 w ith a vaccine schedule of 0and6 month s.
Assuming ~85% evaluable subjects, ~1060 subjects should be enrolled to receive bivalent 
rLP2086 and MenACWY -CRM .
An additional 530 subjects will be enrolled in the MenABCWY- MenABCWY regimen , 
which will allow a probability  of 93.0% to observe at least 1 AE with a true incidence of
0.5%.
A total of 
1590 subjects will therefore be enrolled into this study .  The randomization will be 
performed separatel y for ACWY -
naive and ACWY-experienced subjects.  Equal numbers of 
subjects will be recruited into each stratum.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 19SCHEDULE OF ACTIVITI ES
The Schedule of Activities table provides an overview of the protocol visits and procedures.  Refer to the Study  Procedures and 
Assessments 
sections of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol .
The investigator may  schedule visits (unplanned visits ) inaddition to those listed on the Schedule of Activities table , in order to 
conduct evaluations or assessments required to protect the well -being of the subject.
Stage 1
Visit ID Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Visit Description Vaccination 1 Post–
Vaccination 1 
Blood DrawVaccination 2 Post–
Vaccination 2 
Blood DrawTelephone 
ContactTelephone 
Contact
Approximate Month 0 1 6 7 6 Months After 
Last Study 
Vaccination
Visit Window Day 1 28 to 42 Days 
After Visit 1173 to 194 
Days After 
Visit 128 to 42 Days 
After Visit 3168 to 196 Days 
After Visit 3After Study 
Unblinding 
and Before 
Transition to 
Stage 2a
Informed consent X
Informed consent for optional blood draw for whole blood collectionbX
Review eligibility criteria X
Demography X
Confirm continued eligibilitycX X X
Medical history and physical examination X
Record previous PRP -OMP vaccinations X
Record any previous meningococcal vaccinations X
Record use of antipyretics and other pain medications received on the 
day prior to vaccinationX X
Urine pregnancy test for female subjects X X
Oral temperature X X
Randomization X
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 20Stage 1
Visit ID Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Visit Description Vaccination 1 Post–
Vaccination 1 
Blood DrawVaccination 2 Post–
Vaccination 2 
Blood DrawTelephone 
ContactTelephone 
Contact
Approximate Month 0 1 6 7 6 Months After 
Last Study 
Vaccination
Visit Window Day 1 28 to 42 Days 
After Visit 1173 to 194 
Days After 
Visit 128 to 42 Days 
After Visit 3168 to 196 Days 
After Visit 3After Study 
Unblinding 
and Before 
Transition to 
Stage 2a
Obtain blood sample (s)for serum collectiond20 mL
(up to 100mL 
in subset)20 mL
(up to 100mL 
in subset)20 mL
(20mL in 
subset)20 mL
(up to 100mL 
in subset)
Addit ional o ptional blood draw for whole blood collectione50 mL
Investigational product administration and observationfX X
Record nonstudy vaccinations X X X X
Provide subject with an e -diary, caliper, measuring tape/ruler, and 
thermometer, if necessaryX X
Review and collect e -diary X X
Assess reactogenicity and record use of antipyretic medicationgDays 1 to 7 Days 1 to 7
Provide the subject with a contact card X
Provide the subject with a memory aid X
Complete Study Visit/Telephone Contact AE ChecklisthX X X X
Record concomitant medications used to treat AEs X X X X X
(S)AE collection appropriate for the visitiX X X X X
Notification of Stage 2 participation X
Abbreviations: e -diary = electronic diary; PRP -OMP = polyribosylribitol phosphate oligosaccharide of Haemophilus influenzae type b conjugated to outer 
membrane protein.
a.Visit 6 must be conducted prior to Visit 7.
b.Applicable only at designated sites. This consent relating to the whole blood sample may be obtained at prior visits if appropriate.   
c.Ensure that the subject continues to be eligible for the study, and continues to comply with contraception requirements, as appropriate.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 21Stage 1
Visit ID Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
Visit Description Vaccination 1 Post–
Vaccination 1 
Blood DrawVaccination 2 Post–
Vaccination 2 
Blood DrawTelephone 
ContactTelephone 
Contact
Approximate Month 0 1 6 7 6 Months After 
Last Study 
Vaccination
Visit Window Day 1 28 to 42 Days 
After Visit 1173 to 194 
Days After 
Visit 128 to 42 Days 
After Visit 3168 to 196 Days 
After Visit 3After Study 
Unblinding 
and Before 
Transition to 
Stage 2a
d.Subject participation in the subset w ill be voluntary for subjects 18 to 25 years of age, and the volume of blood d rawn(either 50 or 100 mL) will depend on 
the consent obtained.
e.Applicable only for subjects at designated sites who have given consent for this additional blood draw .
f.Observe the subject for at least 30 minutes (or longer as per local practice) after the investigational product administratio n for any acute reactions.
g.Betw een visits, review the e -diary  data online at frequent intervals.  Contact the subject in order to obtain stop dates for any local reactions, systemic events, 
or use of antipyretic medication that were ongoing on the last day t hat the e -diary was completed.
h.Checklist includes questions regarding newly diagnosed chronic medical conditions, medically attended adverse events, and mis sed days of school or work, 
as well as about neuroinflammatory and autoimmune conditions, such as transverse myelitis, uveitis, optic neuritis, and multi ple sclerosis .
i.Please refer to protocol Section 8.1.4 .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 22Stage 2
Visit ID Visit 7 Visit 8 Visit 9 Visit 10 Visit 1 1 Visit 1 2
Visit Description Antibody 
Persistence 
Blood Draw 1Antibody 
Persistence 
Blood Draw 2Antibody 
Persistence 
Blood Draw 3Booster 
VaccinationPostbooster 
Blood DrawTelephone Contact
Approxim ate Month 18 30 42 54 55 6 Months After 
Booster Vaccination
Visit Window 336 to 694
Days After 
Visit 3700 to 756 
Days After 
Visit 3a1064 to 1120
Days After 
Visit 31428 to 1484
Days After 
Visit 328 to 42 Days 
After Visit 10168 to 196 Days 
After Visit 10
Informed c onsent X
Confirm continued eligibilitybX X X X X
New m edical history and physical examination X
Urine pregnancy test for female subjects X
Oral temperature X
Obtain blood sample 20 mL 20 mL 20 mL 20 mL 20 mL
(up to 100 mL in 
subset)
Record use of antipyretics and other pain medications 
received on the day prior to vaccinationX
Investigational product administration and observationcX
Record nonstudy vaccinations X X X X X
Provide subject with an e -diary, caliper, measuring 
tape/ruler ,and thermometer, if necessaryX
Review and collect e -diary X
Assess reactogenicity and record use of antipyretic 
medicationdDay 1 to 7
Provide the subject with a memory aid X
Complete Study Visit /Telephone Contact AE ChecklisteX X
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2 , 09 July 2019
PFIZER CONFIDENTIAL
Page 23Stage 2
Visit ID Visit 7 Visit 8 Visit 9 Visit 10 Visit 1 1 Visit 1 2
Visit Description Antibody 
Persistence 
Blood Draw 1Antibody 
Persistence 
Blood Draw 2Antibody 
Persistence 
Blood Draw 3Booster 
VaccinationPostbooster 
Blood DrawTelephone Contact
Approxim ate Month 18 30 42 54 55 6 Months After 
Booster Vaccination
Visit Window 336 to 694
Days After 
Visit 3700 to 756 
Days After 
Visit 3a1064 to 1120
Days After 
Visit 31428 to 1484
Days After 
Visit 328 to 42 Days 
After Visit 10168 to 196 Days 
After Visit 10
Record concomitant medications used to treat AEs X X X X X X
(S)AE collection appropriate for the visitfX X X X X X
Abbreviation: e -diary = electronic diary.
a.Visit 7 and Visit 8 should be conducted within no less than 30 days of each other. If Visit 7 cannot be conducted within the protocol -defined visit window , 
Visit 7 can be omitted and Visit 8 performed directly.
b.Ensure that the subject continue s to be eligible for the study, and continues to comply with contraception requirements, as appropriate.
c.Observe the subject for at least 30 minutes (or longer as per local practice) after the investigational product administration for any acute reactions.
d.Betw een visits, review the e -diary  data online at frequent intervals.  Contact the subject in order to obtain stop date s for any local reactions, systemic events, 
or use of antipyretic medication that were ongoing on the last day that the e -diary was completed.
e.Checklist includes questions regarding newly diagnosed chronic medical conditions, medically attended adverse events, and missed days of school or work, 
as well as about neuroinflammatory and autoimmune conditions, such as transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
f.Please refer to protocol Section 8.1.4 .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 241.INTRODUCTION
1.1. Mechanism of Action/ Indication
Bivalent recombinant lipoprotein 2086 vaccine (bivalent rLP2086 ;Trumenba®)is indicated 
for active immunization to prevent invasive disease caused b y Neisseria meningitidis 
group B.  Bivalent rLP2086 is approved for use in individuals 10 through 25 y ears of age.
Pfizer intends to develop a pentavalent meningococcal vaccine (Nmeningitidis group A, B, 
C, W, and Y vaccine [ MenABCWY ]) by combining bivalent rL P2086 and Nimenrix®
(meningococcal polysaccharide group sA, C, W -135, and Y tetanus toxoid conjugate vaccine 
[MenACWY -TT]). The target indication for the candidate pentavalent vaccine is active 
immunization to prevent invasive disease caused by Nmeningitidis groups A, B, C, W ,and 
Y in individuals 10 through 25 years of age.
1.2.Background and Rationale
1.2.1. Background of Disease and Medical Need
N meningitidis is an obligate human pathogen that colonizes the upper respiratory  tract and in 
some individuals can cause serious, life -threatening disease.  Transmission with
Nmeningitidis is via contact with droplets from the upper respiratory tract, ty picall y resulting 
in colonization and asy mptomatic carriage in otherwise healthy  individuals.  Under certain 
instances that are not well understood, N meningitidis is capable of invading the human host, 
leading to bacteremia ,which then manifests as life -threatening invasive meningococcal 
disease (IMD).1  Twel ve (12) sero groups of N meningitidis have been identified based on 
structural differences in their poly saccharide capsule.  Five (5) of these groups (A, B, C, W, 
and Y) currentl y cause virtually  all IMD globally .2,3
Temporal variations in IMD incidence occur naturally .  In industrialized countr ies, disease 
rates range from 0.1 cases per 100,000 individuals during endemic periods to 5 to 15 or more 
cases per 100,000 individuals during prolonged epidemics
.3,4,5,6In Europe, meningococcal 
disease has been declining in general over the past decade.  This decline can be attributed, in 
part,to the introduction of meningococcal group C conjugate vaccine programs; however ,
IMD caused b yN meningitidis group B ( MnB )has also declined. In 2007, overall 
meningococcal rates were 3.76 per 100,000 in Ireland and 2.50 per 100,000 in the United 
Kingdo m but had decreased to 1.99 in Ireland and 1. 66in the United Kingdom by  2011.5,6
While I MD is at a historic low in the U nited States,7the Centers for Disease Control and 
Prevention (CDC) estimates that in 2014 approximately  450 cases of meningococcal disease 
occurred, resulting in a disease incidence nationally  of 0.14 per 100,000 individuals.8  In the 
United States, meningococcal disease is primaril y caused b y groups B, C,
and Y, which are 
responsible for approximate ly 64% of disease across all ages.8  Higher rates of 
meningococcal disease due to groups B and C are seen in younger individuals , whereas 
disease d
ue to group Y tends to occur in older individuals.8
Results from Phase 2 S tudy B1971012, a randomized, single -blind, multicenter trial 
conducted in Europe compar ingthe safet y and immunogenicit y of bivalent rL P2086 
administered using various 2 -and 3 -dose schedules ,demonstrated the safety  and 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 25immunogenicit y of bivalent rL P2086 administered on a 2- dose 0- and 6 -month schedule ; 
these results supported the licensure of b ivalent rLP2086 in the U nited States under 
Accelerated Approval (AA) r egulati ons.  As part of the AA approval , a Phase 3 
postmarketing commitment is required to confirm the data observed in Phase 2.  This study  
will fulfill the Food and Drug Administration ( FDA )postapproval requirement (PAR) to 
verify  and describe the clinical benefit of a 2-dose schedule for the use of bivalent rL P2086 
administered at Months 
0 and 6 in health y subjects 10 years to < 26 years of age.
In the U nited States, prevention of meningococcal disease through vaccinati on has been 
focused on routine immunization of adolescents and also individuals identified at increased 
risk of disease due to either medical or situational factors. In the U nited States it is 
recommended to routinely immunize 11- to 12 -year-olds with a meningococcal group A, C, 
W, and Y conjugate vaccine (MenACWY )(as a single dose), followed b y the addition of a 
booster vaccination at 16 y ears of age .9,10,11In addition to these age -based recommendations
for meningococcal vaccines, the re are recommendations in place to vaccinate at -risk 
individuals aged  2 months to 55 y ears for meningococcal groups A, C, W, and Y and 
10years for meningococcal group B ( MenB ).10,12
The recommendation and use of meningococcal vaccines differ in other regions. Monovalent 
meningococcal group C vaccines have been used in a number of ex -US countries and 
continue to be admin istered in response to increases in disease (eg ,Italy).13In the United 
Kingdom ,there has been an increase in group W disease , and a campaign has started to 
vaccinate adolescents with quadrivalent meningococcal vaccines.14,15The U nited Kingdom
is one of only  a limited number of countries to recommend Bexsero in the infant 
population.16Over the past 10 y ears there have been outbreaks of meningococcal diseases 
recorded in Europe in varied settings ,including kindergarten classes, nursery  schools, and a 
family  cluster.17,18,19,20France has also seen recent groupB outbreaks and has responded 
with local (as opposed to national) vaccination campaigns to manage the outbreaks.21
Recommendations remain complica ted for preventive immunization against IMD due to the 
different age groups targeted for MenACWY and MnB vaccination, the dosing regimens for 
the different vaccines , and regional differences. Currentl y, no combination pentavalent 
(containing groups A, B, C, W , and Y) meningococcal vaccine is available. Development 
and licensure of a pentavalent vaccine for the prevention of IMD due to groups A, B, C, W, 
and Y would allow for optimization of the current schedules in terms of convenience to 
patient and heal thcare providers to prevent meningococcal disease in those considered at 
increased risk. A pentavalent vaccine would also offer the possibility  of using a single 
vaccine to meet the current recommendations and the ability  to simplify  the interpretation of
the schedule for vaccine providers. For example, in countries where MenACWY is 
recommended at 11 years of age, followed b y a MenACWY booster approximately  5 years 
later, use of a pentavalent vaccine could address the recommendation for quadrivalent 
vacci nation while also confer protection against MenB disease.
Meningococcal disease epidemiology isdynamic, andfluctuations intheprevalence of
different groups areobserved. Examples such astheincrease ingroup Wobserved inthe
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 26United Kingdom andSouth America14,22illustrate theneed foracomprehensive approach to
prevent meningococcal disease both interms ofvaccine characteristics andimplementation
ofany recommendations. Development of asafeandimmunogenic pentavalent vaccine
would support these aims.
1.2.2. Prior Clinical Experience
1.2.2.1. Bivalent rLP2086 (Trumenba)
Bivalent rLP2086 is composed of 2 recombinant lipidated factor H binding protein (fHBP) 
variants from MnB, one from fHBP subfamily A and one from subfamil y B (A05 and B01, 
respectivel y).
Bivalent rLP2086 was approved on 29 October 2014, under 21 Code of Federal Regulations 
(CFR) 601 Subpart E 
-Accelerated Approval of Biological Products for Serious or 
Life-Threatening Illnesses, for active immunization of individuals aged 10 through 25 y ears 
to prevent inva sive disease caused b y meningococcal group B.
Approval of bivalent rL P2086 was based on demonstration of safet y and a serological 
correlate that showed in Phase 2 studies the induction of serum bactericidal activity  against 
4group B strains that are representative of the prevalent US strains. These were measured 
using serum bactericidal assay s using human complement (hSBAs). As a requirement of 
licensure, Phase 3 studies were conducted to confirm the safet y and immune responses 
associated with the 3- dose schedule. As of 21 January  2016, it is estimat ed that 21,607 
subjects have participated in the bivalent rL P2086 clinical development program: 11,436 
subjects were exposed to bivalent rLP2086.  A total of 4145 subjects received bivalent 
rLP2086 in combination with the following : diphtheria, t etanus, and acellular pertussis,
Haemophilus influenzae type b, and hepatitis B virus vaccine combined with inactivated 
poliomy elitis virus vaccine (DTaP -Hib- HBV+IPV )/Prevnar(32); dTaP -IPV (372); 
quadrivalent hu man papillomavirus vaccine ( HPV4 )(992); 
quadrivalent meningococcal 
polysaccharide conjugate (MCV4)/ tetanus, diphtheria, and acellular pertussis ( Tdap )vaccine
(884); or saline (1865). In addition, 417 subjects are currentl y receiving blinded therap y, and 
5609 subjects have received control. The total unit distribution in the U nited States from 
launch through 21 January  2016 is approximately  210,380 doses.
Results from 11 Phase 1, 2
,and 3 completed clinical trials concluded that robust functi onal 
and broadl y protective immune responses were observed in individuals receiving bivalent 
rLP2086 on the 2 -dose 0- and 6 -month schedule in Phase 2 Study  B1971012, and on a 3 -dose 
schedule in the Phase 3 program (0 -, 2-, and 6-month schedule ), as measure d in hSBAs that 
used MnB strains (4 primary  or 10 additional ) that were prospectivel y selected to represent 
the diversity  of the target antigen fHBP.  Each primary  and each additional strain expressed 
fHBPs that were heterologous (to vaccine) fHBP variants .
Preliminary  results ofa persistence -of-immunity  and booster study , B1971033, show that 
persistence of immunity  following any of the 2- and 3 -dose primary  bivalent rLP2086 series 
schedules utilized in 
Study  B1971012 follows similar patterns over 4 years.  Of note, 4 -year 
persistence immunity  data w erecomparable following a 2 -dose 0 -and 6-month or 3 -dose 0-,
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 272-,and 6-month primary  bivalent rLP2086 series.   Similarly , the immune response following 
a booster dose with 
bivalent rLP2086 4 y ears after the primary  bivalent rLP2086 series 
resulted in high hSBA titers
,irrespective of whether subjects received a 2-dose or 3- dose 
primary  bivalent rLP2086 series.  hSBA titers observed following the b ooster vaccination are 
higher than th ose seen 1 month following a 2- or 3-dose primary  bivalent rLP2086 series.
Clinical studies also demonstrated that bivalent rLP2086 may  be coadministered with MCV4, 
Tdap, HPV4, and dTap -IPV vaccines, which may
 facilitate introduction of bivalent rL P2086 
into national immunization programs. In addition, a consistent favorable safet y and 
reactogenicity  profile supports the use of bivalent rLP2086 to prevent invasive MnB disease 
in individuals 10 y ears of age and older in the European Union ( EU) .
1.2.2.2. Nimenrix ( MenACWY -TT)
Nimenrix is composed of capsular pol ysaccharides from each of the A, C, W ,and Y groups
of N meningitidis conjugated to tetanus toxoid.
Nimenrix was first approved in the EU on 20 April 2012 via the centralized procedure and is 
currentl y marketed in 67 countries. Nimenrix is not presently  licensed in the U nited States, 
though there is an open investigational new drug application ( IND)
(BB- IND 13278). 
Licensure outside of the Unite d States was based on safet y and demonstration of 
immunologic noninferiority  (based mainly  on comparing proportions of subjects with serum 
bactericidal assay  using rabbit complement [rSBA] titers of at least 1:8) to licensed 
meningococcal vaccines. I mmunog enicit y was measured using rSBA or hSBAs.
In the EU, Nimenrix is indicated for active immunization of individuals from the age of 
12 months and above against IMDcaused b y N meningitidis groups A, C, W -135, and Y.
The cumulative number of subjects who have received Nimenrix within GlaxoSmithKline 
(GSK )
-sponsored interventional studies is estimated to be 13,533 subjects in primary  study  
groups and 992 in booster study  groups (note that some subjects from booster study  groups 
also participated in primary  stud y groups). Additionally , 1991 subjects in primary  study  
groups have received treatment that is still blinded to the GSK/Pfizer study team. Finall y, 
1219 subjects enrolled in the clinical development program for Nimenrix were vaccinated 
with a MenACWY -TTformulation other than the one that is currentl y on the market. 
Information on exposure is sourced from the clinical trial database sas of 19 October 2015.
Since launch in the EU to 30 September 2015, it is estimated that 2,953,217 doses of 
Nimenrix have been distributed. As vaccination with Nimenrix consists of 1dose per subject 
in accordance with the local recommendations and assuming compliance with the 
vaccination schedule, the postmarketing exposure to Nimenrix is estimated to be 2,953,217 
individuals.
The immunogenicit y studies conducted in subjects from 12 months of age and above
demonstrate that 1dose of 
MenACWY -TTinduces a response that is similar to or higher 
than the response induced by  licensed meningococcal vaccines used as control, and that the
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 28vaccine is able to induce an immunologic memory against the 4 meningococcal groups in 
individuals vaccinated as toddlers 12 to 14 months of age, historicall y an age group that is 
not responsive to meningococcal poly saccharide vaccines. Follow - upstudies demonstrate 
that persistence of the responses elicited b y the vaccine is similar or higher than persistence 
of those elicited b y the licensed meningococcal poly saccharide vaccines M eningitecand 
Mencevaxwhen assessed using the GSK rSB A. A variation is under review to extend the 
age indication to 6 weeks of age.
1.2.3. MenA, MenC, MenW, and MenY Functional Antibody Assay sas a Surrogate of 
Efficacy
Meningococcal clearance from the bloodstream is primarily  by complement -mediated 
bacteriol ysis, and an effective complement s ystem is critical for resistance against infections 
caused b y N meningitidis. Individuals with complement deficiencies have an inc reased risk 
of developing meningococcal disease.23,24The in vivo complement- mediated bacterioly sis of 
meningococcus is mimicked by  the in vitro serum bactericidal assay  (SBA), a functional 
serological assay  shown to be the surrogate of protection for meningococcal disease.25
For meningococcal group C conjugate vaccines, postlicensure efficacy  estimates in the 
United Kingdom demonstrated that a cutoff of 1:8 in the rSBA wasthe most consi stent with 
observed efficacy  at 4 weeks after vaccination.26  The established correlate of protection for 
the SBA -MenC assay  using human serum as the exogenous complement source is a titer 
1:4.25,27Even though no correlate of protection has been established for meningococcal 
groups A, W ,and Y,28it is common practice to extend the 1:8 cutoff for rSBA using 
meningococcal groups A, W ,and Y (rSBA- MenA, rSBA -MenW ,and rSB A-MenY )and the 
1:4 cut -off for hSBA -MenA, hSBA -MenW ,and hSBA -MenY.25,29
hSBA responses have been used routinel y as surrogates of efficacy  and as the basis for 
licensure of MnB vaccines.30,31Outer membrane vesicle (OMV) vaccines have been 
deploy ed in some countries in response to outbreaks caused by  specific epidemic MnB 
strains ,32and large -scale efficacy  studies with OMV vaccines have been conducted in Cuba, 
Brazil, Chile, Norway ,and New Zealand.33,34,35,36,37,38  In each instance, a relationship 
between responses measured b y hSBA and protection from MnB disease was demonstrated39
with a 1:4 cutoff for hSBA MnB as the correlate of protection.25
,27,40
Use of hSBA in clinical trials of M enABCWY is scientificall y reasonable as a surrogate of 
vacci ne efficacy  and necessary , because a traditional trial with an efficacy  endpoint is not 
feasible because of the low incidence of meningococcal disease, <1/100,000 in the U nited 
States and Europe ,7,40,41meaning that extremely  large numbers of subjects (>100,000) would 
be required to support a statistically  significant assessment.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 291.2.4. Study Rationale
The study  design is described in Section 3. T his is a Phase 3 study  to verify  and describe the 
clinical benefit of a 2-dose schedule for the use of bivalent rL P2086 administered at 
Months 0 and 6 in healthy subjects 10 years to 
<26 years of age.
This study  will also describe the safet y, tolerability, and immunogenicit y of MenABCWY , 
and describe the immune response to groups A, C , W, and Y following administration of 
MenABCWY ,or bivalent rL P2086 and a meningococcal group A, C, W-135, and Y 
conjugate vaccine (MenACWY -CRM )
.
Pfizer considers the available information from prior studies with MenACWY -TT
(PF-06866681) and bivalent rL P2086 ( PF-05212366 )sufficient to support an expectation of 
a favorable benefit -risk profile for this study  using MenABCWY (PF-06886992) .
Additional information for this compound (MenABCWY) may be found in the single 
reference safet y document (SRSD), which for this study is the MenABCWY investigator’s 
brochure (IB).  Additio nal information for bivalent rL P2086 may  be found in the SRSD, 
which for this study  is the IBfor bivalent rL P2086.  TheSRSD for the comparator agent 
MenACWY -CRM is the Menveo US package insert.
Refer to the most recent version of the MenABCWY IB for a summary  of findings from 
nonclinical studies that potentially  have clinical significance and from clinical studies that are 
relevant to this study .  Also refer to the most recent version of the MenABCWY IB for a 
summary  of the known and potential risks and benefits, if any , to human subjects.
Refer to the most recent version of the Menveo US package insert for a summary  of the 
known and potential risks and benefits, if an y, to human subjects.
2.
STUDY OBJECTIVES AND ENDPOINTS
Subjects having received a vaccine containing 1or more ACWY groups prior to enrol lment 
will be randomized in the ACWY -experienced stratum but, for the pu rposes of A, C, W, and 
Y anal yses, will be considered A, C, W, Y- naive or - experienced based on what group (s) 
were present in the prior ACWY -containing vaccine.
Thesecondary strain immunogenicit y objective is based on hSBA results from subjects in 
Groups 2 and 4 using 10 test strains expressing the following variants:  A29, A06, A12, A07, 
A15, A19, B16, B09, B03, and B15. Three (
3) subsets of study  subjects will be selected for 
this analy sis. Each subset will be used to assess the response to 
3or 4of the 10 secondary
test strains in addition to the 4 primary  test strains.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 30Prim ary Immunogenicity Objective: Prim ary Immunogenicity Endpoints:
 Toassess the immune response induced by bivalent 
rLP2086 as measured by hSBA performed with 4 
primary MnB test strains, 2 expressing an LP2086 
subfamily A protein and 2 expressing an LP2086 
subfamily B protein, measured 1 month after the 
second vaccination , in the bivalent rLP2086 arms 
(Group 2 and 4 subjects )combined .Five (5) coprimary endpoints are defined for the primary
objective ; they are defined for hSBA performed with each of 
the 4 primary test strains: PMB80 (A22), PMB2001 (A56), 
PMB2948 (B24), and PMB2707 (B44).
 One (1)of the 5 coprimary endpoints is the composite 
endpoint defined as the proportion of subjects achieving 
an hSBA titer lower limit of quantitation (LLOQ ; 1:16 
for A22 and 1:8 for A56, B24 ,and B44 ) for all 4 primary 
test strains combined, 1 month after the second 
vaccination inthe bivalent rLP2086 arms (Group 2 and 4 
subjects )combined . 
 Four (4) of the coprimary endpoints are defined as the 
proportion of subjects achieving at least a 4 -fold increase 
in hSBA titer from baseline to 1 month after the second 
vaccination in the bivalent rLP2086 arms ( Group 2 and 4 
subjects )combined for each o f the 4 primary test strains.
For subjects with a baseline hSBA titer below the limit 
of detection (LOD ,or an hSBA titer of <1 :4), a 4 -fold 
response is defined as an hSBA titer of 1:16 or the 
LLOQ (whichever titer is higher).
For subjects with a baseline hSBA titer of LOD 
(ie, hSBA titer of 1:4) and < LLOQ, a 4 -fold 
response is defined as an hSBA titer of  4times the 
LLOQ.
For subjects with a baseline hSBA titer of LLOQ, a 
4-fold response is defined as an hSBA titer of 4times 
the baseline titer.
Prim ary Safety Objective s: Prim ary Safety Endpoints :
 To describe the safety profile of bivalent rLP2086 ,as 
measured by local reactions, systemic events, 
adverse events (AEs ), serious adverse events (SAEs ), 
newly diagnosed chronic medical conditions, 
medically attended AEs, and immediate AEs
,
following Vaccinations 1 and 2 in the bivalent 
rLP2086 arms ( Group 2 and 4 subjects )combined.The following endpoints will be described after Vaccinations 1 
and 2 inthe bivalent rLP2086 arms ( Group 2 and 4 subjects )
combined .
 Percentage of subjects reporting local reactions (pain, 
redness ,and swelling) and by severity within 7 d ays after 
each vaccination visit.
 Percentage of subjects reporting systemic events (fever, 
vomiting, diarrhea, headache, fatigue, chills, muscle pain 
other than muscle pain at any injection site, and joint 
pain) and by severity within 7 days after each vaccination
visit.
 Percentage of subj ects reporting the use of antipyretic 
medication within 7 days after each vaccination visit. 
 Percentage of subjects with at least 1 SAE during the 
following time periods:
 30 Days after each vaccination .
 30 Days after any vaccination .
 During the Stage 1 va ccination phase (from the first 
study vaccination [Visit 1 ]through 1 month after the 
second study vaccination [Visit 4 ]).
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 31 During the Stage 1 follow -up phase (from 1 month 
after the second study vaccination [Visit 4] through 
6months after the second study vaccination [Visit 5]).
 Throughout Stage 1 (from the first study vaccination 
[Visit 1] through 6 months after the second study 
vaccination [Visit 5]).
 Percentage of subjects with at least 1 medically attended 
AE occurring during the following time pe riods:
 30 Days after each vaccination.
 30 Days after any vaccination.
 During the Stage 1 vaccination phase (from the first 
study vaccination [Visit 1] through 1 month after the 
second study vaccination [Visit 4]).
 During the Stage 1 follow -up phase (from 1 month 
after the second study vaccination [Visit 4] through 6 
months after the second study vaccination [Visit 5]).
 Throughout Stage 1 (from the first study vaccination 
[Visit 1] through 6 months after the second study 
vaccination [Visit 5]).
 Percentage of subjects with at least 1 newly diagnosed 
chronic medical condition occurring during the following 
time periods:
 30 Days after each vaccination.
 30 Days after any vaccination.
 During the Stage 1 vaccination phase (from the first 
study vaccination [Visit 1] through 1 month after the 
second study vaccination [Visit 4]).
 During the Stage 1 follow -up phase (from 1 month 
after the second study vaccination [Visit 4] through 
6 months after the second study vaccination [Visit 5]).
 Throughout Stage 1 (from the first study vaccination 
[Visit 1] through 6 months after the second study 
vaccination [Visit 5]).
 Percentage of subjects with at least 1 AE occurring during 
the following time periods:
 30 Days after each vaccination.
 30 Days after any vaccination.
 During the St age 1 vaccination phase (from the first 
study vaccination [Visit 1] through 1 month after the 
second study vaccination [Visit 4]).
 Percentage of subjects reporting at least 1 immediate AE 
after each vaccination.
 Subject days missing school or work because of AEs 
during the Stage 1 vaccination phase (Visit 1 though 
Visit 4).
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 32 To describe the safety profile of MenABCWY, as 
measured by local reactions, systemic events, AEs, 
SAEs, newly diagnosed chronic medical conditions, 
medically attended AEs, and immediate AEs, after 
the booster vaccination .
 To describe the safety profile of bivalent rLP2086, as 
measured by local reactions, systemic events, AEs, 
SAEs, newly diagnosed chronic medical conditions, 
medically attended AEs, and immediate AEs, after 
the booster v accination.The following endpoints will be described after the booster
vaccination in Groups 1 through 4:
Percentage of subjects reporting local reactions (pain, 
redness, and swelling) and by severity within 7 days after 
the booster vaccination.
Percentag e of subjects reporting systemic events (fever, 
vomiting, diarrhea, headache, fatigue, chills, muscle pain 
other than muscle pain at any injection site, and joint pain) 
and by severity within 7 days after the booster vaccination. 
Percentage of subjects re porting the use of antipyretic 
medication within 7 days after the booster vaccination . 
Percentage of subjects with at least 1 SAE during the 
following time periods:
 During the booster vaccination phase (from the 
booster vaccination [Visit 10]through 1 mo nth after 
the booster vaccination [Visit 1 1]).
During the booster follow -up phase (from 1 month 
after the booster vaccination [Visit 1 1]through 
6months after the booster vaccination [Visit 1 2]).
From the booster vaccination (Visit 10) through 
6months after the booster vaccination (Visit 1
2).
Percentage of subjects with at least 1 medically attended 
AE occurring during the following time periods:
During the booster vaccination phase (from the booster 
vaccination [Visit 10]through 1 month after the 
booster vaccination [Visit 1 1]).
During the booster follow -up phase (from 1 month 
after the booster vaccination [Visit 1 1]through 
6months after the booster vaccination [Visit 1 2]).
From the booster vaccination (Visit 10) throug h 
6
months after the booster vaccination (Visit 12).
Percentage of subjects with at least 1 newly diagnosed 
chronic medical condition occurring during the following 
time periods:
During the booster vaccination phase (from the booster 
vaccination [Visit 10]through 1 month after the 
booster vaccination [Visit 1 1]).
During the booster follow -up phase (from 1 month 
after the booster vaccination [Visit 1 1]through 
6months after the booster vaccination [Visit 1 2]).
From the booster vaccination (Visit 10) throug h 
6months after the booster vaccination (Visit 1
2).
Percentage of subjects with at least 1 AE occurring during 
the following time periods:
During the booster vaccination phase (from the booster 
vaccination [Visit 10]through 1 month after the 
booster vaccination [Visit 1 1]).
Percentage of subjects reporting at least 1 immediate AE 
after the booster vaccination.
The number of days miss ed,school or work , by the subject
because of AEs after the booster vaccination .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 33Secondary Immunogenicity Objectives: Secondary Immunogenicity Endpoints:
Todescribe the immune response induced by bivalent 
rLP2086 as measured by hSBA performed with 4 
primary MnB test strains, 2 expressing an LP2086 
subfamily A protein and 2 expressing an LP2086 
subfamily B protein, measured 1 month after the 
second vaccination, in thebivalent rLP2086 arms
(Group 2 and 4 subjects) combined. Proportions of subjects with hSBA titers LLOQ, 1:4, 
1:8, 1:16, 1:32, 1:64, and 1:128 for each of the 4 
primary MenB test strains at Visit 4.
 hSBA geometric mean titers (GMTs) for each of the 4 
primary MnB test strains at Visit 4.
To describe the MenB immune response as measured 
by hSBA performed with secondary MenB test strains 
measured 1 month after the second vaccination in 
Groups 2 and 4 combined.The secondary immunogenicity endpoints for the subsets 
tested with the additional hSBA test strains are as follows :
 Proportions of subjects with hSBA titers LLOQ (1:16 
for A06, A12, and A19 and 1:8 for A07, A15, A29, B03, 
B09, B15, and B16) for each of t he secondary test strains 
1 month after the second vaccination.
 Proportions of subjects with hSBA titers 1:4, 1:8, 
1:16, 1:32, 1:64, and 1:128 for each of the secondary 
test strains 1 month after the second vaccination.
 hSBA GMTs for each of the secondary test strains 
1month after the second vaccination.
To describe the immune response induced by 1 dose 
of MenABCWY compared to the immune response 
induced by 1 dose of MenACWY -CRM, as measured 
by hSBA performed with ACWY test strains, in 
ACWY-naive and ACWY-experienced subjects 
separately.Proportions of subjects with hSBA-MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:8 (or LLOQ, 
whichever is higher) at Visit 2.
Proportions of subjects with hSBA-MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:4, 1:8, 1:16, 
1:32, 1:64, and 1:128 at Visit 2.
hSBA GMTs for each of the ACWY test strains at Visit 2.
To describe the immune response induced by 2 doses 
of MenABCWY compared to the immune response 
induced by 1 dose of MenACWY -CRM, as measured 
byhSBA performed with ACWY test strains, in 
ACWY-naive and ACWY -experienced subjects 
separately.Proportions of subjects with hSBA-MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:8 (or LLOQ, 
whichever is higher) at Visit 4 in Groups 1 and 3 and at 
Visit 2 in Groups 2 and 4. 
Proportions of subjects with hSBA-MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:4, 1:8, 1:16, 
1:32, 1:64, and 1:128 at Visit 4 in Groups 1 and 3 and 
Visit 2 in Groups 2 and 4.
hSBA GMTs for each of the ACWY test strains at Visit 4 in 
Groups 1 and 3 and Visit 2 in Groups 2 and 4.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 34 To describe the immune response induced by 
MenABCWY compared to the immune response 
induced by bivalent rLP2086 ,as measured by hSBA 
performed with 4 primary MnB test strains, 2 
expressing an LP2086 subfamily A protein and 2 
expressing an LP2086 subfamily B protein, measured 
1month after the second vaccination in the ACWY -
naive and ACWY -experienced subjects combine d.Proportions of subjects who achieve the 5 MnB endpoints 
1 month after the second vaccination, which are defined 
for hSBA performed with each of the 4 primary test 
strains: PMB80 (A22), PMB2001 (A56), PMB2948 (B24), 
and PMB2707 (B44), as detailed below:
One (1)of the 5 endpoints is the composite endpoint 
defined as the proportion of subjects achieving an 
hSBA titer LLOQ (1:16 for A22 and 1:8 for A56, 
B24, and B44) for all 4 primary test strains combined, 
1month after the second vaccination. 
Four (4)of the endpoints are defined as the proportion 
of subjects achieving at least a 4-fold increase in hSBA 
titer from baseline to 1 month after the second 
vaccination for each of the 4 primary test strains.
For subjects with a baseline hSBA titer below the 
LOD(ie,an hSBA titer of <1:4), a 4 -fold response 
is defined as an hSBA titer of 1:16 or the LLOQ 
(whichever titer is higher).
For subjects with a baseline hSBA titer of LOD 
(ie, hSBA titer of 1:4) and < LLOQ, a 4 -fold 
response is defined as an hSBA ti ter of 4 times 
the LLOQ.
For subjects with a baseline hSBA titer of 
LLOQ, a 4 -fold response is defined as an hSBA 
titer of 4 times the baseline titer.
Proportions of subjects with hSBA titers LLOQ, 1:4, 
1:8, 1:16, 1:32, 1:64, and 1:128 for each of the 4 
primary MenB test strains at Visit 4.  
hSBA GMTs for each of the 4 primary MnB test strains at 
Visit 4.
 To describe the immune response induced by 
MenABCWY compared to the immune response 
induced by MenACWY -CRM and bivalent rLP208 6,
as measured by hSBA performed with ACWY test 
strains and 4 primary MenB test strains, 2 expressing 
an LP2086 subfamily A protein and 2 expressing an 
LP2086 subfamily B protein, at blood sampling time 
points prior to the booster vaccination (Stage 1).Proportions of subjects with hSBA-MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:8 (or LLOQ, 
whichever is higher) at Visits 1 and3, in the ACWY -naive 
and ACWY -experienced subjects separately.
Proportions of subjects with hSBA-MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:4, 1:8, 1:16, 
1:32, 1:64, and 1:128 at Visits 1 and3, in the ACWY -
naive and ACWY -experienced subjects separately.
hSBA GMTs for each of the ACWY test strains at Visits 1
and 3, in the ACWY -naive and ACWY -experienced 
subjects separately.
Proportions of subjects with hSBA titers LLOQ 1:4, 
1:8, 1:16, 1:32, 1:64, and 1:128 for each of the 4 
primary MenB test strains at Visits 1 and3, in the ACWY -
naive and ACWY -experienced subjects combined.  
hSBA GMTs for each of the 4 primary MenB test strains 
at Visits 1 and3,in the ACWY -naive and 
ACWY-experienced subjects combined. 
 To describe the immune response induced by 
MenABCWY compared to the immune response 
induc ed by MenACWY -CRM and bivalent rLP2086 ,
as measured by hSBA performed with ACWY test 
strains and 4 primary MenB test strains, 2 expressing 
an LP2086 subfamily A protein and 2 expressing an 
LP2086 subfamily B protein, at blood sampling time Proportions of subjects with hSBA-MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:8 (or LLOQ, 
whichever is higher) at Visits 7, 8, 9, and 10, in the 
ACWY-naive and ACWY -experienced subjects 
separately.
Proportions of subjects with hSBA titers LLOQ for each 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 35points prior to the booster vaccination (Stage 2). of the 4 primary MenB test strains at Visits 7, 8, 9, and 10, 
in the ACWY -naive and ACWY -experienced subjects 
combined.  
 To describe the immune response induced by 
MenABCWY ,as measured by hSBA performed with 
ACWY and 4 primary MnB test strains, 1 month 
after a booster vaccination in Group s 1and 3 .Proportions of subjects with hSBA-MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:8 (or LLOQ, 
whichever is higher) at Visit 11in Groups 1 and 3,
separately . 
Proportions of subjects with hSBA titers LLOQ for each 
of the 4 primary MenB test strains at Visit 11 , in Groups 1 
and 3 combined . 
 To describe the immune response induced by 
bivalent rLP2086, as measured by hSBA perf ormed 
with 4 primary MnB test strains, 2 expressing an 
LP2086 subfamily A protein and 2 expressing an 
LP2086 subfamily B protein, measured 1 month after 
the booster vaccination in Group s 2and 4 .Proportions of subjects with hSBA titers LLOQ for each 
of the 4 primary MenB test strains at Visit 11 , in Groups 2 
and 4 combined . 
Secondary Safety Objectives : Secondary Safety Endpoints : 
 To describe the safety profile of MenABCWY, as 
measured by local reactions, systemic events, AEs, 
SAEs, newly diagnosed chronic medical conditions, 
medically attended AEs, and immediate AEs, after 
Vaccinations 1 and 2 in the ACWY-naive and 
ACWY-experienced subjects separately. The following endpoints will be described after Vaccination s1 
and 2 in Groups 1 and 3:
Percentage of subjects reporting local reactions (pain, 
redness, and swelling) and by severity within 7 days after 
each vaccination visit.
Percentage of subjects reporting systemic events (fever, 
vomiting, diarrhea, headache, fatigue, chills, muscle pain 
other than muscle pain at any injection site, and joint pain) 
and by severity within 7 days after each vaccination visit. 
Percentage of subjects reporting the use of antipyretic 
medication within 7 days after each vaccination visit. 
Percentage of subjects with at least 1 SAE during the 
following time periods:
30 Days after each vaccination .
30 Days after any vaccination .
During the Stage 1 vaccination phase (from the first 
study vaccination [Visit 1 ]through 1 month after the 
second study vaccination [Visi t 4]).
During the Stage 1 follow -up phase (from 1 month 
after the second study vaccination [Visit 4]through 
6 months after the second study vaccination [Visit 5]).
Throughout Stage 1 (from the first study vaccination 
[Visit 1 ]through 6 months after the second study 
vaccination [Visit 5 ]).
Percentage of subjects with at least 1 medically attended 
AE occurring during the following time periods:
30 Days after each vaccination .
30 Days after any vaccination .
During the Stage 1 vaccination phase (from the first 
study vaccination [Visit 1 ]through 1 month after the 
second study vaccination [Visit 4 ]).
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 36During the Stage 1 follow -up phase (from 1 month 
after the second study vaccination [Visit 4]through 
6months a fter the second study vaccination [Visit 5]).
Throughout Stage 1 (from the first study vaccination 
[Visit 1 ]through 6 months after the second study 
vaccination [Visit 5 ]).
Percentage of subjects with at least 1 newly diagnosed 
chronic medical condition oc curring during the following 
time periods:
30 Days after each vaccination .
30 Days after any vaccination .
During the Stage 1 vaccination phase (from the first 
study vaccination [Visit 1 ]through 1 month after the 
second study vaccination [Visit 4 ]).
During the Stage 1 follow -up phase (from 1 month 
after the second study vaccination [Visit 4]through 
6 months after the second study vaccination [Visit 5]).
Throughout Stage 1 (from the first study vaccination 
[Visit 1 ]through 6 months after the second study 
vaccination [Visit 5 ]).
Percentage of subjects with at least 1 AE occurring during 
the following time periods:
30 Days after each vaccination .
30 Days after any vaccination .
During the Stage 1 vaccination phase (fro m the first 
study vaccination [Visit 1 ]through 1 month after the 
second study vaccination [Visit 4 ]).
Percentage of subjects reporting at least 1 immediate AE 
after each vaccination.
The number of days miss ed,school or work , by the subject
because of AEs after vaccination .
Exploratory Objectives: Exploratory Endpoints:
To describe the immune response induced by 
MenACWY -CRM as measured by hSBA performed 
with ACWY test strains, 1 month after a booster 
vaccination in Group s 2and 4 .Proportion of subjects with hSBA -MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:8 (or LLOQ, 
whichever is higher) at Visit 11 , in Groups 2 and 4 
separately .
Todescribe the immune response induced by bivalent 
rLP2086 as measured by hSBA performed with 4 
primary MnB test strains, 2 expressing an LP2086 
subfamily A protein and 2 expressing an LP2086 
subfamily B protein, measured 1 month after the first 
vaccination, in the bivalent rLP2086 arms (Group 2 
and 4 subjects) combined.Proportion of subjects who achieve the 5 MnB endpoints 
at Visit 2.
Proportions of subjects with hSBA titers LLOQ, 1:4, 
1:8, 1:16, 1:32, 1:64, and 1:128 for each of the 4 
primary MenB test strains at Visit 2. 
hSBA GMTs for each of the 4 primary MnB test strains at 
Visit 2.
Tofurther describe the immune response induced by 
MenABCWY compared to the immune response 
induced by MenACWY -CRM and bivalent rLP2086 ,
as measured by hSBA performed with ACWY test 
strains and 4 primary MenB test strains, 2 expressing 
an LP2086 subfamily A protein and 2 expressing an 
LP2086 subfamily B protein, at blood sampling time 
points prior to the booster vaccination (Stage 2). Proportions of subjects with hSBA-MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:8, 1:16, 
1:32, 1:64, and 1:128 at Visits 7, 8, 9, and 10, in the 
ACWY-naive and ACWY -experienced subjects 
separately.
 hSBA GMTs for each of the ACWY test strains at Visits 
7, 8, 9, and 10, in the ACWY -naive and 
ACWY-experienced subjects separately.
 Proportions of subjects with hSBA titers 1:4, 1:8, 
1:16, 1:32, 1:64, and 1:128 for each of the 4 primary 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 37MenB test strains at Visits 7, 8, 9, and 10, in the ACWY-
naive and ACWY -experienced subjects combined.   
 hSBA GMTs for each of the 4 primary MenB test strains 
at Visits 7, 8, 9, and 10, in the ACWY -naive and ACWY -
experienced subjects combined. 
Tofurther describe the immune response induced by 
MenABCWY ,as measured by hSBA performed with 
ACWY and 4 prim ary MnB test strains, 1 month after 
a booster vaccination in Group s 1and 3 .Proportions of subjects with hSBA-MenA, hSBA -MenC, 
hSBA -MenW, and hSBA -MenY titers 1:8, 1:16, 1:32, 
1:64, and 1:128 at Visit 11 , in Groups 1 and 3 
separately .
hSBA GMTs for each of the ACWY test strains at 
Visit 11, in Groups 1 and 3 sepa rately . 
Proportion of subjects who achieve the 5 MnB endpoints 
at Visit 11 , in Groups 1 and 3 combined . 
Proportions of subjects with hSBA titers 1:4, 1:8, 1:16, 
1:32, 1:64, and 1:128 for each of the 4 primary MenB 
test strains at Visit 11 , in Groups 1 and 3 combined .
hSBA GMTs for each of the 4 primary MnB test strains at 
Visit 11 , in Groups 1 and 3 combined . 
To further describe the immune response induced by 
bivalent rLP2086, as measured by hSBA performed 
with 4 primary MnB test strains, 2 expressing an 
LP2086 subfamily A protein and 2 expressing an 
LP2086 subfamily B protein, measured 1 month after 
the booster vaccination in Group s 2and 4 .Proportion of subjects who achieve the 5 MnB endpoints 
1month after the booster vaccination , in Groups 2 and 4 
combined .
Proportions of subjects with hSBA titers 1:4,1:8, 1:16, 
1:32, 1:64, and 1:128 for each of the 4 primary MenB 
test strains at Visit 11 , in Groups 2 and 4 combined.
hSBA GMTs for each of the 4 primary MnB test strains at 
Visit 11 , in Groups 2 and 4 combined.
3.STUDY DESIGN
This is a P hase 3, randomized, active -controlled, observer -blinded multicenter trial in which 
approximately  1590 subjects will be randoml y assigned to receive either MenABCWY and 
placebo
,or bivalent rL P2086 andMenACWY -CRM . All subjects will be nai ve to an y
meningococcal group B vaccine prior to enrollment.
Randomization will be stratified b y prior vaccination history ; approximately  795 
ACWY -
naive subjects and 795 ACWY -experienced (having received 1 prior dose of a 
vaccine containing 1or more ACWY groups 4 years prior to the date of randomization) 
subjects will be enrolled.
Randomization will also be stratified b y geographic region.  Approximately  1320 subjects 
from US investigative sites and 270subjects from ex-US countries will be randomized.  
Regional stratification will ensure sufficient population representation.
Enrol lment targets willalso be a djusted to achieve appropriate representation by  age
(subjects 10 to <18 years old and subjects 18 to <26 y ears old) , agewithin ACWY strata ,and 
ACWY strata within a geographic region .
Additional details will be provided during pretrial 
assessment and si te initiation visits.
The study  will be conducted in 2stages :
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 38Stage 1: from study  entry (Visit 1) through Visit 6 .  See Table 1.  A pilot cohort 
consisting of 10 subjects 18 to <26 y ears of age will first be enrolled at selected site(s).  
These pilot cohort subjects will be assigned to either Group 1 or 3, 
and therefo re will 
receive MenABCWY at Vaccination 1 .  The sponsor will be unblinded to vaccine 
assignment for the pilot cohort. Seven (7) day s after the last 
pilot cohort subject has 
received 
MenABCWY , 7-day electronic diary  (e-diary )and AE data will be summarized
for review bythe sponsor’s
independent review committee (I RC).  No further enroll ment 
will be permitted until review of these safet y data is complete.  If the IRC finds the safet y 
data from the 
pilot cohort acceptable , enrol lment will be opened to all ages and 
randomization groups , and pilot cohort subjects will proceed through the study. During 
Stage 1, the sponsor will be blinded to vaccine assignment beyond completion of pilot 
cohort enrollment (Section 5.4).
In order to support assay  development, a subset of up to approximately  600 subjects 18 to 
25years of age will have up to 100mL,rather 
than 20 mL ,of blood drawn at Visits 1, 2,
and 4 ; and a subset of up to approximately 150 subjects 18 to 25 years of age will have 
up to 100 mL , rather than 20 mL , of blood drawn at Visit 11 .  Subject participation in this 
subset will be voluntary , and the volume of blood drawn will de pend on the consent 
obtained .  Stage 1 will be observer-blinded.
At designated sites
, an additional optional whole blood sample of approximately  50 mL 
will be obtained at Visit 4 from up to approximately  30 subjects 18 to 25 y ears of age .  
This sample will be used for exploratory  purposes.
Stage 2: from 
Months 18 to 60 (Visit s 7to 12).Subjects from both the ACWY -naïve and 
ACWY -experienced strata, approximately 132 from each of Groups 1 and 3 and 
approximately  65 from each of Groups 2 and 4 ,will participa te in Stage 2.  Stage 1 will 
be observer -blinded and Stage 2 will be open -label .
Table 1. Stage 1 Study Design
Vaccination 1 Post–
Vaccinatio
n 1 Blood 
DrawVaccination 2 Post–
Vaccination 
2 Blood 
DrawSafety 
Telephone 
CallTelephone 
Call
Approximate 
Month0 1 6 7 12
Visit Number 1 2 3 4 5 6
ACWY-
Naive 
SubjectsGroup 1a
(n=265)MenABCWY + 
salineMenABCWY
Group 2 
(n=530)Bivalent 
rLP2086 + 
MenACWY -
CRMBivalent 
rLP2086
Blood Draw
for serum 
collection20 mL
(or up to 100 mL 
in subset)20 mL
(or up to 
100mL in 
subset)20 mL 20 mL
(or up to 
100mL in 
subset)
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 39Table 1. Stage 1 Study Design
Vaccination 1 Post–
Vaccinatio
n 1 Blood 
DrawVaccination 2 Post–
Vaccination 
2 Blood 
DrawSafety 
Telephone 
CallTelephone 
Call
ACWY-
Experienced 
SubjectsGroup 3a
(n=265)MenABCWY + 
salineMenABCWY
Group 4 
(n=530)Bivalent 
rLP2086 + 
MenACWY -
CRMBivalent 
rLP2086
Blood Draw
for Ser um
Collection20 mL
(up to 100mL in 
subset)20 mL
(up to
100mL in 
subset)20 mL
20 mL
(up to
100mL in 
subset)
Subjects 18 to 
25 years of 
age (naïve or 
experienced)Optional 
Blood Draw 
for Whole 
Blood 
Collection50 mL
a.Pilot cohort subjects w ill be assigned to either Group 1 or 3, but will receive only MenABCWY at 
Vaccination 1. Pilot cohort subjects will not receive saline at Vaccination 1. 
Table 2. Stage 2 Study Design
Antibody
PersistenceBooster
VaccinationPostbooster
Blood DrawSafety
Telephone
Call
Approxim ate
Month18-42 54 55 60
Visit Number 7-9 10 11 12
ACWY- Naive 
SubjectsGroup 1 (n~132) MenABCWY
Group 2 (n ~65) Bivalent rLP2086 + 
MenACWY -CRM
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 40Table 2. Stage 2 Study Design
Antibody
PersistenceBooster
VaccinationPostbooster
Blood DrawSafety
Telephone
Call
Approxim ate
Month18-42 54 55 60
Visit Number 7-9 10 11 12
ACWY-
Experienced 
SubjectsGroup 3 ( n ~132) MenABCWY
Group 4 ( n ~65) Bivalent rLP2086 + 
MenACWY -CRM
Blood Draw for 
Serum Collection20 mL × 3 20 mL 20 mL
(or up to 100 mL 
in subset)
In Stage 2, the t otal number subjects for Groups 1 and 3 combined will be approximately  264
and the 
total number of subjects for Groups 2 and 4 combined will be approximately  130.  
3.1.Approximate Duration of Subject Participation
Subjects will participate in Stage 1 for approximately 1 8months.  This includes a telephone 
contact 6 months after the last 
Stage 1 study  vaccination.  
Subject participation in Stage 2 will last for approximately  4 years.
The total study  duration for subjects who complete Stage 2 will be approximately  5 years 
(60months).
3.2.Approximate Duration of Study
This study  will be completed in approximately  66months.
3.3.Approximate Number of Subjects
Approximately  1590 subjects will be randomized to participate in this study.  Subjects 
withdrawn from the study will not be replaced, regardless of the reason for withdra wal.
Approximately  394 subjects may continue into Stage 2. Subjects from both ACWY -naïve 
and ACWY -experienced strata, approximately 132 from each of Groups 1 and 3 and 
approximately  65 from each of Groups 2 and 4, will participate in Stage 2.  Stage 1 will be 
observer -blinded and Stage 2 will be open -label .  
4.SUBJECT ELIGIBILITY CRITERIA
This study  can fulfill its objectives only  if appropriate subjects are enrolled.  The following 
eligibility  criteria are designed to select subjects for whom participation in the study is 
considered appropriate.  All relevant medical and nonmedical conditions should be taken into 
consideration when deciding whether a particular subject
is suitable for this protocol.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 41Subject eligibility should be reviewed and documented by  an appropriate member of the 
investigator’s stud y team before subjects are included in the study.
4.1. Inclusion Criteria
Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the 
study :
1.Evidence of a personally  signed and dated informed consent document (ICD) indicating 
that the subject (or parent(s)/legal guardian ) hasbeen informed of all p ertinent aspects of 
the study .
2.Willing and able to comply  with scheduled visits, treatment plan, laboratory tests, and 
other study  procedures.
3.Male and female subject aged 10 and <26 years, at the time of randomization.
4.Subjects who have never received a prior dose , or who have received not more than 
1prior dose 
no sooner than 4 years prior to the date of randomization, of a vaccine 
containing 1 or more ACWY groups .  Written confirmation of ACWY vaccination 
history  should be obtained prior to randomization; however, if written ACWY 
vaccination history  is not available, history  obtained verball y from the subject 
(orparent(s)/legal guardian) is acceptable, if deemed reliable by  the investigator.
5.Available for the entire st udy period and can be reached by  telephone.
6.Health y subject as determined by medical history, physical examination, and judgment of 
the investigator.
7.Male and female subjects of childbearing potential must agree to use a highly effective 
method of contrace ption throughout Stage 1 (through the follow -up telephone contact at 
Month 12), and from Visit 10 (booster vaccination) to Visit 11.  A subject is of 
childbearing potential if, in the opinion of the investigator, he/she is biologically  capable 
of having children and is sexually  active.
8.
Negative urine pregnancy  test for all female subjects.
4.2. Exclusion Criteria
Subjects with any  of the following characteristics/conditions will not be included in the 
study :
1. Previous vaccination with any  meningococcal group B vaccine or any  purely  
polysaccharide (nonconjugate) meningococcal vaccine .  Written vaccination history  
should be obtained prior to randomization ;however, if written vaccination history  is not 
available, history  obtained verball y from the subject (or parent(s)/legal guardian) is 
acceptable, if deemed reliable by  the investigator.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 422.Previous vaccination with >1 dose of a vaccine containing 1or more A CWY group .
3.Subjects having received 1 prior dose of a vaccine containing 1 or more ACWY group
<4years prior to the date of randomization.
4.A previous anaph ylactic reaction to an y vaccine or vaccine -related component.
5.Subjects receiving an y allergen immunot herap y with a nonlicensed product or receiving 
allergen immunotherap y with a licensed product and are not on stable maintenance doses.
6. Bleeding diathesis or condition associated with prolonged bleeding time that would 
contraindicate intramuscular injection
.
7.A known or suspected defect of the immune s ystem that would prevent an immune 
response to the vaccine, such as subjects with congenital or acquired defects in B -cell 
function, those receiving chronic s ystemic (oral, intravenous, or intramuscular) 
corticosteroid therapy , or those receiving immunosuppressive therapy .  Subjects in the 
United States with terminal complement deficiency  are excluded from participation in 
this study . Please refer to the study  reference manual ( SRM )for additional details .
8.History  of microbiologically  proven disease caused by  Neisseria meningitidis or 
Neisseria gonorrhoeae .
9.Significant neurological disorder or history  of seizure (excluding simple febrile seizure).
10.Receipt of an y blood products, including immunoglobulin ,within 6 months before the 
first study  vaccination.
11.Current chronic use of s
ystemic antibiotics.
12.Participation in other studies involving investigational drug(s) within 28 day sprior to 
study  entry  and/or during study  participation.
13.Any neuroinflammatory  or autoimm une condition, including, but not limited to, 
transverse m yelitis, uveitis, optic neuritis, and multiple sclerosis.
14.Other acute or chronic medical or ps ychiatric condition including recent (within the past 
year) or active suicidal ideation or behavior or l aboratory  abnormality  that may  increase 
the risk associated with study  participation or investigational product administration or 
may interfere with the interpretation of study results and, in the judgment of the 
investigator, would make the subject inappr opriate for entry into this study .
15.Investigator site staff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by  the investigator, or subjects 
who are Pfizer emplo yees, including their fa mily members, directl y involved in the 
conduct of the stud y.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 4316.Pregnant female subjects; breastfeeding female subjects; fertile male subjects and female 
subjects of childbearing potential who are unwilling or unable to use a highly  effective 
method of contraception as outlined in Section 4.5.
4.3.Criteria for Temporarily Delaying Vaccine Administration
The following conditions are temporary  or self -
limiting and a subject may be vaccinated 
once the conditions have resolved and the subject is eligible for vaccination:
1.Current febrile illness (temperature 38.0C [100.4 F]) or other acute illness within 
48hours before investigational 
product administration.
2. Subject has received a nonlive vaccine (or intramuscular/sublingual allergen 
immunotherapy ) within 14 days, or live vaccine within 28 days, before investigational 
product administration.
3.Subject has received a vaccine containing all or individual antigens included in Tdap 
vaccine within the previous 28 day s.
4. Subject is less than 5 days into a course of s ystemic antibiotic therapy .
5.Subject has received s ystemic (oral, intravenous, or intramuscular) corticosteroid therapy  
within the previous 28 day s.
If a subject meets an y delay criteria for vaccination, all study procedures, including blood 
sample collection relating to that visit, should be delay ed until the day  of vaccination.  Blood 
samples must alway s be collected prior to vaccina tion.
4.4. Criteria for Temporarily Delaying Blood Collection
The following condition is temporary  or self -limiting and blood may  be drawn once the 
condition has resolved and the subject is eligible for blood collection:
1.Subject has received s ystemic antibiotic therap y within the last 5 days.
4.5.Lifestyle Requirements
4.5.1. Contraception
All fertile male subjects and female subjects who are of childbearing potential who are, in the 
opinion of the investigator, sexually  active and at risk for pregnancy  with their partner(s) 
must agree to use a highly effective method of contraception consistentl y and correctly 
throughout Stage 1 (through the follow -up telephone contact at 
Month 12), and from Visit 10
(booster vaccination) to Visit 11.  The investigator or his or her designee , in consultation 
with the subject, will confirm that the subject has selected anappropriate method of 
contraception for the individual subject from the permitted list of contraception methods 
(seebelow) and will confirm that the sub
ject has been instructed in its consistent and correct 
use.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 44At time points indicated in the Schedule of A ctivities, t he investigator or designee will 
inform the subject of the need to use highly  effective contraception consistently and correctly  
and document the conversation and the subject’s affirmation in the subject’s chart (subject s
need to affirm their consistent and correct use of at least 1 of the selected methods of 
contraception) .  In addition, the investigator or designee will instruct the subject to call 
immediately  if the selected contraception method is discontinued or if pregnancy  is known or 
suspected in the subject or the partner .
Highl y effective methods of c ontraception are those that, alone or in combination, result in a 
failure rate of less than 1% per year when used consistently  and correctly  (ie,perfect use) and 
include
the following:
1.Established use of hormonal methods of contraception associated with i nhibition of 
ovulation (eg, oral, inserted, injected, implanted, transdermal) ,provided the subject or 
male subject’s female partner plans to remain on the same treatment throughout the entire 
study  and has been using that hormonal contraceptive for an ade quate period of time to 
ensure effectiveness.
2.Correctl y placed copper -containing intrauterine device (IUD).
3.Male condom or female condom used WI TH a separate spermicide product (ie,foam, gel, 
film, cream, or suppository ).For countries where spermicide i s not available or condom 
plus spermicide is not accepted as highl y effective contraception, this option is not 
appropriate.
4.Male sterilization with absence of sperm in the postvasectomy  ejaculate .
5.Bilateral tubal ligation/ bilateral salpingectom y or bilateral tubal occlusive procedure 
(provided that occlusion has been confirmed in accord ance with the device’s label).
NOTE: Sexual abstinence, defined as completel y and persistently  refraining from all 
heterosexual intercourse (including during the entire period of risk associated with the study  
treatments) may  obviate the need for contraception ONLY if this is the preferred and usual 
lifesty le of the subject.
4.6.Sponsor ’sQualified Medical Personnel
The contact information for the sponsor's appropriate ly qualified medical personnel for the 
study  is documented in the study  contact list located in theSRM.
To facilitate access to appropriatel y qualified medical personnel on stud y
-related medical 
questions or problems, subjects are provided with a contact card.   The contact card contains, 
at a minimum, protocol and investigational product identifiers, subject study numbers, 
contact information for the investigat orsite, and contact details for a contact center in the 
event that the investigat orsite staff c annot be reached to provide advice on a medical 
question or problem originating from another healthcare professional not involved in the 
subject’s participation in the study .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 45The contact number can also be used b y investiga torstaff if they  are seeking advice on 
medical questions or problems; however, it should be used onl
yin the event that the 
established communication pathway s between the investigator site and the study  team are not 
available. It is therefore intended to augment, but not replace, the es tablished communication 
pathway s between the investigator site and the study  team for advice on medical questions or 
problems that may  arise during the study .The contact number is not intended for use b y the 
subject directl y, and if a subject calls that number, he or she will be directed back to the 
investigat orsite.
5.INVESTIGATIONAL PRODUCTS
For the purposes of this study , and per International Co uncil for Harmoni sation ( ICH )
guidelines ,investigational product is defined as a pharmaceutical form of an active 
ingredient or placebo being tested or used as a reference /comparator in a clinical trial, 
including a product with a marketing authorization when used or assembled (formulated or 
packaged) in a way  different from the approved form, or when used for an unapproved 
indication, or when used to gain further information about an approved use (ICH E6 1.33) .
For this study , the investigational product(s) to be provided are:
Bivalent rLP2086 (bivalent rL P2086 and meningococcal group B vaccine [Trumenba ]
may be used interchangeabl y)
MenABCWY, consisting of:
oBivalent rLP2086 
oMenACWY -TT(Nimenrix)
MenACWY -CRM (Menveo)
Placebo (normal saline) .  Any reference to normal saline or placebo refers to a solution 
containing 0.85% sodium chloride and water for injection. The placebo solution is also 
referred to as “saline” throughout the protocol.
The investigational products will be provided by  the sponsor to each study  site.  Study  
vaccines will be packe d into kits and labeled as investigational product in accordance with 
current guidelines and applicable local and legal regulatory  requirements.  Investigational 
product kits will be labeled with a unique dispensable unit (DU) or container number.
Subjects will receive investigational products at each of the vaccination visits ( Visits 1, 3,
and 10) according to Table 1and Table 2.
5.1.Allocation to Investigational Product
Allocation of subjects to vaccine groups will proceed through the use of an interactive 
response technology  (IRT) sy stem that is accessible 24 hours a day , 365 day s ayear.  Having 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 46logged in, the site personnel (study  coordinator or specified designee) will be required to 
enter or select certain information including but not limited to the user’s identification (ID) 
and password, protocol number, the subject number, ifthe subject should be considered 
ACWY na ive or experienced, and the date of birth of the subject.  The site personnel will 
then be provided with a subject randomization number and DU or container number.  The 
randomization number and the date on which the randomization number was assigned will be 
recorded on the case report form ( CRF ).  Once subject numbers, DU numbers, and 
randomization numbers have been assigned, they  cannot be reassigned.  The I RT s ystem will 
provide a confirmation report containing the subject randomization number and DU or 
container number assigned.  The confirmation report must be stored in the site’s files.
The study -specific I RT reference manual will provide the contact information and further 
details on the use of the IRT system . 
5.2.Blinding of Site Personnel
In this observer -blinded study , the study  staff dispensing , preparing, and administering the 
vaccine will be unblinded .  All other study  and site personnel, including the investigator, 
investigator staff, subjects, and subjects’ parent(s)/legal guardian, will be blinded to 
investigational product assignments during Stage 1.  In particular, the individuals who 
evaluate subject safet y will be blinded during Stage 1 .  Because the study  vaccines are 
different in ph ysical appearance, t he stud y vaccine syringes will be administered in a manner 
that prevents the stud y subjects from identify ing the vaccine t ype based on its appearance.
The responsibility  of the unblinded dispenser and administrator must be assigned to an 
individual or indi viduals who will not participate in the evaluation of an y study  subjects.  
Contact between the unblinded dispenser and study subjects and unblinded administrator and 
study  subjects should be kept to a minimum.  The remaining site personnel must not know 
investigational product assignments.
5.3.Blinding of the Sponsor
Those study  team members who are involved in ensuring that protocol requirements for 
investigational product preparation, handling, allocation, and administration are fulfilled at 
the site will be unblinded for the duration of the study  (eg, unblinded study  manager, 
unblinded clinical research associate). An unblinded clinician who is not a direct member of 
the study  team will review unblinded protocol deviations.  All other study  team members and 
all laboratory  testing personnel performing serology assay s will remain blinded to vaccine 
assigned/received throughout 
Stage 1 of the study to Visit 5 .All laboratory testing personnel 
performing serology  assay s will also remain blinded to visit number throughout Stage 1 of 
the study .
5.4.Blinding of the Pilot Cohort
Depending on prior ACWY vaccination history , pilot cohort subjects will be assigned to 
either Group 1 or 3, and therefore will receive MenABCWY at Vaccination 1 .  For these 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 47subjects only , the subjects, study  personnel at the investigational site ,and study  personnel at 
the sponsor will be unblinded to vaccine assignment during Stage 1.
5.5.Breaking the Blind
At the initiation of the study , the study  site will be instructed on the method for breaking the 
blind.  The method will be either a manual or an electronic process.  Blinding codes should 
only be broken in emergency  situations for reasons of subject safety .
In case of an emergency , when knowledge of the investigational product assignment is 
requi red for the medical management of an individual subject, it may  be unblinded.  The 
investigator must notify  a member of the study  team immediately  after determining that it is 
necessary  to unblind the assignment.  The investigator must also indicate in sou rce 
documents that the blind was broken and provide the date and reason for breaking the blind.  
Any AE or SAE associated with breaking the blind must be recorded and reported as 
specified in this protocol.
5.5.1. Planned Unblinding
Pfizer will release unblinding information to the investigator
safter all subjects have 
completed Visit 5 and will inform the investigator sprior to Visit 7 which subjects may be 
invited to progress to 
Stage 2.  Additional information is included in the SRM.
The booster vaccination wil l be open- label.
5.6.Subject Compliance
All doses of investigational product will be administered by  the appropriately  designated 
study  staff at the investigator site.
5.7.
Investigational Product Supplies
5.7.1. Dosage Form(s) and Packaging
Bivalent rLP2086 is a 0.5 -mL dose supplied as a prefilled s yringe and formulated to contain 
60 µg each of a purified subfamily  A and a purified subfamily  B rLP2086 protein, 0.15 M 
sodium chloride, 2.8 molar ratio pol ysorbate 80, and 0.25 mg of Al3+as aluminum phosphate 
(AlPO 4)in10mM histi dine-buffered saline at pH 6.0.
MenACWY -TT is supplied as a single- dose vial containing l yophilized powder to be 
reconstituted for injection. The vaccine is formulated on the basis of purified capsular 
polysaccharide content and the amount of p rotein carrier is dependent on the 
polysaccharide -to-protein ratio. The vaccine is nonadjuvanted and preservative- free. The 
quantitative composition of the ly ophilized vaccine is shown in the Nimenrix IB .
MenACWY -TTwill be reconstituted with bivalent rLP2086 as detailed in the investigational 
product (IP) m anual , and 0.5 mL  of the resultant MenABCWY will be administered via 
intramuscular injection.  The f inal MenABCWY composition includes rL P2086 subfamily  A 
and B proteins formulated at 120 µg/mL /subfamily , purified capsular pol ysaccharides of 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 48Nmeningitidis types A, C, W ,and Y at concentration of 10 µg/mL /type conjugated to tetanus 
toxoid at ratios of ~1:3, ~1:3, ~1:1.5, and ~1:1.3, respectivel y, in 10 mM histidine and 
1.2
mM Tris buffer containing 150 mM sodium chloride, 0.5 mg/mL aluminum as AlPO 4, 
0.035 mg/mL  polysorbate 80 ,and 56 mg/mL  sucrose.
Menveo is supplied in 2 vials that must be combined prior to administ ration: the MenA 
lyophilized conjugate vaccine component is reconstituted with the meningococcal group C, 
Y,and W -135 ( MenCYW -135)liquid conjugate vaccine component immediatel y before 
administration as a 0.5 -mL intramuscular injection.
The placebo is ste rile normal saline solution for injection and will be administered as a 
0.5-mL intramuscular injection.
5.7.2. Preparation and Dispensing
See the IP 
manual or appropriate package inserts for instructions on how to prepare the 
investigational products for administration.  I nvestigational product should be prepared and 
dispensed by  an unblinded ,appropriatel y qualified , and experienced member of the stud y 
staff (eg, ph ysician, nurse, phy sician’s assistant, practitioner, or pharmacist) as allowed by  
local, state, and institutional guidance.  The investigational product will be administered to 
subjects who are blinded.
5.8.Adm inistration
Standard vaccination practices must be observed and vaccine must not be injected into blood 
vessels.  Appropriate medication and other supportive measures for management of an acute 
hypersensitivity  reaction should be available in accordance wi th local guidelines for standard 
immunization practices.
Administration of investigational products should be performed b y an appropriately 
qualified, Good Clinical Practice (GCP)-trained, and vaccine-experienced member of the 
study  staff (eg, ph ysician, n urse, ph ysician’s assistant, nurse practitioner, pharmacist, or 
medical assistant) as allowed b y local, state, and institutional guidance.
Because the stud y vaccines are different in physical appearance, the stud y vaccine s yringes 
will be administered in a manner that prevents the study  subjects from identify ing the vaccine 
type based on its appearance.
Investigational product administration details will be recorded on the CRF.
Table 3below describes the administration details for each vaccine. Each vaccine will be 
administered as a 0.5 -mL dose in the upper deltoid muscle of the left or right arm.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 49Table 3. Investigational Produ ct Administration Schedule
Investigational Product Group (s) Visit (s) Upper Deltoid Muscle 
Injection Location
MenABCWY 1 and 3 1, 3, 10 Left arm
Placebo (normal saline)a1 and 3 1 Right arm
Bivalent rLP2086 2 and 4 1, 3, 10 Left arm
MenACWY -CRM 2 and 4 1, 10 Right arm
a.Pilot cohort subjects w ill be assigned to either Group 1 or 3, but will receive only MenABCWY at 
Vaccination 1. Pilot cohort subjects will not receive saline at Vaccination 1 .
MenABCWY is administered intramuscularl y by i njecting 0.5 mL into the upper deltoid 
muscle of the left arm at Visit s 1, 3, and 10 (Groups 1 and 3) .
Placebo is administered intramuscularl y by injecting 0.5 mL into the upper deltoid muscle of 
the 
right arm at Visit 1 (G roups 1 and 3 ); pilot cohort subjects will not receive placebo at 
Vaccin ation 1. 
Bivalent rLP2086 is administered intramuscularl y by injecting 0.5 mL into the upper deltoid 
muscle of the left arm at Visit s 1, 3, and 10 (Groups 2 and 4) .
MenACWY -CRM is administered intramuscularly  by injecting 0.5 mL into the upper deltoid 
mus
cle of the right arm at Visit s 1and 10 (Groups 2 and 4).
In the event of a product quality  complaint ,please refer to Section 8.5.
5.9.
Investigational Product Storage
The investigator o r an approved representative, eg , pharmacist, will ensure that all 
investigational products , including an y comparator and/or marketed pro ducts, are stored in a 
secured area with controlled access under required storage conditions and in accordance with 
applicable regulatory  requirements.
Investigational product sshould be stored in their original container sand in accordance with 
the label s.
See the IPmanual and package insert (s)for storage conditions of the product s 
(eg,MenABCWY) once re constituted .
Any storage conditions stated in the SRSD willbe superseded b y the storage conditions 
stated on the product label.
Site sy stems must be capable of measuring and documenting (for example, via a log), at a 
minimum, daily  minimum and maximum temperatures for all site storage locations (as 
applicable, including frozen, refrigerated ,and/or room -temperature products).  This should 
be captured f rom the time of investigational product receipt throughout the study .  Even for 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 50continuous- monitoring sy stems, a log or site procedure that ensures active evaluation for 
excursions should be available .  The intent is to ensure that the minimum and maximum 
temperature is checked each business day  to confirm that no excursion occurred since the last 
evaluation and to provide the site with the capability  to store or view the minimum/maximum 
temperature for all nonworking day s upon return to normal operations. 
The operation of the 
temperature -monitoring device and storage unit (for example, refrigerator), as applicable, 
should be regularl y inspected to ensure they are maintained in working order.
Any excursions from the product label storage conditions should be reported to Pfizer upon 
discovery . The site should actively  pursue options for returning the product to the storage 
conditions described in the labeling , as soon as possible.  Deviations f rom the storage 
requirements, including any  actions taken, must be documented and reported to Pfizer .
Once an excursion is identified, the investigational product must be quarantined and not used 
until Pfizer provides permission to use the investigational product.  It will not be considered a 
protocol deviation if Pfizer approves the use of the investigational product after the 
temperature excursion. Use of the investigational product prior to Pfizer approval will be 
considered a protocol deviation. Speci fic details regarding information the site should report 
for each excursion will be provided to the site.
Receipt of materials, door opening and closing, and other routine handling operations where 
the products are briefl y out of thetemperature range described in the labeling are not 
considered excursions.
5.10. Investigational Product Accountability
The investiga torsite must maintain adequate records documenting the receipt, use, loss, or 
other disposition of the investigational product supplies.   All investigational products will be 
accounted for using a drug accountabilit y form/record.
5.10.1. Destruction of Investigational Product Supplies
The sponsor or designee will provide guidance on the destruction of un used investigational 
product (eg , at the site). If destruction is authorized to take place at the investigator site, the 
investigator must ensure that the materials are destroy ed in compliance with applicable 
environmental regulations, institutional policy , and any  special instructions provided by  
Pfize r,and all destruction must be adequatel y documented.
Unused investigational product may  be destro yed according to procedures and local 
environmental regulations after all investigational product accountability  documentation has 
been completed, unless ther e are regulatory  requirements for this to be returned.  Empty  
investigational product containers may  be destroyed after the sponsor has performed 
accountability .  Onl y outer containers are used to perform accountabilit y while syringes and 
vials are discarded at the point of use.  Investigational product return must be documented on 
the accountability  log.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 515.11. Concomitant Treatment(s)
The name and date of administration of any  nonstudy  vaccine (or allergen immunotherapy ) 
given from the signing of the I CD up to V isit 1 1 will be recorded on the CRF.
The name, start and stop date s, and route of administration for concomitant medications 
(prescription and nonprescription) used to treat an AE (excluding events recorded onl y in the 
e-diary ) from the signing of the I CD to Visit 12 will be recorded in the CRF.
The name, start and stop date s, and route of administration of antipy retic and other pain 
medications received b y the subject on the day  prior to investigational product administration
will be recorded in the CRF.
5.11.1. P rohibited During the Study
Receipt of an y blood products, including immunoglobulin.
Nonstudy  meningococcal vaccines or vaccines containing 1 or more A BCWY group are 
prohibited throughout the course of the stud y.
Nonlive or live nonstudy  vaccines are not permitted within 14 and 28 day s, respectivel y, 
of an y study vaccination.
Vaccine containing all or individual antigens included in Tdap vaccine are not permitted 
within 28 day s of any study  vaccination .
Intramuscular/sublingual allergen immunotherap y is no t permitted within 14 days of an y 
study  vaccination.
Systemic (oral, intravenous, or intramuscular) corticosteroid therap y within 28 days of 
any study  vaccination.
5.11.2. Permitted During the Study
Nonstudy  vaccines used in the event of a disease outbreak or pandemic are allowed.  
However, while prioritizing standard clinical care, efforts should be made not to 
administer nonstudy  vaccines within 14 day s (for nonlive vaccines) or 28 day s (for live 
vaccine) as specified below .
Nonstudy  vaccines (other than any  meni ngococcal vaccines or vaccines containing 1 or 
more A BCWY group , or vaccines containing all or individual antigens included in Tdap
vaccine ) that are part of recommended immunization schedules are allowed any time 
during the stud y but should not be administered within 14 days (for nonlive vaccines) and 
28 day s (for live vaccines) of study  vaccine administration.  Please refer to Section 5.11.1
restrictions on administration 
on meningococcal vaccines or vaccines containing 1or 
more ABCWY group , and on admini stration of all or individual antigens included in
Tdap vaccines.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 52Antipy retic medication may  be administered.
A local anesthetic may  be used at the site of the blood draw.
Topical antibiotics are permitted.
Topical and inhaled corticosteroids are permitted .
5.11.3. Prior Treatment
If the subject is known to have ever received a poly ribosy lribitol phosphate oligosaccharide 
of Haemophilus influenzae type b conjugated to outer membrane protein (PRP -OMP) 
vaccine, the name of the vaccine and date of administration will be recorded on the CRF.  
Please refer to the SRM for a list of PRP -OMP –containing vaccines that are or have been 
commerciall y available.
If the subject has received any  prior meningococcal vaccines or vaccines containing 1or 
more ACWY group , the trade name (if known) and date of administration will be recorded 
on the CRF.  Please refer to the SRM for a list of ACWY -containing vaccines that are or 
have been commercially  available.   Written confirmation of ACWY vaccination history  
should be obtained prior to randomization ;however, if written ACWY vaccination history is 
not available, history  obtained verbally  from the subject (or parent( s)/legal guardian) is 
acceptable, if deemed reliable by  the investigator.
If the subject has received antipy retic and other pain medications on the day  prior to 
investigational product administration at Visit 1
, the name , start and stop date s, and route of
administration of the medication will be recorded on the CRF.
5.11.4. Prohibited Prior Treatments
The following are prohibited:
Receipt of an y blood products, including immunoglobulin, within 6 months before the 
first study  vaccination.
6. STUDY PROCEDURES 
6.1.Informed Consent Process
The investigator or authorized designee is responsible for obtaining written informed consent 
for each subject enrolled prior to an y study procedures.  Each signature on the I CD must be 
personall y dated b y the signatory.  A cop y of the sig ned and dated ICD will be given to the 
subject.  The subject’s source documents must reflect that informed consent was obtained 
before participation in the study .
For subjects who have not reached the legal age of majority  and are not legally  able to 
provi de informed consent, the investigator or authorized designee is responsible for obtaining 
written informed consent from the parent(s)/legal guardian .  In addition, a study -specific 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 53assent form will be provided to the subject (age dependent on local require ments). It is to be 
understood as the child’s will to participate in a study  after having received age -appropriate 
information and is sometimes also referred to as “knowing agreement.”  It is understood that 
wherever informed consent is used in this docum ent, this also applies to assent for minor 
subjects.
If a subject reaches the age at which he or she is legally able to provide consent during the 
study , consent must be obtained. Since the subject is no longer a minor, the parent/ legal 
guardian consent is no longer valid.  References in this protocol and other study  documents 
to parent/legal guardian responsibility  should be understood to be the direct responsibility  of 
study  subjects rather than parent/legal guardian after the subject has reached the lega l age of 
majority .
6.2.Stage 1
6.2.1. Visit 1 (Day 1): Vaccination 1
In the case of temporary  delay  of vaccination, procedures and assessments below will be 
redone or reconfirmed, as applicable, on the day  of vaccination.
Obtain written informed consent , and assent i f appropriate, before performing 
study -specific procedures.  The date of informed consent will be recorded on the CRF.
Record the subject’s demographic information (including date of birth, sex, race, and 
ethnicity ).
Record the presence of chronic conditions and/or medical history  of significance, 
including relevant surgical procedures and cardiac medical history .
Record previous PRP -OMP vaccinations as described in the Prior Treatment section 
(Section 5.11.3).
Record any prior meningococcal vaccines or vaccine
scontaining 1 or more ACWY 
groups as described in the Prior Treatment section ( Section 5.11.3).
Record an y antipy reticsand other pain medications received b y the subject on the day 
prior to investigational product administration as described in 
Section 5.11.3 .
Perform ph ysical examination evaluating an y clinically significant abnormalities within 
the following bod y systems: general appearance ;skin;head, ey es, ears, nose, throat;
heart ;lungs ;abdomen; extremities ;neurological ;musculoskeletal ;and ly mph nodes; 
including worsening of medical history  conditions.  Results must be recorded on source 
documents and the CRF.  Fi ndings from a ph ysical examination conducted as part of 
standard routine care and before informed consent may  be used for purposes of the study  
only if the examination was performed no more than 2 day s before vaccination.  A brief 
examination must be perfo rmed on the day  of vaccination to document that no change in 
health has occurred in the interim.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 54On the day  of vaccination, perform a urine pregnancy  test on female subjects.  A negative 
pregnancy  test result is required before the subject may  receive the investigational 
product.
On the day  of and before vaccination, measure and record the subject’s oral temperature .
Ensure that all of the inclusion criteria, none of the exclusion criteria, and none of the 
temporary  delay  criteria are met.
If a subject is eligible for the study , randomize the subject to 1 of the 4 groups using an 
interactive voice response sy stem ( IVRS ), interactive W eb-based response sy stem 
(IWRS)
,or an equivalent sy stem.
On the day  of and before vaccination, collect a blood sample (approximately  20 mL) 
from the subject.  Alternatively , for subjects who have consented to participate in the
subset , depending on the consent obtained :
Collect approximately  50 mL of blood, or
Collect approximately 100mLof blood.  
Collect the blood sample only  if the subject is eligible for vaccination on the same day .
For all subjects apart from the pilot cohort: The unblinded administrator administers a 
single 0. 5-mL intramuscular injection of either MenABCWY ( Groups 1 and 3) or 
bivalent rL P2086 ( Groups 2and 4 ) into the upper deltoid muscle of the left arm; and 
either MenACWY -CRM (Groups 2 and 4) or saline ( Groups 1 and 3 ) into the upper 
deltoid muscle of the right arm.  The time of investigational product administration will 
be recorded on the CRF.
oFor pilot cohort subjects: the unblinded administrator administers a single 0.5 -mL 
intramuscular injection of MenABCWY into the upper deltoid muscle of the left arm. 
The time of investigat ional product administration will be recorded on the CRF. Pilot 
cohort subjects will not receive placebo at Vaccination 1.
Observe the subject for at least 30 minutes (or longer as per local practice) after the 
investigational product administration for an y acute reactions.  Record an y AEs observed 
during the 30 -minute observation period, these AEs are defined as immediate AEs 
(Section 8).
Record AEs as described in the AE Reporting Requirements section (Section 8) and the 
Schedule of 
Activitie s.  Time of onset will be recorded for any  AEs that occur on the 
same day  as investigational product administration.
Record concomitant medications used to treat AEs as described in the Concomitant 
Treatment (s)section ( Section 5.11).
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 55Issue a subject e -diary  and provide instruction on its completion.  Ask the parent(s)/legal 
guardian or subject to complete the e -diary  from Day 1 to Day 7 after vaccination. Day 1 
is the day  of vaccination.
Issue a caliper, measuring tape/ruler, and a digital thermometer and provide instructions 
on their use.
Measuring tape/ruler data must be collected b y the parent(s)/legal guardian for minor 
subjects.   All data must be recorded in the e- diary  by the parent(s)/legal guardian for 
minor subjects.
Ask the parent(s)/legal guardian or the subject to use the caliper to measure the maximum 
diameter of redness and swelling at the left arm injection site each day  for the 7 day s after 
study  vaccination and record in the e -diary  as described in Section 7.4.
Ask the parent( s)/legal guardian or the subject to contact the investigator immediately  if 
the subject experiences a severe redness or swelling (>20 caliper units) at the left arm 
injection site, a fever 39.0C (102.1F), or a severe headache within 7 days after 
vaccina tion, as an unscheduled visit should be arranged ( Section 6.4).
oIf the reaction exceeds the maximum size the caliper is able to measure (>21 caliper 
units, Section 7.4.1), the parent(s)/legal gu ardian or the subject should also use the 
measuring tape/ruler to measure the maximum diameter of redness and/or swelling at 
the injection site, and report this immediately  to the investigator. 
oAsk the 
parent(s)/legal guardian or subject to report the max imum diameter of the 
redness and/or swelling at the injection site to the investigator daily  until the reaction 
becomes  21 caliper units.
Provide the subject with a contact card ( Section 4.6 ).
Ask the 
parent(s)/legal guardian or the subject to contact the investigator immediately  if 
any significant illness or hospitalization occurs.
Schedule an appointment for the next study  visit a nd confirm that it is scheduled within 
the time window per protocol.
Remind the parent(s)/legal guardian or subject to bring the e -diary  to the next study  visit.
Complete the source documents.
Complete the CRF and update the investigational product accountability  records.
Between visits, review the e -diary  data online at frequent intervals. Contact the 
parent(s)/legal guardian or the subject to obtain stop dates for an y local reactions, systemic 
events, or use of antipy retic medication that were ong oing on the last day  that the e -diary  was 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 56completed.  The stop dates should be documented in the source documents and the 
information entered into the CRF at the next study  visit of the subject.
6.2.2. Visit 2 (28 to 42 Days After Visit 1), Post –Vaccination 1 Blo od Draw
Ensure that the subject continues to be eligible for the study , and continues to comply  
with contraception requirements detailed in Section 4.5.
Ensure that the subject continues to meet none of the withdrawal criteria as described in 
Section 6.5and none of the temporary  delay  of blood draw criteria as described in 
Section 4.4.
Collect the subject’s e -diary .
Review the subject’s e
-diary  data since the previous visit and follow up on any ongoing 
reactogenicity  or use of antipy retic medication.
Complete the Study  Visit/Tel ephone Contact AE Checklist to:
oInquire whether the subject had an y newly diagnosed chronic medical conditions 
since the last visit.  I nquire whether the subject had any  of the following related to an 
AE since the last visit: hospitalizations, visits to other medical facilities, medication 
use, or missed day s of school or work.  Please refer to the SRM for additiona l details.
oInquire about neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis. Please refer to the SRM for 
additional details.
Record AEs as described in the AE Reporting Requirements section ( Section 8) and the 
Schedule of Activities
.
Review AEs that were ongoing since the previous visit a nd record their end dates or 
confirm that they  are still continuing.
Record nonstudy vaccinations as described in the Concomitant Treatment (s)section 
(Section 5.11).
Record concomitant medications used to treat AEs as described in the Concomitant 
Treatment (s)section ( Section 5.11).
Collect a blood sample (approximately  20 mL). Alternativel y, for subjects who have 
consented to participate in the subset, depending on the consent obtained:
Collect approximately  50mL of blood, or
Collect approximately  100 mLof blood .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 57Ask the parent(s)/legal guardian or the subject to contact the investigator immediately  if 
any significant illness or hospitalization occurs.
Schedule an appointment for the next visit and confirm that it is scheduled within the 
time window per protocol.
Complete the source documents.
Complete the CRFs.
6.2.3. Visit 3 (173 to 194 Days After Visit 1): Vaccination 2
In the case of temporary  delay  of vaccination, procedures and assessments below will be 
redone or reconfirmed, as applicable, on the day  of vaccination.
Ensure that the subject continues to be eligible for the study , and continues to comply  
with contraception requirements detailed in Section 4.5.
Ensure that the subject continues to meet none of the withdrawal criteria as described in 
Section 6.5and none of the temporary  delay  of vaccination or blood draw criteria as 
described in 
Section 4.3 and Section 4.4.
Complete the Study  Visit/Tel ephone Contact AE Checklist to:
oInquire whether the subject had an y newly diagnosed chronic medical conditions 
since the last visit.  I nquire whether the subject had any  of the following related to an 
AE since the last visit: hospitalizations, visits to other medical facilities, medicati on 
use, or missed day s of school or work.  Please refer to 
the SRM for additional details.
oInquire about neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis.  Please refer to the SRM for
additional details.
Record AEs as described in the AE Reporting Requirements section ( Section 8) and the 
Schedule of Activities.  Time of onset will be recorded for any  AEs that occur on the 
same day  as investigational product administration.
Review AEs that were ongoing from the previous visit and record their end dates or 
confirm that they  are still continuing.
Record nonstudy vaccinations as described in the Concomitant Treatment (s)section 
(Section 5.11).
Record concomitant medicat
ions used to treat AEs as described in the Concomitant 
Treatment (s)section (Section 5.11).
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 58Record an y antipy reticsand other pain medications received b y the subject on the day 
prior to investigational product administration as described in Section 5.11.
On the day  of and before vaccination, collect a blood sample (approximately  20 mL) 
from the subject.  Collect the blood sample only if the subject is eli gible for vaccination 
on the same day .
On the day  of vaccination, perform a urine pregnancy  test on female subjects.  A negative 
pregnancy  test result is required before the subject may  receive the investigational 
product.
On the day  of and before vaccinat ion, measure and record the subject’s oral temperature.
The unblinded administrator administers a single 0.5- mL intramuscular injection of either 
MenABCWY ( Groups 1 and 3) or bivalent rL P2086 ( Groups 2 and 4 ) into the upper 
deltoid muscle of the left arm.  The time of investigational product administration will be 
recorded on the CRF.
Observe the subject for at least 30 minutes (or longer as per local practice) after the 
investigational product administration for any  acute reactions.  Record any  AEs obser ved 
during the 30 -minute observation period ;these AEs are defined as immediate AEs 
(Section 8).
Issue a subject e -diary  and provid e instruction on its completion.  Ask the parent(s)/legal 
guardian or subject to complete the e -diary  from Day 1 to Day 7 after vaccination. Day  1 
is the 
day of vaccination.
Issue a caliper, measuring tape/ruler, and a digital thermometer and provide instr uctions 
on their use.
Measuring tape/ruler data must be collected b y the parent(s)/legal guardian for minor 
subjects.  All data must be recorded in the e- diary  by the parent/legal guardian for minor 
subjects.
Ask the parent(s)/legal guardian or the subject to use the caliper to measure the maximum 
diameter of redness and swelling at the left arm injection site each day  for the 7 day s after 
study  vaccination and record in the e -diary  as described in Section 7.4.
Ask the parent(s)/legal guardian or the subject to contact the investigator immediately  if 
the subject experiences a severe redness or swelling (>20 caliper unit s) at the left arm 
injection site, a fever 39.0C (102.1F), or a severe headache within 7 days after 
vaccination, as an unscheduled visit should be arranged ( Section 6.4).
oIf the reaction exceeds the maximum size the caliper is able to measure (>21 caliper 
units, Section 7.4.1), the parent/ legal guardian or the subject should also use the 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 59measuring tape/ruler to measure the maximum diameter of redness and/or swelling at 
the injection site, and report this immediately  to the investigator. 
oAsk the parent(s)/legal guardian or subject to report the maximum diameter of the 
redness and/or swelling at the injection site to the investigator daily  until the reaction 
becomes  21 caliper units.
Ask the parent(s)/legal guardian or the subject to contact the i nvestigator immediately  if 
any significant illness or hospitalization occurs.
Schedule an appointment for the next study  visit and confirm that it is scheduled within 
the time window per protocol.
Ask the parent(s)/legal guardian or the subject to bring the e- diary  to the next visit.
Complete the source documents. 
Complete the CRF and update the investigational product accountability  records.
Between visits, review the e -diary  data online at frequent intervals. Contact the 
parent (s)/legal guardian or the subject to obtain stop dates for an y local reactions or systemic 
events, or use of antipy retic medication that were ongoing on the last day  that the e-diary  was 
completed.  The stop dates should be documented in the source documen ts and the 
information entered into the CRF at the next study  visit of the subject.
6.2.4. Visit 4 (28 to 42 Days After Visit 3), Post –Vaccination 2 Blood Draw
Ensure that the subject continues to be eligible for the study , and continues to comply  
with contracept ion requirements detailed in 
Section 4.5.
Ensure that the subject continues to meet none of the withdrawal criteria as described in 
Section 6.5and none of the temporary  delay  of blood draw criteria as described i n 
Section 4.4.
Collect the subject’s e -diary .
Review the subject’s e
-diary  data since the previous visit and follow up on any  ongoing 
reactogenicity  or use of antipy retic medication.
Complete the Study  Visit/Tel ephone Contact AE Checklist to:
oInquire whether the subject had an y newly diagnosed chronic medical conditions 
since the last visit.  I nquire whether the subject had any  of th e following related to an 
AE since the last visit: hospitalizations, visits to other medical facilities, medication 
use, or missed day s of school or work.  Please refer to 
the SRM for additional details.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 60oInquire about neuroinflammatory  and autoimmune condi tions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis. Please refer to the SRM for 
additional details.
Record AEs as described in the AE Reporting Requirements section ( Section 8) and the 
Schedule of Activities
.
Review AEs that were ongoing since the previous visit and record their end dates or 
confirm that they  are still continuing.
Record nonstudy vaccinations as described in the Concomitant Treatment (s)section 
(Section 5.11).
Record concomitant medications used to treat AEs as described in the Concomitant 
Treatment (s)section ( Section 5.11).
Provide the parent(s)/legal guar dian or the subject with a memory  aid. Instruct the subject 
to use the memory  aid between Visits 4 and 5 to remind him or her to review an y 
significant illnesses, hospitalizations, newly  diagnosed medical conditions ,or visits to a 
medical facility  with study  site personnel. The memory  aid is not a diary  for the 
collection of reactogenicity .  Please refer to the SRM and Section 7.3 foradditional 
details.
Collect a blood sample (approximately  20 mL).   Alternatively , for subjects who have 
consented to participate in the subset, depending on the consent obtained:
Collect approximately  50mL of bloo d, or
Collect approximately  100 mL  of blood.
At designated sites participating in collection of blood samples for exploratory purposes, 
the following additional procedures may  be completed:
oObtain written informed consent from subjects agreeing to the additional blood 
sample.  This consent may  be obtained at prior visits if appropriate.
oCollect a whole blood sample of approximately  50 mL  for exploratory  testing .  The 
maximum amount of blood to be obtained at this visit is 150 mL .
Ask the 
parent(s)/legal guardian or the subject to contact the investigator immediately  if 
any significant ill ness or hospitalization occurs.
Schedule a telephone contact and confirm that it is scheduled within the time window per 
protocol.
Complete the source documents.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 61Complet e the CRFs.
6.2.5. Visit 5 (168 to 196 Days After Last Vaccination), Telephone Contact
This telephone contact should occur approximately 6 months after the last Stage 1 study  
vaccination; this contact should be attempted for all subjects who have received at leas t 
1Stage 1 study  vaccination, unless they  have withdrawn consent.
Contact the parent(s)/legal guardian or the subject by  telephone.
Complete the Study  Visit/Telephone Contact AE Check list to:
oInquire about SAEs, newly  diagnosed chronic medical conditions, or AEs that 
resulted in evaluation at a medical facility  since the last visit.  Please refer to the SRM 
for additional details.
oInquire about neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple s clerosis. A checklist will be provided as 
a guide. Please refer to the SRM for additional details.
Report an y SAEs to the sponsor as defined in Section 8.
Record AEs as described in the AE Reporting Requirements section ( Section 8) and the 
Schedule of Activities
.
Record nonstudy vaccinations as described in the Concomitant Treatment (s)section 
(Section 5.11).
Record concomitant medications used to treat AEs as described in the Concomitant 
Treatment (s)section ( Section 5.11).
Review AEs that were ongoing since the previous visit and record their end dates or 
confirm that they  are still continuing .
Complete the source documents.
Complete the CRFs.
Inform subjects from the ACWY -
naive strat um to expect a telephone contact to confirm 
if they  are able to participate in Stage 2.
6.2.6. Visit 6 ( After Study Unblinding and P rior to Transition to Stage 2) Telephone 
Contact
Visit 6 will be conducted once the sponsor has informed the investigator if the subject may  
progress to Stage 2 (Section 5.5.1 ). Visit 6 must be conducted prior to Visit 7.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 62Notify the parent(s)/legal guardian or the subject by  telephone if the subject may  progress 
to Stage 2.
For subjects progressing to Stage 2, schedule an appointment for the next study  visit and 
confirm that it is scheduled within the time window per protocol .
6.3.Stage 2
Subjects from both the ACWY -naïve and ACWY -experienced strata, approximately  132 
from each of Groups 1 and 3 and approximately  65 from each of Groups 2 and 4, will 
participate in Stage 2.  Stage 1 will be observer -blinded and Stage 2 will be open -label . 
Investigators will be informed if a subject can be screen edfor Stage 2 based on a randoml y 
generated list of eligible subjects and a randomly  generated backup list to allow for 
replacement of subjects who decline participation in S tage 2 or are deemed ineligible after 
screening at Visit 7.
Visit 7 and Visit 8 should be conducted within no less than 30 day s ofeach other. If Visit 7 
cannot be conducted within the protocol- defined visit window, Visit 7 can be omitted and 
Visit 8 performed directly.
6.3.1. Visit 7(336 to 694 Days After Visit 3), Antibody Persistence Blood Draw 1
Obtain written informed consent, and assent if applicable, before performing further 
study -specific procedures.  The date of informed consent will be recorded on the CRF.
Ensure that the subj ect continues to be eligible for the study , meets none of the 
withdrawal criteria as described in Section 6.5, and meets none of the temporary  delay  of 
blood draw criteria as described in Section 4.4.
Record nonstud
y vaccinations as described in the Concomitant Treatment (s)section 
(Section 5.11).
Collec t a blood sample (approximately  20 mL).
Record concomitant medications used to treat AEs as described in the Concomitant 
Treatment (s)section ( Section 5.11).
Schedule an appointment for the next visit and confirm that it is scheduled within the 
time window per protocol.
Complete the source documents.
Complete the CRFs.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 636.3.2. Visit 8 (700 to 756 Days After Visit 3), Antibody Persistence Blood Draw 2
Ensure that the subject continues to be eligible for the study , meets none of the 
withdrawal criteria as described in Section 6.5, and meets none of the temporary  delay  of 
blood draw criteria as described in Section 4.4.
Record nonstud y vaccinations as described in the Concomitant Treatment (s)section 
(Section 5.11).
Collect a blood sample (approximately  20 mL).
Record an y AEs and research
-related inju ries(RRIs ) occurring within 48 hours after the 
Visit 7blood draw as described in Section 8.
Record concomitant medications used to treat AEs as described in the Concomitant 
Treatment (s)section ( Section 5.11).
Schedule a n appointment for the next visit and confirm that it is scheduled within the 
time window per protocol.
Complete the source documents.
Complete the CRFs.
6.3.3.
Visit 9 (1064 to 1120 Days After Visit 3), Antibody Persistence Blood Draw 3
Ensure that the subject continues to be eligible for the study , meets none of the 
withdrawal criteria as described in Section 6.5, and meets none of the temporary  delay  of 
blood draw criteria as described in Section 4.4.
Record nonstud y vaccinations as described in the Concomitant Treatment (s)section 
(Section 5.11).
Collect a blood sample (approximately  20 mL).
Record an y AEs and RRIs occu rring within 48 hours after the Visit 8blood draw as 
described in 
Section 8.
Record concomitant medications used to treat AEs as described in the Concomitant 
Treatment (s)section ( Section 5.11).
Schedule an appointment for the next visit and confirm that it is scheduled within the 
time window per protocol.
Complete the source documents.
Complete the CRFs.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 646.3.4. Visit 10 (1428 to 148 4Days After Vis it 3): Booster Vaccination
In the case of temporary  delay  of vaccination, procedures and assessments below will be 
redone or reconfirmed, as applicable, on the day  of vaccination.
Ensure that the subject continues to be eligible for the study , and continue s to comply  
with contraception requirements detailed in Section 4.5.
Ensure that the subject continues to meet none of the withdrawal criteria as described in 
Section 6.5and none of the temporary  delay  of vaccination or blood draw criteria as 
described in Section 4.3 and Section 4.4.
Record nonstud
y vaccinations as described in the Concomitant Treatment (s)section 
(Section 5.11).
Record an y antipy reticsand other pain medications received b y the subject on the day 
prior to investigational produ
ct administration as described in Section 5.11.
Record the presence of chronic conditions and/or medical history  of significance, 
including relevant surgical procedures and cardiac medical history that have been 
diagnosed since Visit 1.
Perform ph ysical examination evaluating an y clinically significant abnormalities within 
the following bod y systems: general appearance; skin;head, e yes, ears, nose, throat ;
heart ;lungs ;abdomen; extremities ;neurological ;musculoskeletal ;and ly mph nodes; 
including worsening of medical history  conditions.  Results must be recorded on source 
documents and the CRF.  Findings from a ph ysical examination conducted as part of 
standard routine care and before informed consent may  be used for purposes of the study  
only if the examination was performed no more than 2 day s before vaccination.  A brief 
examination must be performed on the day  of vaccination to document that no change in 
health has occurred in the interim.
On the day  of vaccination, perform a urine pregnancy  test on female subjects.  A negative 
pregnancy  test result is required before the subject may  receive the investigational 
product.
On the da y of and before vaccination, measure and record the subject’s oral temperature.
On the day  of and before vaccination, collect a blood sample (approximately  20 mL) 
from the subject.  Collect the blood sample only  if the subject is eligible for vaccination 
on the same day .
Administer a single 0.5 -mL intramuscular injection of either MenABCWY ( Groups
1
and3) or bivalent rL P2086 ( Groups 2and 4 ) into the upper deltoid muscle of the left 
arm; and MenACWY -CRM (Groups 2and 4 ) into the upper deltoid muscle of the right 
arm.  The time of investigational product administration will be recorded on the CRF .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 65Observe the subject for at least 30 minutes (or longer as per local practice) after the 
investigational product administration for any  acute reactions.  Record any AEs observed 
during the 30 -minute observation period ;these AEs are defined as immediate AEs 
(Section 8).
Record AEs as described in the AE Reporting Requirements section ( Section 8) and the 
Schedule of Activities
.  Time of onset will be recorded for any  AEs that occur on the 
same day  as investigational product administration.
Record concomitant medications used to treat AEs as described in th e Concomitant 
Treatment (s)section ( Section 5.11).
Issue a subject e -diary  and provide instruction on its completion.  Ask the parent(s)/legal 
guardian or subject to complete the e -diary  from Day 1 to Day 7 after vaccination. Day  1 
is the 
day of vaccination.
Issue a caliper, measuring tape/ruler, and a digital thermometer and provide instructions 
on their use.
Measuring tape/ruler data must be collected b y the parent(s)/legal guardian for minor 
subjects.  All data must be recorded in the e- diary  by the parent/legal guardian for minor 
subjects.
Ask the parent(s)/legal guardian or the subject to use the caliper to measure the maximum 
diameter of redness and swelling at the left arm injection site each day  for the 7 day s after 
study  vaccination and record in the e -diary  as described in Section 7.4.
Ask the parent(s)/legal guardian or the subject to contact the investigator immediately  if 
the subject experiences a severe redness or swelling (>20 caliper unit s) at the left arm 
injection site, a fever 39.0C (102.1F), or a severe headache within 7 days after 
vaccination, as an unscheduled visit should be arranged ( Section 6.4).
oIf the reaction exceeds the maximum size the caliper is able to measure (>21 caliper 
units, Section 7.4.1), the parent/legal guardian or the subject should also use the 
measuring tape/ruler to measure the maximum diameter of redness and/or swelling at 
the injection site, and report this immedi ately  to the investigator. 
oAsk the 
parent(s)/legal guardian or subject to report the maximum diameter of the 
redness and/or swelling at the injection site to the investigator daily  until the reaction 
becomes  21 caliper units.
Ask the parent(s)/legal guar dian or the subject to contact the investigator immediately  if 
any significant illness or hospitalization occurs.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 66Schedule an appointment for the next study  visit and confirm that it is scheduled within 
the time window per protocol.
Remind parent(s)/legal guardian or subject to bring the e -diary  to the next study  visit. 
Complete the source documents.
Complete the CRF and update the investigational product accountability  records.
Between visits, review the e -diary  data online at frequent intervals. Contact the 
parent(s)/legal guardian or the subject to obtain stop dates for an y local reactions, systemic 
events, or use of antipy retic medication that were ongoing on the last day  that the e -diary  was 
completed.  The stop dates should be documented in the source documents and the 
information entered into the CRF at the next study  visit of the subject.
6.3.5. Visit 11 (28 to 42 Days After Visit 10), Postbooster Blood Draw
Ensure that the subject continues to be eligible for the study , and continues to comply  
with contrac eption requirements detailed in 
Section 4.5.
Ensure that the subject continues to meet none of the withdrawal criteria as described in 
Section 6.5and none of the temporary  delay  of blood draw criteria as described in 
Section 4.4.
Collect t he subject’s e -diary .
Review the subject’s e
-diary  data since the previous visit and follow up on any ongoing 
reactogenicity  or use of antipy retic medication.
Complete the Study  Visit/Tel ephone Contact AE Checklist to:
oInquire whether the subject had an y newly  diagnosed chronic medical conditions 
since the last visit.  I nquire whether the subject had any  of the following related to an 
AE since the last visit: hospitalizations, visits to other medical facilities, medication 
use, or missed day s of school or w ork.  Please refer to the SRM for additional details.
oInquire about neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis. Please refer to the SRM for 
additional details.
Record AEs as des cribed in the AE Reporting Requirements section ( Section 8) and the 
Schedule of Activities
.
Review AEs that were ongoing since the previous visit and record their end dates or 
confirm that they  are still continuing.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 67Record nonstudy vaccinations as described in the Concomitant Treatment (s)section 
(Section 5.11).
Record concomitant medications used to treat AEs as described in the Concomitant 
Treatment (s)section ( Section 5.11).
Provide the parent(s)/legal guardian or the subject with a memory  aid. Instruct the 
subject to use the memory  aid between Visits 11and 12
to remind him or her to review 
any significant illnesses, hospitalizations, newly  diagnosed medical conditions, or visits 
to a medical facility  with study  site personnel. The memory  aid is not a diary  for the 
collection of reactogenicity .  Please refer to the SRM and Section 7.3 for additional 
details.
Collect a blood sample (approximately  20 mL).  Alternatively , for subjects who have 
consented to parti cipate in the subset, collect approximately
 100 mL of blood.  
Ask the parent(s)/legal guardian or the subject to contact the investigator immediately  if 
any significant illness or hospitalization occurs. 
Schedule a final telephone contact and confirm that it is scheduled within the time 
window per protocol.
Complete the source documents.
Complete the CRFs.
6.3.6. Visit 12 (168 to 196 Days After Booster Vaccination), Final Telephone Contact
The final telephone contact should occur approximately  6 months after 
the booster 
vaccination; this contact should be attempted for all subjects who have received the 
booster vaccination, unless they  have withdrawn consent.
Contact the parent(s)/legal guardian or the subject by  telephone.
Complete the Study  Visit/Tel ephone C ontact AE Checklist to:
oInquire about SAEs, newly  diagnosed chronic medical conditions, or AEs that 
resulted in evaluation at a medical facility  since the las t visit.  Please refer to the SRM 
for additional details.
oInquire about neuroinflammatory  and auto immune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis. Please refer to the SRM for 
additional details.
Report an y SAEs to the sponsor as defined in Section 8.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 68Record AEs as described in the AE Reporting Requirements section ( Section 8) and the 
Schedule of Activities
.
Record concomitant medications used to treat AEs as described in the Concomitant 
Treatment (s)section ( Section 5.11).
Review AEs that were ongoing since the previous visit and record their end dates or 
confirm that they  are still continuing .
Complete the sourc e documents.
Complete the CRFs.
6.4.Unscheduled Visits
If the subject experiences a severe redness or swelling at the left arm injection site 
(>20 caliper units), a temperature 39.0C (102.1F), or a severe headache in the 7 day s after 
vaccination ,a stud
y site visit should be arranged as soon as possible to assess the extent of 
the event.  The parent(s)/legal guardian or subject contact will be documented in the CRF.
If the reaction exceeds the maximum size the caliper is able to measure (>21 calip er units, 
Section 7.4.1), ensure the parent(s)/legal guardian or subject has also measured the maximum 
diameter of the redness and /or swelling at the injection site using the measuring tape/ruler 
provided.  Ask the 
parent(s)/legal guardian or subject to report the maximum diameter of the 
redness and/or swelling at the injection site daily  until the reaction becomes 21 caliper 
units.   Record these measurements in the CRF.
At an unscheduled visit, the subject’s oral temperature should be measured and the s ymptom 
that prompted the visit should be assessed b y a medically  qualified member of the study  staff.  
Findings will be recorded on the CRF.  If the subject experiences an y unsolicited AEs, these 
should be recorded on the AE CRF.
If the unscheduled visit does not take place following subject report of fever 39.0C, severe 
redness/swelling, or severe headache, the reason must be docume nted in the CRF 
(forexample, reaction no longer pr esent or e -diary entry  error).
For the purpose of assessments performed during unscheduled visits, a medically  qualified 
member of the stud y staff is a study ph ysician or a study  nurse, as applicable to th
e 
investigator’s local practice.
6.5.Subject Withdrawal
The investigator and/or sponsor may  withdraw a subject from the study  if deemed 
appropriate at an y time.  Eligibility  criteria as listed under inclusion criteria (refer to 
Section 4.1) and exclusion criteria (refer to Section 4.2)should be taken into consideration 
when determining if a subject must be withdrawn from the study . The investigator is not 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 69required to repeat the physical examination completed at Visit 1 or 10, unless clinically  
indicated.
Reasons wh y a subject may discontinue or be wi
thdrawn from the study  may  include, but are 
not limited to, AEs (including an y neuroinflammatory and autoimmune conditions, such as 
transverse m yelitis, uveitis, optic neuritis, and multiple sclerosis), parent(s)/legal guardian or 
subject request, investig ator request, death, discontinuation of the study  by the sponsor, 
protocol violation, and being lost to follow -up.  Subjects who have received investigational 
product will not be replaced.
An effort must be made to determine wh y a subject fails to return f or the necessary  visits or 
is withdrawn from the study .  Information detailing the circumstances leading to the 
withdrawal of a subject from the study , as well as the date of withdrawal, will be recorded on 
the study  outcome CRF.
The decision to withdraw a subject from the stud y should be discussed with the sponsor.  
Every  attempt must be made to collect all prompted reactogenicity  data, AEs, or SAEs 
following each vaccination.  Any  AEs or SAEs that are continuing at the time of withdrawal 
from the study  must be followed until the events have subsided, until values have returned to 
baseline, or, in case of permanent impairment, until the condition stabilizes.  When a subject 
discontinues or is withdrawn from the stud y, the invest igator will notify  the sponsor.
For subjects who withdraw during Stage 1, when possible, the investigator will perform the 
procedures indicated for the next visit, provide the subject with a memory  aid, and complete 
Visit 5 (telephone contact) if the subject has received at least 1 st udy vaccination.
For subjects who withdraw during Stage 2 between Visit 6and the booster vaccination, 
follow up on AEs as indicated above .
For subjects who withdraw during Stage 2 after having received the booster vaccination , 
when possible, the investigator will perform the procedures indicated for the next visit, 
provide the subject with a memory  aid, and complete Visit 12 (f inal telephone c ontact).
Subjects may withdraw from the study  at any  time at their own request, or they  may  be 
withdrawn a t any time at the discretion of the investigator or sponsor for safety (see also 
Withdrawal From the Study  Due to Adverse Events [Section 8.1.3]) or behavioral reasons, or 
the inability  of the subject to comply  with the protocol -required schedule of study  visits or 
procedures at a given study  site.
If a subject does not return for a scheduled visit, every  effort should be made to contact the 
subject.  
All attempts to contact the subject and information received during contact attempts 
must be documented in the subject’s medical record.  In an y circumstance, every  effort 
should be made to document subject outcome, if possible.  The inv estigator should inquire 
about the reason for withdrawal, request that the subject return for a final visit, if applicable, 
and follow up with the subject regarding an y unresolved AEs.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 70If the subject withdraws from the study , and also withdraws consent for disclosure of future 
information, no further evaluations should be performed, and no additional data should be 
collected.  The sponsor may  retain and continue to use any  data collected before such 
withdrawal of consent.
7.ASSESSMENTS
Every  effort should be made to ensure that the protocol-required tests and procedures are 
completed as described. However ,it is anticipated that from time to time there may  be 
circumstances outside of the control of the investigator that may  make it unfeasible to 
perform the t est. In these cases the investigator will take all steps necessar y to ensure the 
safet y and well -being of the subject. When a protocol -required test cannot be performed ,the 
investigator will document the reason for this and any corrective and preventive actions that 
heor she has taken to ensure that normal processes are adhered to as soon as possible. The 
study  team will be informed of these incidents in a timely  manner .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
7.1.Pregnancy Testing
For the purposes of pregnancy  testing in this study , all female subjects are considered to be 
of childbearing p otential.
For female subjects of childbearing potential, a urine pregnancy  test, with sensitivity  of at 
least 25 mIU/mL , will be performed immediately  before administration of each vaccine dose.  
A negative pregnancy  test result is required before the subj ect may  receive the investigational 
product.  Pregnancy  tests may  also be repeated if requested by  institutional review boards 
(IRBs)/ethics committees (ECs) or if required by  local regulations.  In the case of a positive 
confirmed pregnancy , the subject w ill be withdrawn from administration of investigational 
produc t but may  remain in the study .
7.2.
Biological Samples
Serum and whole blood samples will be used only  for scientific research.  Each sample will 
be labeled with a code so that the laboratory  personn el testing the samples will not know the 
subject’s identity .  Samples that remain after performing assay s outlined in the protocol may  
be stored b y Pfizer. Unless a time limitation is required by local regulations or ethical 
requirements, the samples wil l be stored for up to 15 y ears after the end of the study  and then 
destroy ed.
If allowed b y the informed consent document, stored samples may  be used for additional 
testing to better understand the immune responses to the vaccine(s) under study  in this 
protocol, to inform the development of other products, and/or for vaccine -related assay  work 
supporting vaccine programs.  No testing of the subject’s genet ic material will be performed.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 71A mechanism (eg, ICD addendum) will be established that enables testing of serum samples 
obtained during the study to assess for the preexistence of select AEs reported during study  
participation.
The subject /parent/legal guardian may request that his or her or child’s 
samples, if still 
identifiable, be destro yed at any  time; however, any  data already  collected from those 
samples will still be used for this research.  The biological samples may  be shared with other 
researchers as long as confidentiality  is maintained and no testing of the subject’s genetic 
material is perfor med.
7.2.1. Immunogenicity
To facilitate immunogenicity  anal yses, subjects will have approximately  20 mL  of blood 
collected as shown in Table 1andTable 2.  In order to support assay  development, a subset 
of up to approximately  600 subjects 18to 25 years of age will, depending on the consent 
obtained, have up to 100mL,rather than 20 mL ,of blood drawn at Visits 1, 2
,and 4 ; and a 
subset of up to approximately  150 subjects 18 to 25 years of age will have up to 100 mL , 
rather than 20 mL, of blood drawn at Visit 11.
Sample collection, storage, and shipping information can be found in the SRM.
Serum samples should be processed and stored as indicated in the SRM.  All serum samples 
should be stored in an upright position in a laboratory -grade manual -defrost freezer that does 
not undergo freeze -thaw cy cles and where ice must be removed manually . A frost -free 
freezer must not be used , as the continuous freeze- thaw cy cles of such freezers may  affect the 
integrit y of the samples.  The freezer must maintain a temperature of -15C or colder .
It is the responsibility  of the investi
gator(s) (or designee) to record dail y freezer temperature 
readings (working day s only ), to maintain a daily  temperature log for the freezer, and to alert
the sponsor of an y deviations. Deviations from storage requirements, including an y actions 
taken, must be document ed and reported to the sponsor. Guidance on temperature 
monitoring and procedures for the review of temperature deviations will be provided in the 
SRM.
7.2.2. Serum Bactericidal Assays
For assessment of the immune response, functional antibodies will be analyzed in hSBAs 
with meningococcal group A, B, C, W, and Y strains. The hSBA measures antibodies in 
human sera that result in complement
-dependent killing of th e target meningococcal s train.
Sera obtained from subjects at all time points as shown in Table 1and Table 2will be used in 
these assay s.  All MenA , MenC, Men W, and MenY assay sand MenB assay s using the 10 
secondary MnB test strains will be qualified before an y testing is performed. All MenB 
assay s using the 4 primary  MnB test strains will be validated before any  testing is performed.
SBAs will be conducted at one or both of the following laborator ies:
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 72Pfizer Vaccine Research -High Throughput Clinical Testing, 401 N Middletown Road, 
Pearl River, NY 10965, USA
Pharmaceutical Product Development, Inc, Bioanaly tical Laboratories, 2244 Dabney  
Road, Richmond, VA 23230, USA
7.2.2.1. Men B Serum Bactericidal Assays
For assessment of the immune response to bivalent rLP2086 and the B component of 
MenABCWY, 4 primary  MnB test strains, PMB80 (A22), PMB2001 (A56), PMB2948 
(B24), and PMB2707 (B44), will be used in the hSBAs for determination of the 
immunogenicit y endpoints in this study .
Validated hSBA LOD sand LLOQ sfor the 4 primary  strains are shown below.
Table 4. Validated hSBA LOD sand LLOQ s for the 4 Primary MenB Strains
Strain Variant LOD LLOQ
A22 1:4 1:16
A56 1:4 1:8
B24 1:4 1:8
B44 1:4 1:8
Abbreviations:  hSBA = serum bactericidal assay using human complement; 
LLOQ = lower limit of quantitation; LOD = limit of detection; MenB = Neisseria meningitidis group B.
Ten (10) secondary test strains will be used to perform hSBA testing so that at least 150
(125 from US investigative sites and 25 from other investigative sites) evaluable 
post-
Vaccination 2hSBA results are available for each secondary test strain. The hSBA 
assay s for the 10 secondary test strains will be performed on up to 750 subjects ( up to 
600subjects from US investigative sites and up to 150subjects from other investigative sites ,
as described in Step 2 below ) from Groups 2and 4 , combined.
Step 1: The 10 secondary test strains will be allocated across the 3 subsets. The first 2 subsets 
will each include 3 secondary  test strains and the last subset will in clude 4 secondary  test 
strains.
Step 2: Once all subjects have completed enrollment (Visit 1), the independent statistical 
center (I SC; a statistical team not involved in the conduct of the study ) will randomly  
allocate up to 600 US subjects (up to 200 per subset) and up to 150 subjects (up to 50 per 
subset) from other investigative sites from G roups 2and 4 across the 3 subsets.
Among the G roup 2 and 4 subjects, a maximum of 8 test strains (up to 4 additional test 
strains and 4 primary  test strains) may  be tested.
Stage 1 s era obtained prior to the first vaccination with bivalent rL P2086 and 1 month after 
the second vaccination with bivalent rL P2086 (Visit 4) will be used for hSBA testing on the 
10secondary test strains.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 73hSBAs have been qualified for the 10 secondary test strains.
Qualified hSBA LOD sand LLOQ sfor the 10 secondary  strains are shown below.
Table 5. Qualified hSBA LOD sand LLOQ s for the 10 S econdary MenB S trains
Strain Variant LOD LLOQ
A29 1:4 1:8
A06 1:4 1:16
A12 1:4 1:16
A07 1:4 1:8
A15 1:4 1:8
A19 1:4 1:16
B16 1:4 1:8
B09 1:4 1:8
B03 1:4 1:8
B15 1:4 1:8
Abbreviations:  hSBA = serum bactericidal assay using human complement; 
LLOQ = lower limit of quantitation; LOD = limit of detection; MenB = Neisseria meningitidis group B.
7.2.2.2. MenA, Men C, Men W, and MenY Serum Bactericidal Assays
For assessment of the immune response to MenACWY- CRM and the ACWY components of 
MenABCWY, test strains specific for each of the ACWY groups (A [PMB277 ], 
C [PMB3204] , W [PMB 6270 ], and Y [PMB3385 ]) will be used in the hSBAs for 
determination of the immunogenicity  endpoints in this study . The qualified LLOQs and 
LODs for the ACWY test strains are as follows:
Table 6. Qualified hSBA LODs and LLOQs for the ACWY Strains
Strain Variant LOD LLOQ
Men A 1:4 1:8
Men C 1:4 1:8
Men W 1:4 1:8
Men Y 1:4 1:8
Abbreviations:  hSBA = serum bactericidal assay using human complement; 
LLOQ = lower limit of quantitation; LOD = limit of detection; MenB = Neisseria meningitidis group B.
7.2.3. Exploratory Assays
At designated sites, an additional optional whole blood sample of approximately  50 mL will 
be obtained at Visit 4 from subjects who have consented to this.   This sample will be used for 
exploratory  purposes.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 747.3.Safety
Any subject who receives at least 1 dose of investigational product will be included in the 
evaluation for safet y.  The following safet y parameters will be assessed as described in the 
Study  Procedures section ( Section 6) and Schedule of Activities :
Physical examination.
Reactogenicit y: solicited local reactions and s ystemic events, including fever.
Use of antip yretic medication.
Unsolicited AEs and SAEs.
A medical history  will be obtained and a phy sical examination will be performed on all 
subjects at Visit 1 to establish a baseline , and at Visit 10prior to the booster vaccination .  
When taking the medical history  and performing the phy sical examination, particular care 
must be taken to note any  neuroinflammatory  and autoimmune conditions, such as transverse 
myelitis, uveitis, optic neuritis, and multiple sclerosis.  Significant medical history  and 
observations from the physical e xamination will be documented on the CRF.  In addition, a 
urine pregnancy  test will be performed on all female subjects.
The safet y parameters include reactogenicit y, ie, both local reactions and systemic events that 
occur in the 7 day s (Days 1 to 7) after investigational product administration.  These 
prompted e -diary  events are:
Local reactions at the site of investigational product administration (redness, swelling, 
and pain).
Systemic events (fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other 
than muscle pain at the injection site, and joint pain).
Local reactions, s ystemic events, and use of antipyretic medication associated with vaccine 
administration will be collected using an e -diary .  For events that resolve after D ay 7, the end
date will be collected in the symptoms resolved date CRF.  If a subject does not complete the 
e-diary  for 7 day s, end dates of local reactions, s ystemic events, or antip yretic medication use
that were ongoing on the last day  the e-diary  was completed by  the subject will be collected 
on the sy mptoms resolved date CRF.
Immediate AEs, defined as AEs occurring within the first 30 minutes after investigational 
product administration, will be assessed and documented on the AE CRF. The time of onset 
will be rec orded for any  AEs that occur on the same day  as investigational product 
administration.
Medically  attended AEs and newl y diagnosed chronic medical conditions will also be 
assessed throughout the study  and documented on the appropriate AE CRF.  A medicall y 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 75attended AEis defined as a nonserious AEthat results in an evaluation at a medical facility .  
A newl y diagnosed chronic medical condition is defined as a disease or medical condition, 
not previously  identified, that is expected to be persistent or otherw ise long-lasting in its 
effects.
AEs (serious and nonserious), newly diagnosed chronic medical conditions, and visits to 
other medical facilities will be assessed at study visits as specified in the Schedule of 
Activities and repo rted as defined in Section 8.  AE -related hospitalizations, visits to other 
medical facilities, medication use, and day s of school or work missed will be collected and 
recorded in the AE CRF.  Hospitalizations and visits to medical facilities not associated with 
an AE, such as elective hospitalizations, healthcare visits for preventive care ,or routine 
physical examinations ,will not be collected.  Non –AE- related concomitant medications and 
days of school or work missed not associated with an AE will not be collected.  A Study  
Visit/Telephone Contact AE Checklist will be used as a guide, will be completed at each 
scheduled stud y visit/ telephone contact ,
and will be included in the source documentation.  
Please refer to the SRM for details.
Subjects will be given a memory  aid at Visit 4 and Visit 1 1. The memory  aid will be used to 
remind subjects to review an y significant illnesses, hospitalizations, newly  diagnosed 
medical conditions, or visits to a medical facility  with study  site personnel. Subjects may  use 
the memory  aid as needed during the t eleph one contact at Visit 5 and Visit 12 to prompt 
recall of events.  These may  be used to assist in reporting and discussion of events with study  
staff, but these memory  aids will not be considered source documents and will not be 
collected at stud y visits.  O nly information collect ed by  study  staff as part of a study  visit or 
telephone contact (Visit 5 or 12) will be included in the source documents and entered into 
the CRF.
In addition, AEs and SAEs will be collected as defined in 
Section 8.
7.4.Electronic Diary
An e -diary  will be issued based on a personal digital assistant or equivalent technology , and 
used to monitor and record the subject’s local reactions, sy stemic events, and use of 
antipy retic medication for 7 days after each vaccination.  Grading scales fo r local reactions 
and sy stemic events are based on US FDA Guidance for Industry , Toxicity  Grading Scale for 
Health y Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials.42  
The e -diary  allows recording of these assessments only  within a fixed time -window, thus 
providing the accurate representation of the subj ect’s experience at that time.
For local reactions and sy stemic events that resolve after D ay7, the end date will be 
collected on the CRF.  If the e- diary  is not completed for 7 day s, the end dates of local 
reactions, s ystemic events ,or antipy retic medication use that occurred during the 7 day s will 
be collected on the CRF.  The investigator or designee should contact the parent(s)/legal 
guardian or subject in order to obtain stop dates for any  solicited reactions or other solicited 
data ongoing on the last day  that the e -diary  was com pleted.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 76Data reported on the e- diary  will be transferred electronicall y to the e -diary  vendor (a trusted 
third party ), where they  will be available for review by  investigators at all times via an 
Internet -based portal.  At intervals agreed upon between the vendor and Pfizer, these data 
will be transferred electronically  into Pfizer’s database for anal ysis and reporting.  These data 
do not need to be reported by  the investigator on the CRF.
Investigators will be required to review the e -diary data online at frequent intervals to 
evaluate subject compliance and as part of the ongoing safet y review.
7.4.1. Local Reactions
Local reactions (redness, swelling, and pain) at the site of investigational product 
administration will be recorded dail y for 7 days (Days 1 to 7) after each vaccination.   Only 
local reactions at the site of investigational product administration on the left arm will be 
recorded.
7.4.1.1. Redness and Swelling
Redness and swelling will be measured and recorded in caliper units (range: 1 to 21+), and 
then categ orized as none, mild, moderate, or severe based on the scale given inTable 7
below.  Each caliper unit represents 0.5 cm.  A caliper will be issued with instructions for 
measuring an y redness or swelling at the injection site.  The caliper will be used to measure 
and to report the largest diameter of a local reaction.  I n the event that a caliper measurement 
is between 2 values, the higher value should be reported.  The measurements will t hen be 
recorded in the e -diary .
In the event the reaction exceeds the maximum size the caliper is able to measure 
(>21 caliper units), the parent(s)/legal guardian or subject will also measure the maximum 
diameter of the redness and/or swelling at the injection site using the measuring tape/ruler 
provided and report this immediately  to the investigator.  The parent(s)/legal guardian or 
subject will report the maximum diameter of the redness and/or swelling at the injection site 
to the investigator daily  until the reaction becomes 21 caliper units.  These measurements 
will be recorded in the CRF.
Table 7. Grading of Redness and Swelling
None 0 to 2.0 cm (0 to 4 caliper units)
Mild >2.0to 5.0 cm (5 to 10 caliper units)
Moderate >5.0to 10.0 cm (11 to 20 caliper units)
Severe >10.0 cm (>20 caliper units)
7.4.1.2. Pain
If the subject experiences injection site pain, the pain will be graded using the scale in 
Table 8.  The assessment will then be recorded in the e -diary .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 77Table 8. Grading of Pain
Mild Does not interfere with activity
Moderate Interferes with activity
Severe Prevents daily activity
7.4.2. Systemic Events
7.4.2.1. Temperature
A digital thermometer will be given to the parent(s)/legal guardian or the subject with 
instructions on how to measure the subject’s oral temperature at home.  Oral temperature will 
be collected at in the evening daily for 7 days (Day 1 to Day 7) after each vaccination, and at 
any time during the 7 day s when fever is suspected.  The highest temperature for each day  
will be recorded in the e -diary .  Fever is defined as temperature of 38.0C (100.4F).
Temperature will be measured and recorded to 1 decimal place and then categorized 
according to the 
severit y scale inTable 9:
Table 9. Severit y Scale for Fever
Temperature 38.0 C to 38.4 C (100.4 F to 101.1 F)
Temperature 38.5 C to 38.9 C (101.2 F to 102.0 F)
Temperature 39.0 C to 40.0 C (102.1 F to 104.0 F)
Temperature >40.0 C (>104.0 F)
7.4.2.2. Other Systemic Events
The e -diary  will be used to record the presence of other systemic events, including vomiting, 
diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site, 
and joint pain daily  for 7 days (day 1 to day  7) after each vaccination, using the scales in 
Table 10.
Table 10. Grading of Other Systemic Events
Grade 1 (Mild) Grade 2 (Moderate) Grade 3 (Severe)
Vom iting 1 to 2 times in 24 hours >2 times in 24 hours Requires IV hydration
Diarrhea 2 to 3 loose stools in 
24hours4 to 5 loose stools in 
24hours6 or more loose stools in 
24 hours
Headache Does not interfere with 
activitySome interference with 
activityPrevents daily routine 
activity
Fatigue Does not interfere with 
activitySome interference with 
activityPrevents daily routine 
activity
Chills Does not interfere with 
activitySome interference with 
activityPrevents daily routine 
activity
Muscle pain (other than 
muscle pain at the injection 
site)Does not interfere with 
activitySome interference with 
activityPrevents daily routine 
activity
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 78Table 10. Grading of Other Systemic Events
Grade 1 (Mild) Grade 2 (Moderate) Grade 3 (Severe)
Joint pain Does not interfere with 
activitySome interference with 
activityPrevents daily routine 
activity
Abbreviation: IV = intravenous.
7.4.3. Use of Antipyretic Medication
The use of antip yretic medication will be recorded in the e -diary  daily  during the active 
safet y observation periods ( Day 1 to Day 7) for each vaccination.
7.5.Pilot Cohort Safety Assessments
After Vaccination 1, 7 -day e-diary  and AE data will be collected for each pilot cohort 
subject .  The se safet y data from the pilot cohort will be reviewed by the sponsor ’s IRCto
determine if the safet y, reactogenicity, and tolerability  profile of MenABCWY is sat isfactory  
and supports further enroll ment into the study .
The external data monitoring committee (EDMC) will not participate in the decision whether 
or not to open enrollment further after review of the pilot cohort safet y data, but will 
participate in review of safet y data from this study as detailed in the EDMC charter
(Section 9.7) .
8.ADVERSE EVENT REPORT ING
8.1.Requirements
The table below summarizes the requirements for recording safet y events on the CRF and for 
reporting safety  events on the Clinical Trial (CT) Serious Adverse Event (SAE) Report Form 
to Pfizer Safety .  These requirements are delineated for 3 ty pes of events: (1) SAEs ; (2) 
nonserious AEs; and (3) exposure to the investigational product under study during 
pregnancy  or breastfeedi ng, and occupational exposure.
Safety Event Recorded on the CRF Reported on the CT SAE Report 
Form  to Pfizer Safety Within 
24Hours of Awarenes s
SAE All All
Nonserious AE All None
Exposure to the investigational 
product under study during 
pregnancy or breastfeeding, and 
occupational exposureNone Exposure during pregnancy, 
exposure via breastfeeding, 
occupational exposure (regardless of 
whether associated with an AE)
All observed or volunteered events regardless of vaccine group or suspected causal 
relationship to the investigational product(s) will be reported as described in the following 
paragraphs.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 79Events listed in the table above that require reporting to Pfizer Safet y on the CT SAE Report 
Form within 24 hours of awareness of the event by  the investigator are to be reported 
regardless of whether the event is determined by the investigator to be related to an 
investigational product under study.  I n particular, if the SAE is fatal or life -threatening, 
notification to Pfizer Safety  must be made immediately , irrespective of the extent of available 
event information.  This time frame also applies to additional new (follow -up) information on 
previously  forwarded reports.  I n the rare situation that the investigator does not become 
immediately  aware of the occurrence of an event, the investigator must report the event 
within 24 hours after learning of it and document the time of his/her fir st awareness of the 
event.
If the investigator is aware of an SAE with an onset on the day  of investigational product 
administration or during the calendar day following investigational product administration, 
the investigator must contact the Pfizer study physician directl y immediately after sending 
the SAE report form to Pfizer as described above. The investigator must also contact the 
Pfizer study  physician directl y as soon as possible after becoming aware of an AE that 
required medical attention that be gan on the day  of investigational product administration or 
during the calendar day  following investigational product administration.  These procedures 
do not replace an y of the standard AE reporting requirements. Additional information 
regarding such events and the reporting requirements are included in the SRM.
For each event, the investigator must pursue and obtain adequate information both to 
determine the outcome and to assess whether it meets the criteria for classification as an SAE 
(see Serious Adverse Events [Section 8.2.3 ]below ).  In addition, the investigator may  be 
requested b y Pfizer Safety to obtain specific follow -up information in an expedited fashion.  
This information is more detailed than that recorded on the CRF .  In general, this will include 
a description of the event in sufficient detail to allow for a complete medical assessment of 
the case and indep endent determination of possible causalit y.  An y information relevant to 
the event, such as concomitant medications and illnesses, must be provided.  I n the case of a 
subject death, a summary of available autopsy  findings must be submitted as soon as possi ble 
to Pfizer Safety .  An y pertinent additional information must be reported on the CT SAE 
Report Form; additional source documents (eg, medical records, CRF, laboratory  data) are to 
be sent to Pfizer Safet y ONLY upon request.
As part of ongoing safet y rev iews conducted b y the sponsor, an y nonserious AE that is 
determined b y the sponsor to be serious will be reported by the sponsor as an SAE.  To assist 
in the determination of case seriousness, further information may  be requested from the 
investigator to p rovide clarity  and understanding of the event in the context of the clinical 
study .
8.1.1. Additional Details on Recording Adverse Events on the CRF
All events detailed in the table above will be recorded on the AE page(s) of the CRF.  I t 
should be noted that the
CT SAE Report Form for reporting of SAE information is not the 
same as the AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 80terminology  and the same AE term should be used on both the CRF and the CT SAE Report 
Form for reporting of SAE information.
8.1.2. Eliciting Adverse Event Information
The investigator is to record on the CRF all directly  observed AEs and all AEs spontaneously  
reported b y the stud y subject /parent(s)/legal guardian.  I n addition, each study  
subject/parent(s)/legal guardian will be questioned about the occurrence of AEs in a 
nonleading manner.
8.1.3. Withdrawal From the Study Due to Adverse Events (S ee Also the Subject 
Withdrawal Section)
Withdrawal due to AEs should be distinguished from withdrawal due to other causes, 
according to the definition of AE noted b elow, and recorded on the CRF.
When a subject withdraws from the study  because of an SAE, the SAE must be recorded on 
the CRF and reported, as appropriate, on the CT SAE Report Form, in accordance with the 
Requirements section 
(Section 8.1)above.
8.1.4.
Time Period for Collecting AE/SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each subject begins from the time the subject/parent(s)/legal guardian provides 
informed consent, which is obtained before the subject’s participation in the study  (ie, before 
undergoing an y stud y-related procedure and/or receiving investigational product), through 
and including Visit 4 , and from Visit 10 to Visit 11.
At M onth 12 (Visit 5: telephone contact), the parent(s)/legal guardian or subject will be 
contacted b y telephone to inquire about SAEs, newly  diagnosed chronic medical conditions,
or AEs that resulted in evaluation at a medical facility  since Visit 4.  These events must be 
recorded in the CRF and the event must be fo llowed.
At M onth 60 (Visit 1 2: final telephone contact), the parent(s)/legal guardian or subject will 
be contacted b y telephone to inquire about SAEs, newly diagnosed chronic medical 
conditions
,or AEs that resulted in evaluation at a medical facility  since Visit 11.  These 
events must be recorded in the CRF and the event must be followed.
At Visits 7, 8,and 9,the site will inquire about any AEs, as well as RRIs ( Section 8.2.4 ), for 
events occurring during the 48 -hour period after each blood draw.  These events must be 
recorded in the CRF and the event must be followed.
AEcollection is summarized in Table 11.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 81Table 11. Summary of Adverse Event Collection
Visits 1
-4 Visit 5 Visit 6 Visits 7-9 Visit s10-11 Visit 1 2
Approximate 
Month0-7 12 18-42 54-55 60
Nonserious AEs ICD through 
and including 
Visit 4Within 48 
hours of blood 
drawFrom  Visit 10
to Visit 11
SAEs ICD through 
and including 
Visit 4Since Visit 4 Nonactive SAE collection 
periodFrom  Visit 10
to Visit 11Since Visit 11
MAEs ICD through 
and including 
Visit 4Since Visit 4 From  Visit 10
to Visit 11Since Visit 1 1
NDCMC s ICD through 
and including 
Visit 4Since Visit 4 From  Visit 10
to Visit 11Since Visit 1 1
RRIs Within 48 
hours of blood 
draw
Abbreviations: ICD = informed consent document; MAE = medically attended adverse event; 
NDCMC = newly diagnosed chronic medical condition; RRI = research -related injury.
For subjects who are screen failures, the active collection period ends when screen failure 
status is determined.
8.1.4.1. Reporting SAEs to Pfizer Safety
All SAEs occurring in a subject during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form.
SAEs occurring in a subject after the active collection period has e nded are reported to Pfizer 
Safety  if the investigator becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility  of being related to investigational 
product must be reported to Pfizer Safety .
Follow -up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.
8.1.4.2. Recording Nonserious AEs and SAEs on the CRF
During the active collection period, both nonserious AEs and SAEs are recorded on the CRF.
Follow -up by  the investigator may  be required until the event or its sequelae resolve or 
stabilize at a level acceptable to the investigator, and Pfize r concurs with that assessment.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 828.1.5. Causality Assessment
The investigator’s assessment of causalit y must be provided for all AEs (serious and 
nonserious); the investigator must record the causal relationship on the CRF, and report such 
an assessment in accorda nce with the SAE reporting requirements, if applicable.  An 
investigator’s causalit y assessment is the determination of whether there exists a reasonable 
possibility  that the investigational product caused or contributed to an AE; generall y the facts 
(evid ence) or arguments to suggest a causal relationship should be provided.  If the 
investigator does not know whether or not the investigational product caused the event, then 
the event will be handled as “related to investigational product” for reporting pur poses, as 
defined b y the sponsor.  If the investigator's causality assessment is “unknown but not 
related” to investigational product, this should be clearl y documented on study  records.
In addition, if the investigator determines that an SAE is associated with study  procedures, 
the investigator must record this causal relationship in the source documents and CRF, and 
report such an assessment in the dedicated section of the CT SAE Report Form and in 
accordance with the SAE reporting requirements.
8.1.6. Sponsor’s Reporting Requirements to Regulatory Authorities
AE reporting, including suspected unexpected serious adverse reactions, will be carried out 
in accordance with applicable local regulations.
8.2.Definitions
8.2.1. Adverse Events
An AE is an y untoward medical occurrence in a study  subject administered a product or 
medical device; the event need not necessaril y have a causal relationship with the treatment 
or usage.  Examples of AEs include, but are not limited to:
Abnormal test findings;
Clinically  significant signs and sy mptoms;
Changes in ph ysical examination findings;
Hypersensitivity ;
Progression/worsening of underl ying disease ;
Drug abuse;
Drug dependency .
Additionally , AEs may  include signs and s ymptoms resulting from:
Drug overdose;
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 83Drug withdrawal;
Drug misuse; 
Drug interactions;
Extravasation;
Exposure during pregnancy  (EDP);
Exposure via breastfeeding;
Medication error;
Occupational exposure.
8.2.2. Abnormal Test Findings
Abnormal objective test findings should be recorded as AEs when an y of the following 
conditions are met: 
Test result is associated with accompan ying symptoms; and/or
Test result requires additional diagnostic testing or medical/surgical intervention; and/or
Test result leads to a change in stud y dosing (outside of an y protocol -specified dose
adjustments) or discontinuation from the study , significant additional concomitant drug 
treatment, or other therapy; and/or
Test result is considered to b e an AE b y the investigator or sponsor.
Merel y repeating an abnormal test, in the absence of an y of t he above conditions, does not 
constitute an AE.  An y abnormal test result that is determined to be an error does not require 
recording as an AE.
8.2.3. Serious Adverse Events
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospitalization or prolongation of existing hospitalization;
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life f unctions);
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 84Results in congenital anomaly/birth defect.
Or that is considered to be:
An important medical event .
Medical and scientific judgment is exercised in determining whether an event is an important 
medical event.  An important medical event may  not be immediately  life-threatening and/or 
result in death or hospitalization.  However, if it is determined that the event may  jeopardize 
the subject or may  require intervention to prevent one of the other AE outcomes, the 
important medical event should be re ported as serious.
Examples of such events are intensive treatment in an emergency  room or at home for 
allergic bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; 
or development of drug dependency  or drug abuse.
Medical de vice complaints may  meet the SAE reporting requirement criteria (see Medical 
Device Complaint Reporting Requirements [Section 8.5] ).  An incident is any  malfunction 
(ie, the failure of a device to meet its performance specifications or to perform as intended; 
performance specifications include all claims made in the labeling for the device) that, 
directly  or indirectl y, might lead to or might have led to the death of a subject, or user, or of 
other persons, or to a serious deteriora tion in their state of health.
A serious injury
 that can cause a serious deterioration in state of health can include:
Alife-threatening illness, even if temporary  in nature;
Apermanent impairment of a body function or permanent damage to a body structure; 
A condition necessitating medical or surgical intervention to prevent the above 2 bulleted 
items;
Examples: clinically  relevant increase in the duration of a surgical procedure; a condition 
that requires hospitalization or significant prolongation of existing hospitalization;
Any indirect harm as a consequence of an incorrect diagnostic or in vitro diagnostic 
device test results when used within the manufacturer’s instructions for use;
F
etal distress, fetal death, or an y congenital abnormality  or birth defects.
8.2.4. Research -Related Injury
Should a subject, in the investigator’s opinion, suffe r a medicall y important research related 
injury  caused b y their participation in the study , the designated Pfizer clinician or medical 
monitor must be notified immediately .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 85A medicall y important research related injury is any untoward medical occurrence t hat:
Results in death;
Is life -threatening (immediate risk of death);
Requires inpatient hospitalization or prolongation of existing hospitalization;
Results in persistent or significant disability /incapacity  (substantial disruption of the 
ability  to conduct normal life functions) ;
Results in congenital anomaly /birth defect.
Medical and scientific judgment is exercised in determining whether an injury is an 
important medical event.  An important medical event may  not be immediately  
life-threatening and /or result in death or hospitalization.  However, if it is determined that the 
event may  jeopardize the subject or may  require intervention to prevent one of the other 
outcomes listed in the definition above, the important medical event should be reported as a 
research -related injury .
An investigator may  be requested b y the designated Pfizer clinician or medical monitor to 
obtain specific additional follow -up information in an expedited fashion.  In general, this will 
include a description of the injury  in sufficient detail to allow for a complete medical 
assessment of the case and independent determination of possible causality.  I nformation on 
other possible causes of the event, such as concomitant treatments, vaccines, and/or illnesses 
must be provided.  In the case of a subject death, a summary  of available autopsy  findings 
must be submitted as soon as possible to Pfizer or its designated representative.
8.2.5. Hospitalization
Hospitalization is defined as any initial admission (even less than 24 hours) in a hos pital or 
equivalent healthcare facility , or any  prolongation of an existing admission.  Admission also 
includes transfer within the hospital to an acute/intensive care unit (eg, from the psy chiatric 
wing to a medical floor, medical floor to a coronary  care unit, or neurological floor to a 
tuberculosis unit).  An emergency  room visit does not necessarily constitute a hospitalization; 
however, the event leading to the emergency  room visit is assessed for medical importance.
Hospitalization does not include th e following:
Rehabilitation facilities;
Hospice facilities;
Respite care (eg, caregiver relief);
Skilled nursing facilities;
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 86Nursing homes;
Same -day surgeries (as outpatient/same -day/ambulatory  procedures).
Hospitalization or prolongation of hospitalizatio n in the absence of a precipitating clinical 
AE is not in itself an SAE.  Examples include:
Admission for treatment of a preexisting condition not associated with the development 
of a new AE or with a worsening of the preexisting condition (eg, for workup of a 
persistent pretreatment laboratory  abnormality );
Social admission (eg, subject has no place to sleep);
Administrative admission (eg, for yearly physical examination);
Protocol -specified admission during a stud y (eg, for a procedure required by the stu dy 
protocol);
Optional admission not associated with a precipitating clinical AE (eg, for elective 
cosmetic surgery );
Hospitalization for observation without a medical AE;
Preplanned treatments or surgical procedures.  These should be noted in the baseline
documentation for the entire protocol and/or for the individual subject .
Diagnostic and therapeutic noninvasive and invasive procedures, such as surgery , should not 
be reported as SAEs.  However, the medical condition for which the procedure was 
performed should be reported if it meets the definition of an SAE.  For example, an acute 
appendicitis that begins during the reporting period should be reported if the SAE 
requirements are met, and the resulting appendectomy  should be recorded as treatment of the 
AE.
8.3.Severity Assessment
GRADE If required on the AE page of the CRF, the investigator will use the adjectives MILD, 
MODERATE, orSEVERE to describe the maximum  intensity of the AE. For purposes of 
consistency, these intensity grades are defined as follows:
1 MILD Does not interfere with subject's usual function.
2 MODERATE Interferes to some extent with subject's usual function.
3 SEVERE Interferes significantly with subject's usual function.
Note the distinction between the severit y and the seriousness of an AE.  A severe event is not 
necessarily  an SAE.  For example, a headache may  be severe (interferes significantly  with 
the subject's usual function) but would not be classified as serious un less it met one of the 
criteria for SA Es, listed above.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 878.4.Special Situations
8.4.1. Protocol -Specified Serious Adverse Events
There are no protocol -specified SAEs in this study.  All SAEs will be reported to Pfizer 
Safety  by the investigator as described in previou s sections, and will be handled as SAEs in 
the safet y database.
8.4.2. Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who s how transient liver injury , but adapt 
are termed “adaptors.”  In some subjects, transaminase elevations are a harbinger of a more 
serious potential outcome.  These subjects fail to adapt and therefore are "susceptible" to 
progressive and serious liver inju ry, commonly  referred to as drug -induced liver injury  
(DILI).  Subjects who experience a transaminase elevation above 3 times the upper limit of 
normal ( ×ULN) should be monitored more frequently  to determine if they are an “adaptor” 
or are “susceptible.”
Liver function tests (LFTs) are not required as a routine safet y monitoring procedure in this 
study .  However, should an investigator deem it necessary  to assess LFTs because a subject 
presents with clinical signs/sy mptoms, such LFT results should be manag ed and followed as 
described below.
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (TBili) elevations (>2 ×ULN) by  several 
days or weeks.  The increase in TBili t ypically occurs while AST/ALT is/are still elevated 
above 3 ×ULN (ie, AST/AL T and TBili values will be elevated within the same lab sample).  
In rare instances, b y the time TBili elevations are detected, AST/ALT values might have 
decreased.  This occurren ce is still regarded as a potential DILI.
Therefore, abnormal elevations in either AST OR AL T in addition to TBili that meet the 
criteria outlined below are considered potential DILI (assessed per Hy ’s law criteria) cases
and should alway s be considered im portant medical events, even before all other possible 
causes of liver injury  have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the subject’s 
individual baseline values and underl ying conditions.  Subjects who present with the 
following laboratory  abnormalities should be evaluated further as potential DILI (Hy ’s law) 
cases to definitivel y determine the etiology of the abnormal laboratory  values:
Subjects with AST/AL T and TBili baseline values within the norm al range who 
subsequently  present with AST OR AL T values >3 ×ULN AND a TBili value >2 ×ULN 
with no evidence of hemoly sis and an alkaline phosphatase value <2 ×ULN or not 
available;
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 88For subjects with baseline AST OR ALT ORTBili values above the ULN, the following 
threshold values are used in the definition mentioned above, as needed, depending on 
which values are above the ULN at baseline:
oPreexisting AST or ALT baseline values above the normal range: AST or ALT values 
>2times the baseline values AND >3 ×ULN; or >8 ×ULN (whichever is smaller).
oPreexisting values of TBili above the normal range: TBili level increased from 
baseline value b y an amount of at least 1 × ULN orif the value reaches >3 × ULN 
(whichever is smaller).
Rises in AST/AL T and TBili s eparated b y more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the sponsor.
The subject should return to the inv estigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory
 tests, detailed his tory, and physical assessment.
In addition to repeating measurements of AST and AL T and TBili, laboratory  tests should 
include albumin, creatine kinase (CK), direct and indirect bilirubin, gamma -glutam yl 
transferase (GGT), prothrombin time (PT)/international normalized ratio (INR), tota l bile 
acids, alkaline phosphatase and acetaminophen drug and/or protein adduct levels.  
Consideration should also be given to drawing a separate tube of clotted blood and an 
anticoagulated tube of blood for further testing, as needed, for further contempo raneous 
analyses at the time of the recognized initial abnormalities to determine etiology .  A detailed 
history , including relevant information, such as review of ethanol, acetaminophen (either b y 
itself or as a coformulated product in prescription or over -the-counter medications) , 
recreational drug, supplement (herbal) use and consumption, family  history , sexual history , 
travel history , history  of contact with a jaundiced person, surgery , blood transfusion, history  
of liver or allergic disease, and potenti al occupational exposure to chemicals, should be 
collected.  Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging 
(eg, b iliary  tract) may  be warranted.
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
TBili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the LFT abnormalities has yet been found.  Such potential DILI (Hy’s law) 
cases are to be reported as SAEs, irrespective of availabili ty of all the results of the 
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy ’s law) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alte rnative etiology .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 898.4.3. Exposure to the Investigational Product During Pregnancy or Breastfeeding, and 
Occupational Exposure
Exposure to the investigational product under study  during pregnancy  or breastfeeding and 
occupational exposure are reportable to Pfizer Safety  within 24 hours of investigator 
awareness.
8.4.3.1. Exposure During Pregnancy
For both unapproved/unlicensed products and for marketed products, an EDP occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg , because of treatment or environmental exposure) to the investigational 
product; or the female becomes or is found to be pregnant after discontinuing and/or 
being exposed to the investigational product;
oAn example of environmental exposure would be a case involving direct contact with 
a Pfizer product in a pregnant woman (eg, a nurse reports that she is pregnant and has 
been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
investigat ional product prior to or around the time of conception and/or is exposed during 
his partner’s pregnancy .
If a subject or subject’s partner becomes or is found to be pregnant during the subject’s 
treatment with the investigational product, the investigator must report this information to 
Pfizer Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of 
whether an SAE has occurred.  In addition, the investigator must submit information 
regarding environmental exposure to a Pfizer product in a pregnant woman (eg, a subject 
reports that she is pregnant and has been exposed to a cy totoxic product by inhalation or 
spillage) to Pfizer Safety  using the EDP supplemental form.  This must be done irrespective 
of whether an AE has occurred and within 24 hours of awareness of the exposure.  The 
information submitted should include the anticipated date of delivery  (see below for 
information related to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pregnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the 
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus sho uld be assessed by  gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the findings are 
reported).
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 90If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortio n, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fetal demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information abou t pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed abortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard to 
causality , as SAEs.  In addition, infant deaths after 1 month should be reported as SAEs 
when the investigator assesses the infant death as related or possibly  related to exposure 
to the investigational product.
Additional information regarding the EDP may  be requested by  the sponsor.  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  In the case of paternal exposure, the 
investigator will provide the subject with the Pregnant Partner R elease of Information Form 
to deliver to his partner.  The investigator must document in the source documents that the 
subject was given the Pregnant Partner Release of Information Form to provide to his 
partner.
8.4.3.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfizer Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accord with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.
8.4.3.3. Occupational Exposure
An occupational exposure occurs when, during the performance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not perta in to a subject enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of the completed CT SAE Report 
Form is maintained in the investigator site file.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 918.4.4. Medication Errors and Lack of Efficacy
Other exposures to the investigational product under study  may  occur in clinical trial settings, 
such as medication errors and lack of efficacy .
Safety Event Recorded on the CRF Reported on the CT SAE Report Form  to 
Pfizer Safety Within 24 Hours of 
Awareness
Medication errors and lack of 
efficacyAll (regardless of whether 
associated with an AE)Only if associated with an SAE
8.4.4.1. Medication Errors
Medication errors may  result from the administration or consumption of the investigational 
product b y the wrong subject, or at the wrong time, or at the wrong dosage strength .
Medication errors include :
Medication errors involving subject exposure to the investigational product;
Potential medication errors or uses outside of what is foreseen in the protocol that do or 
do not involve the participatin g subject.
Other examples include but are not limited to:
The administration of expired investigational product.
The administration of an incorrect investigational product.
The administration of an incorrect dosage.
Administration of an investigational pro duct that has undergone temperature excursion 
from the specified storage range, unless it is determined prior to administration by  the 
sponsor that the investigational product under question is acceptable for use.
Such medication errors occurring to a stud y participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified immediately .
Whether o r not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 928.4.4.2. Lack of Efficacy
Lack of efficacy  in an approved indication should be reported as an SAE to Pfizer Safety .
8.5.Medical Device Complaint Reporting Requirements
All medical device complaints, regardless of whether the medical device complaint is 
associated with an AE, will be recorded on the applicable pages within the CRF.  This 
includes potential incidents or malfunctions associated with the use of a medical device 
product.  An incident or malfunction is an event that might have led to death or serious 
deterioration in health, or if it occurred again might lead to death or serious deterioration in 
health.
Pfizer is to be notified of all medical device complaints within 24 hours of the investigator’s 
awareness of the event.
Please note, no unblinded investigational product information should be entered on the 
medical device complaint CRF when reporting medical device complain ts.  Please refer to 
the IP manual for further details regarding reporting medical device complaints.
9. DATA ANALYSIS/STATIS TICAL METHODS
Methodology for summary  and statistical anal yses of the data collected in this study  is 
outlined here and will be furthe r detailed in a statistical anal ysis plan (SAP) . The SAP may  
modify  what is outlined in the protocol where appropriate (however, any  major modifications 
of the primary  endpoint definitions or their anal yses will also be reflected in a protocol 
amendment ) and will be finalized before data unblinding in Stage 1.
9.1.Sample Size Determination
Both h ypothesis testing and estimation will be performed.   The h ypothesis -testing component 
will address the need to confirm the immunogenicity  of bivalent rL P2086 administe red at 
Months 
0 and 6 in all subjects 10 through 25 years of age, using prespecified criteria for the 
primary  MnB immunogenicity  endpoints.  Safet y of bivalent rL P2086 administered at 
Months 0 and 6 will also be described.  Immunogenicity  and safet y inform ation for the 
MenABCWY arms will be described.
Hypothesis testing will be performed on the 5 coprimary  MnB endpoints in all subjects, 
which 
will include a 4 -fold rise from baseline in hSBA titers for each of the 4 primary  strains 
and the composite response (hSBA titer  LLOQ for all 4 primary  strains combined) 1 month 
after the second vaccination.  If the lower limit of the 2 -sided 95% confidence interval (CI) 
exceeds each of the target lower limit of theconfidence interval (LCI) values, the study ’s
primary  objective will be met.
The null hy pothesis will be that the true proportion of subjects is less than or equal to the 
target L CI criterion for 1or more primary  endpoints.  The alternate hy pothesis is that the true 
proportion of subjects for each o f the primary  immunogenicity  endpoints exceeds the target 
LCI.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 93Hypothesis testing will be performed by  calculating 2- sided 95% CIs on each of the 5 MnB 
endpoints limited to Groups 2 and 4 in which ACWY -naive and ACWY -experienced cohorts 
will be combined.  The Clopper -
Pearson method will be used to calculate the CIs for the 
proportions.  If the LCI exceeds the corresponding target L CI for each strain and the 
composite, then the null hypothesis will be rejected .
The study sample size is mainly based on h ypoth esis-testing criteria to verify  the clinical 
benefit of a 2- dose schedule for the use of bivalent rL P2086 administered at Months 0 and 
6in healthy  subjects 10 years to <26 years of age in both Group 2 and Group 4. Given the 
observed response proportions from Study  B1971012 for each endpoint, with 900 evaluable 
subjects , the primary  objective based on all 5 primary  endpoints will be met with a power of 
95.2% ( Table 12).  Furthermore, with 748 evaluable subjects from US sites, the L CI criteria 
for the primary  objective will also be met with a power of 89.9%. For the global study , 
assuming that~85% of enrolled subjects qualify  for the 
evaluable immunogenicity  
population, ~1060 subjects should be enrolled to receive bivalent rLP2086 and 
MenACWY -CRM.  This assumes that every  subject has sufficient sera for the 4 hSBAs.
Table 12. Overall Power to Meet the Primary Objectives
Prim ary Endpoint 
Test Strain 
(Variant)LCI Criteria Study B1971012 0 -
and 6 -Month 
Responses With 95% 
Confidence Interval 
(%)aNumber of 
Evaluable 
SubjectsPower
hSBA titer fold rise 
4 from baselinePMB80
(A22)LL of 95% CI 
>75%82.3
(76.3, 87.3)900 99.97 %
PMB2001 (A56) LL of 95%
CI >8590.1
(85.1, 93.8)900 99.60%
PMB2948 (B24) LL of 95%
CI >5564.5
(57.4, 71.1)900 99.99%
PMB2707 (B44) LL of 95%
CI >6066.0
(58.9, 72.6)900 95.7%
Com posite response
(hSBA titer 
LLOQ for all 4 
primary strains 
combined)LL of 95%
CI >6572.9
(65.9, 79.1)900 99.92 %
Overall pow er 95.2%
Abbreviations: hSBA = serum bactericidal assay using human complement; LCI = low er limit of the confidence 
interval; LL = lower limit; LLOQ = low er limit of quantitation.
a.The pow er calculation was based on Study B1971012 w ith a vaccine schedule of 0and6 month s.
An additional 530 subjects will be enrolled in the MenABCWY- MenABCWY regimen.  
Assuming 85% evaluable subjects, there will be 450 evaluable subjects in this regi men. 
These subjects will be further split between ACWY -naive and ACWY -experienced strata.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 94Given 530 subject sreceiving at least 1 dose of MenABCWY, the probability  of observing at 
least 1 AE will be 93.0% with a true incidence of 0.5% (see Table 13).
Table 13. Probabilities of Detecting AEs at Specified Incidences
Sample Size True Incidence of AE Probability of at Least 1 AE
530 0.01% 5.2%
530 0.10% 41.2%
530 0.25% 73.5%
530 0.50% 93.0%
530 1.00% 99.5%
A total of 1590 subjects will therefore be enrolled into this study .  The randomization will be 
performed separatel y for ACWY -naive and ACWY-experienced subjects.  Equal numbers of 
subjects will be recruited intoeach strat um.
9.2. Immunogenicity Analyses
Subjects having received a vaccine containing 1or more ACWY groups prior to enrol lment 
will be randomized in the ACWY -experienced str atum but, for the purposes of group A, C, 
W, and Y anal yses, will be considered A, C, W, Y- naive or - experienced based on what 
group(s) were present in the prior ACWY -containing vaccine.
For the calculation of GMTs, hSBA results below LLOQ will be set as ½ of LLOQ (see 
Table 4and Table 5).  Two (2)-sided 95% CIs will be provided f or all proportions and 
GMTs .
Exact 2 -sided 95% 
CIs will be compiled using the Clopper -Pearson method for any  
proportions of subjects with hSBA titers cutoff or L CI criteria.
Geometric means will be obtained by  log transformation of titers, averaging the transformed 
values, then exponentiating the results.  Ninety -
five percent CIs will also be obtained for the 
geometric means.  The CIs will be calculated in the log scale with reference to the 
appropriate t -distribution.  Then the lower and upper limits will be exponentiated.
9.2.1. Analysis of the Primary Immunogenicity Objective
The assessment of the MnB immune response induced b y bivalent rLP2086 will be 
performed b y compiling the proportions of subjects (point estimate) in the bivalent rLP2086
+MenA CWY -CRM vaccine groups (Group 2 –ACWY -
naive and 
Group 4 –ACWY -experienced) for each MnB coprimary  endpoint , along with the exact 
2-sided 95% CI for each endpoint .The primary  endpoints are defined as a 4-fold rise from 
baseline in hSBA titer as follows :
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 95For subjects with a baseline hSBA titer below the LOD (or an hSBA titer of <1:4), a 
4-fold response is defined as an hSBA titer of 1:16 or the LLOQ (whichever titer is 
higher).
F
or subjects with a baseline hSBA titer of LOD (ie, hSBA titer of 1:4) and < LLOQ, a 
4-fold response is defined as an hSBA titer of 4 times the LLOQ.
F
or subjects with a baseline hSBA titer of LLO Q, a 4 -fold response is defined as an 
hSBA titer of  4 times the baseline titer.
The composite endpoint defined as
the proportion of subjects achieving an hSBA titer LLOQ (1:16 for A22 and 1:8 for 
A56, B24 ,and B44) for all 4 primary  test strains combined .
If each of the LCIs meet sor exceeds the associated target L CI (Table 12),then the null 
hypothesis will be rejected , and the study  objective in terms of the immunogenicity  will be
met.
The evaluation for all 5 primary  endpoints will also be performed for US subjects only .
9.2.2. Analyses of the 
Secondary Objectives
The MnB immune response induced by 2 doses of bivalent rL P2086 will be described by 
compiling results for Groups 2 and 4 .
The MnB immune response induced b y 2 doses of MenABCWY (combined Groups 1 and 3) 
compared to the immune r esponse induced b y 2 doses of bivalent rLP2086 (combined 
Groups 2 and 4) will be described .
The ACWY immune response induced b y 1 dose of MenABCWY compared to the immune 
response induced b y 1 dose of MenACWY -CRM will be anal yzed forthe ACWY -naive and 
ACWY -experienced subjects separatel y.
The ACWY immune response induced b y 2 dose s of MenABCWY compared to the immune 
response induced b y 1 dose of MenACWY -CRM will be anal yzed forthe ACWY -naive and 
ACWY -experienced subjects separ ately.
Prior to the booster vaccination ,the immune response induced b y MenABCWY compared to 
the immune response induced b y MenACWY- CRM and bivalent rL P2086 will be described 
for ACWY test strains in ACWY -naive and ACWY- experienced subjects separately ,and for
MnB strains forthe ACW Y-naive and ACWY- experienced subjects combined , at each of the 
blood sample time points .
The following table shighlight the anal yses for the evaluation of the secondary  objective sfor 
immunogenicit y (all the anal yses are descriptive).
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 96Table 14. Highlights of the Analyses for the Secondary I mmunogenicity Objectives –
Stage 1
Vaccine Group Analysis Time Point Strain Analysis
Bivalent rLP2086 +
MenACWY -CRM 
(Group s2 and 4 
combined)1 Month after the second dose 
of bivalent rLP2086 (Visit 4)PMB80 (A22), PMB2001
(A56), PMB2948 (B24), 
PMB2707 (B44)Proportion of subjects 
with hSBA titer LLOQ 
for each strain
Proportion of subjects 
with hSBA titer 1;4, 
1;8,  1;16, 1;32, 1;64, 
1;128 for each strain
hSBA GMTs for each 
strain
Baseline and 1 month after the 
second dose of bivalent 
rLP2086 (Visit 1 and Visit 4)Each secondary MenB test 
strain (see Table 5)Proportion of subjects 
with hSBA titer LLOQ
Proportion of subjects 
with hSBA titer 1:4, 
1:8, 1:16, 1:32, 1:64, 
1:128 
hSBA GMTs
MenABCWY 
(ACWY -naive and 
ACWY- experience d
group sseparately)
MenACWY -CRM 
(ACWY -naive and 
ACWY- experience d
group sseparately )1 Month after the first dose of 
MenABCWY (Visit 2) for 
Group s1 and 3
1 Month after the first dose of 
MenACWY -CRM (Visit 2)
for Group s2 and 4hSBA -MenA, 
hSBA -MenC, 
hSBA -MenW, 
hSBA -MenYProportion of subjects 
with hSBA -MenA/C/ W/Y
titer 1:8 (or LLOQ , 
whichever is higher)
Proportion of subjects 
with hSBA -MenA/C/W/Y
titer 1:4, 1:8, 1:16, 
1:32, 1:64, 1:128 
hSBA -MenA/C/W/Y 
GMTs
MenABCWY 
(ACWY -naiveand 
ACWY- experience d 
groups separately)
MenACWY -CRM 
(ACWY -naive and 
ACWY- experience d
group sseparately )1 Month after the second dose 
of MenABCWY (Visit 4)
1 Month after the first dose of 
MenACWY -CRM (Visit 2)hSBA -MenA, 
hSBA -MenC, 
hSBA -MenW, 
hSBA -MenYProportion of subjects 
with hSBA -MenA/C/ W/Y 
titer 1:8 (or LLOQ, 
whichever is higher) 
Proportion of subjects 
with hSBA -MenA/C/W/Y
titer1:4, 1:8, 1:16, 
1:32, 1:64, 1:128 
hSBA -MenA/C/W/Y 
GMTs
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 97Table 14. Highlights of the Analyses for the Secondary I mmunogenicity Objectives –
Stage 1
Vaccine Group Analysis Time Point Strain Analysis
MenABCWY 
(ACWY -naiveand 
ACWY- experience d 
groups combined)1 Month after the second dose 
of MenABCWY (Visit 4)PMB80 (A22), PMB2001
(A56), PMB2948 (B24), 
PMB2707 (B44)Com posite response 
(proportion of subjects 
achieving an hSBA titer 
LLOQ for all 4 strains )
Proportion of subjects 
achieving at least a 4 -fold 
increase in hSBA titer 
from baseline for each of 
the 4 strains 
Proportion of subjects 
with hSBA titer LLOQ 
for each strain
Proportion of subjects 
with hSBA titer1:4, 
1:8, 1:16, 1:32, 1:64, 
1:128 for each strain
hSBA GMTs for each 
strain
MenABCWY 
(ACWY -naiveand 
ACWY- experience d 
groups separately)
Bivalent rLP2086 + 
MenACWY -CRM 
(ACWY -naive and 
ACWY- experience d 
groups separately )Before and after MenABCWY 
or MenACWY- CRM +
bivalent rLP2086 at Visits 1
and3 hSBA -MenA, 
hSBA -MenC, 
hSBA -MenW, 
hSBA -MenYProportion of subjects 
with hSBA -MenA/C/ W/Y 
titer 1:8 (or LLOQ ,
whichever is higher)
Proportion of subjects 
with hSBA -MenA/C/W/Y
titer 1:4, 1:8, 1:16, 
1:32, 1:64, 1:128 
hSBA -MenA/C/W/Y 
GMTs
MenABCWY 
(ACWY -naiveand 
ACWY- experience d 
groups combined)
Bivalent rLP2086 + 
MenACWY -CRM 
(ACWY -naive and 
ACWY- experience d 
groups combined)Before and after MenABCWY 
vaccination at Visit s 1and3 PMB80 (A22), PMB2001
(A56), PMB2948 (B24), 
PMB2707 (B44)Proportion of subjects 
with hSBA titer LLOQ 
for each strain
Proportion of subjects 
with hSBA titer1:4, 
1:8, 1:16, 1:32, 1:64, 
1:128 for each strain
hSBA GMTs for each 
strain
Abbreviations: GMT = geometric mean titer; hSBA = serum bactericidal assay using human complement; 
LLOQ = lower level of quantitation; MenA, MenB, MenC, MenW, and MenY = Neisseria meningitidis groups 
A, B, C, W, and Y.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 98Table 15. Highlights of the Analyses for the Secondary I mmunogenicity Objectives –
Persistence
Vaccine Group Analysis Time Point Strain Analysis
MenABCWY (ACWY -
naive and ACWY -
experienced groups 
separately )
Bivalent rLP2086 + 
MenACWY -CRM 
(ACWY -naive and 
ACWY- experienced 
groups separately )At Visits 7, 8, and 9, and 
before booster vaccination 
at Visit 10hSBA -MenA, 
hSBA -MenC, 
hSBA -MenW, 
hSBA -MenYProportion of subjects 
with hSBA -MenA/C/ W/Y 
titer 1:8 (or LLOQ , 
whichever is higher)
MenABCWY (A CWY -
naive and ACWY -
experienced groups 
combined)
Bivalent rLP2086 + 
MenACWY -CRM 
(ACWY -naiveand 
ACWY- experience d 
groups combined)At Visits 7, 8, and 9, and 
before booster vaccination 
at Visit 10PMB80 (A22), PMB2001
(A56), PMB2948 (B24), 
PMB2707 (B44)Proportion of subjects 
with hSBA titer ≥LLOQ 
for each strain
Abbreviations: GMT = geometric mean titer; hSBA = serum bactericidal assay using human complement; 
LLOQ = lower level of quantitation; MenA, MenB, MenC, MenW, and MenY = Neisseria meningitidis groups 
A, B, C, W, and Y.
Table 16. Highlights of the Analyses for the Secondary I mmunogenicity Objectives –
Booster
Vaccine Group Analysis Time Point Strain Analysis
MenABCWY (Gr oups 1
and 3 combined inStage 
2)1 Month after the booster 
dose of MenABCWY 
(Visit 1 1)PMB80 (A22), PMB2001
(A56), PMB2948 (B24), 
PMB2707 (B44)Proportion of subjects 
with hSBA titer LLOQ 
for each MnB strain
MenABCWY (Gr oups 1
and 3 separately inStage 
2)1 Month after the booster 
dose of MenABCWY 
(Visit 1 1)hSBA -MenA, 
hSBA -MenC, 
hSBA -MenW, 
hSBA -MenYProportion of subjects 
with 
hSBA -MenA/C/ W/Y titer 
1:8 (or LLOQ , 
whichever is higher)
Bivalent rLP2086 + 
MenACWY -CRM 
(Groups 2 and 4 
combined in Stage 2)1 Month after the booster 
dose of bivalent rLP2086 
+ MenACWY -CRM 
(Visit 1 1)PMB80 (A22), PMB2001
(A56), PMB2948 (B24), 
PMB2707 (B44)Proportion of subjects 
with hSBA titer LLOQ 
for each strain
Abbreviations: GMT = geometric mean titer; hSBA = serum bactericidal assay using human complement; 
LLOQ = lower level of quantitation; MenA, MenB, MenC, MenW, and MenY = Neisseria meningitidis groups 
A, B, C, W, and Y; MnB = Neisseria meningitidis group B.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 999.2.3. Analyses of Exploratory Objectives
The table below outlines the exploratory  anal ysis for immunogenicity.
Table 17. A nalyses for the Exploratory Immunogenicity Objectives –Stage s1 and 2
Vaccine Group Analysis Time Point Strain Analysis
Bivalent rLP2086 + 
MenACWY -CRM 
(ACWY -naive and 
ACWY- experience d 
groups combined: Groups
2 and 4 in Stage 1)1 Month after the first 
dose of bivalent rLP2086
+MenACWY -CRM 
(Visit 2)PMB80 (A22), PMB2001
(A56), PMB2948 (B24), 
PMB2707 (B44)Com posite response 
(proportion of subjects 
achieving an hSBA titer 
LLOQ for all 4 strains )
Proportion of subjects 
achieving at least a 4 -fold 
increase in hSBA titer 
from baseline for each of 
the 4 MnB strains 
Proportion of subjects 
with hSBA titer LLOQ 
for each MnB strain
Proportion of subjects 
with hSBA titer1:4, 
1:8, 1:16, 1:32, 1:64, 
1:128 for each MnB 
strain
hSBA GM Ts for each 
MnB strain
Bivalent rLP2086 +
MenACWY -CRM 
(Group s 2and 4separately 
in Stage 2)1 Month after the booster 
dose of bivalent rLP2086
+MenACWY -CRM 
(Visit 11)hSBA -MenA, 
hSBA -MenC, 
hSBA -MenW, 
hSBA -MenYProportion of subjects 
with hSBA -MenA/C/ W/Y 
titer 1:8 (or LLOQ ,
whichever is higher)
MenABCWY ( Groups 1 
and 3 separately )
Bivalent rLP2086 + 
MenACWY -CRM 
(Groups 2 and 4 
separately )At Visits 7, 8, and 9, and 
before booster vaccination 
at Visit 10hSBA -MenA, 
hSBA -MenC, 
hSBA -MenW, 
hSBA -MenYProportion of subjects 
with hSBA -MenA/C/W/Y
titer1:8, 1:16, 1:32, 
1:64,1:128 
hSBA -MenA/C/W/Y 
GMTs
MenABCWY ( Groups 1 
and 3 combined )
Bivalent rLP2086 + 
MenACWY -CRM 
(Groups 2 and 4 
combined )At Visits 7, 8, and 9, and 
before booster vaccination 
at Visit 10PMB80 (A22), PMB2001
(A56), PMB2948 (B24), 
PMB2707 (B44)Proportion of subjects 
with hSBA titer 1:4, 
1:8, 1:16, 1:32, 1:64, 
1:128 for each strain
hSBA GMTs for each 
strain
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 100Table 17. A nalyses for the Exploratory Immunogenicity Objectives –Stage s1 and 2
Vaccine Group Analysis Time Point Strain Analysis
MenABCWY (Gr oups 1
and 3combined in
Stage 2)1 Month after the booster 
dose of MenABCWY 
(Visit 1 1)PMB80 (A22), PMB2001
(A56), PMB2948 (B24), 
PMB2707 (B44)Com posite response 
(proportion of subjects 
achieving an hSBA titer 
LLOQ for all 4 MnB
strains )
Proportion of subjects 
achieving at least a 4 -fold 
increas ein hSBA titer 
from baseline for each of 
the 4 MnB strains 
Proportion of subjects 
with hSBA titer 1:4, 
1:8, 1:16, 1:32, 1:64, 
1:128 for each MnB 
strain
hSBA GM Ts for each 
MnB strain
MenABCWY (Gr oups 1
and 3 separately in
Stage 2)1 Month after the booster 
dose of MenABCWY 
(Visit 1 1)hSBA -MenA, 
hSBA -MenC, 
hSBA -MenW, 
hSBA -MenYProportion of subjects 
with hSBA -MenA/C/W/Y
titer1:8, 1:16, 1:32, 
1:64, 1:128 
hSBA -MenA/C/W/Y 
GMTs
Bivalent rLP2086 + 
MenACWY -CRM 
(Group s2 and 4 combined 
in Stage 2)1 Month after the booster 
dose of bivalent rLP2086 
+ MenACWY -CRM (Visit 
11)PMB80 (A22), PMB2001
(A56), PMB2948 (B24), 
PMB2707 (B44)Com posite response 
(proportion of subjects 
achieving an hSBA titer 
LLOQ for all 4 strains )
Proportion of subjects 
achieving at least a 4 -fold 
increase in hSBA titer 
from baseline for each of 
the 4 strains
Proportion of subjects 
with hSBA titer 1:4, 
1:8, 1:16, 1:32, 1:64, 
1:128 for each strain
hSBA GM Ts for each 
strain
Abbreviations: GMT = geometric mean titer; hSBA = serum bactericidal assay using human complement; 
LLOQ = lower level of quantitation; MenA, MenB, MenC, MenW, and MenY = Neisseria meningitidis groups 
A, B, C, W, and Y; MnB = Neisseria meningitidis group B.
The exploratory  anal ysis to investigate the association of the primary  strains and additional 
MenB testing strains, as well as a sensitivity  analy sisthat may  be performed for
immunogenicit y in Stage 1, will be detailed in the SAP.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 1019.3. Demographic and Baseline Characteristics
The following demographic characteristics will be descriptivel y summarized: sex, race, 
ethnicity , and age at first vaccination.  Medical history  and baseline phy sical examination 
data will also be descriptively  summarized.  Demographic characteristics will be summarized 
by cohort and by  combined cohorts.  Demographic characteristics will also be compiled for 
subjects participating in Stage 2 .
9.4.Safety Analyses
9.4.1. Analysis for S afety and Reactogenicity
The proportion of subjects re porting local reactions at the investigational product 
administration sites and sy stemic events within the 7 -day period after each vaccination will 
be descriptivel y summarized by  group.  Two (2)-sided 95% CIs based on the 
Clopper -Pearson method will be pre sented with the proportions.  Severities of local reactions 
and sy stemic events reported after each vaccination will also be descriptively  summarized by  
vaccine group.  Local reactions will be summarized only for the left arm, which is the 
MenABCWY or bivalent rLP2086 injection site.
The proportion of subjects reporting the use of antipy retic medication for Day s 1to 7 will be 
compiled for each vaccine group after each vaccination.
All AEs and SAEs will be categorized according to the latest version of the Medical 
Dictionary  for Regulatory  Activities (MedDRA).  A medicall y attended AE is defined as a 
nonserious AE that results in an evaluation at a medical facilit y.  A newl y diagnosed chronic 
medical condition is defined as a disease or medical condition not previously  identified that 
is expected to be persistent or otherwise long -lasting in its effects.  AEs, SAEs, medicall y 
attended AEs, and newl y diagnosed chronic med ical conditions will b e summarized by  
vaccine group.
All of the anal yses will be performed for each ACWY stratum as well as for the combined 
strata.  Safet y anal yses may  also be summarized by  other demographic variables.
Detailed analy ses for each safet y endpoint will be addressed in the SAP.
9.5.Analysis Population s
9.5.1. Full Analysis Set
The full anal ysis set will be referred to as the intent- to-treat (ITT) population.
9.5.2. Per-Protocol Analysis Set 
The per -protocol analy sis set will be referred to as the evaluable immunogenicity  population ,
which is the primary  population for the primary  objective assessm entsand for the analy ses of 
the 
secondary  endpoints related to MnB strains in Stage 1 .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 102All randomized subjects who are included in the Stage 1 modified intent- to-treat ( mITT)
population as well as who meet the following criteria will be included in the Stage 1 
evaluable immunogenicity  population :
1.Were randomized to the study  group of interest.
2.Were eligible, ie, fulfilling all of the inclusion criteria and none of the exclusion criteria.
3.Received all investigational products as randomized.
4.Had blood drawn for assay  testing within the required time frames at Months 0 (Visit 1: 
before V accination 1) and 7 (Visit 4: 1 month after the second vaccination: window 
28-42 day s).
5.Had as least 1 valid and determinate MenB assay  result after the second vaccination.
6.
Had no important protocol deviations. An important protocol deviation is a protocol 
deviation that, in the opinion of the sponsor’ s global medical monitor, would materially  
affect assessment of immunogenicity , eg, subject receipt of a prohibit ed vaccine or 
medication that might affect immune response or a medication error with suspected 
decrease in potency  of the vaccine.
An evaluable immunogenicity  population for booster response will be used for booster 
immunogenicit y anal ysis, which includes subjects who were eligible for the study  (ie,met all 
Stage 1and booster stage eligibility  criteria), received a booster dose as intended (same 
vaccine as they  received in Stage 1), hadblood drawn for assay  testing within the required 
time frame at Mont h 55 (Visit 11), andha
da valid and determinate MenB or MenA/C/W/Y 
assay  result after the booster dose , as well as no major protocol violations as determined by  
the sponsor’s global medical monitor. This population will be referred to as the booster
evaluable immunogenicity  population.
9.6.Modified Intent -to-Treat (mITT) P opulation
All randomized subjects who have at least 1 valid and determinate MenB or MenA/C/W/Y
assay  result available at any  time point from Visit 1 to Visit 4 will be included in the mITT 
population for S tage 1. This will be the primary  immunogenici ty population for the analy ses
of the secondary  endpoints related to ACWY endpoints in Stage 1.
The mITT population for Stage 2 is defined as all subjects who signed informed consent at 
Visit 7 and who have at least 1 valid and determinate MenB or MenA/C/W/Y assay  result 
available in Stage 2.
The mITT populations will be used for the evaluation of th e primary , secondary , and 
exploratory immunogenicity  endpoints
,and subjects will be anal yzed according to the 
investigational product to which they were randomized. E ndpoints to assess antibody  
persistence will include subjects in the Stage 2 m ITT populat ion.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 103Subjects included in the sentinel cohort will be included in the Stage 1 mITT population for 
immunogenicit y anal yses.
A booster mITT immunogenicity  population will also be defined for supportive anal yses for 
booster endpoints. This population will con sist of subjects who received a booster 
vaccination and who have an y booster immunogenicity  data.
9.7.Safety Analysis Set
The safet y population will be used for all safet y analyses. The safet y population for Stage 1 
will include all subjects who have received at least 1dose of investigational product during 
Stage 1 and for whom safety  data are available. The safet y population for Stage 2 will 
include all subjects who received the booster vaccination and for whom safety  data are 
available. For the safet y analysis, subjects will be anal yzed according to the in vestigational 
product received. Additionally , a persistence safety  population will include all subjects who 
signed the informed consent to participate in Stage 2.
Separate safet y populations will be define d for each vaccination visit and follow -up phase : 
V
accination 1, V accination 2, follow -up phase for Stage 1, booster vaccination visit, and 
follow -up phase for Stage 2 . These populations are detailed below.
1.Vaccination 1 safety population: This population will include all subjects who receive d
the first dose of investigational product (MenABCWY
+ saline or bivalent rLP2086 + 
MenACWY -CRM) at V isit 1, and for whom safety information from Visit1 to before
V
isit 3 is available.
2.Vaccination 2 safety population: This population will include all subjects who receive d
the second dose of investigational product (MenABCWY or bivalent rL P2086) at Visit 3, 
and for whom safet y information from 
Visit 3 up to and including Visit 4 is available.
3.Follow -up s afety population for Stage 1: This population will include all subjects who 
received at least 1 dose of investigational product and for whom safet y information is 
available from after V
isit 4 up to and including V isit 5. Subjects who receive dthe wrong 
investigational pro duct and are followed for 6 months for safet y will not be included in 
this population.
4.Booster vaccination safety  population: This population will include all subjects who 
receive d
the booster dose of investigational product (MenABCWY or b ivalent rL P2086) 
at Visit 10, and for whom safet y information from V isit 10 up to and including Visit 11 is 
available.
5.Follow -up s afety population for Stage 2: This population will include all subjects who 
received the booster dose of investigational product and for whom s afety information is 
available from after V
isit 11 up to and including V isit 12. Subjects who receive dthe 
wrong investigational product and are followed for 6 months forsafet y will not be 
included in this population.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 1049.8.Analysis Timing
No formal interim ana lyses are planned for this study .
The study  database will be unblinded after the last subject has completed the Visit 5 
telephone contact.
Analy ses will be completed after Stage 1 and after Stage 2. The Stage 1 analy ses will 
include immunogenicit y analyses up to and including the post–Vaccination 2 blood draw 
(approximately  1 month after Vaccination 2) and safet y assessments up to and including the 
Visit 5 
telephone contact (approximately 6 months aft er Vaccination 2).
The Stage 2 anal yses (persistence and booster analy ses) will include all data collected after 
Visit 5 through the end of the study .
After unblinding following the completion of Stage 1 (through Visit 5) and testing the 
hypothesis associated with the primary  immunogenicity  objective, interim summaries of 
immunogenicit y and safety data may  be generated. The alpha level (confidence level of 95% 
CIs) will not be adjusted for these descriptive summaries.
9.9.Data Monitoring Committee
This study will use an EDMC.  The ISCwill provide unblinded safet y reports to the EDMC
for review .  Safet y data will be reviewed b y the EDMC throughout the study  and no t ype I 
error will be adjusted for the multiple looks at the data.
The EDMC will be responsi ble for ongoing monitoring of the safety  of subjects in the study  
according to the charter. The recommendations made b y the EDMC to alter the conduct of 
the study  will be forwarded to Pfizer for final decision.  Pfizer will forward such decisions, 
which ma y include summaries of aggregate analyses of endpoint events and of safet y data 
that are not endpoints, to regulatory  authorities, as appropriate.
Please see the EDMC charter for further details.
10.QUALITY CONTROL AND QUALITY ASSURANCE
Pfizer or its agent wi ll conduct periodic monitoring visits during stud y conduct to ensure that 
the protocol and GCPs are being followed.  The monitors may  review source documents to 
confirm that the data recorded on CRFs areaccurate.  The investigator and institution will 
allow Pfizer monitors /auditors or its agents and appropriate regulatory  authorities direct 
access to source documents to perform this verification.
  This verification may  also occur 
after stud y completion.
During stud y conduct and/or after stud y completion, t he investigator 
site may  be subject to 
review b y the IRB/EC , and/or to quality  assurance audits performed by  Pfizer, or companies 
working with or on behalf of Pfizer, and/or to inspection by  appropriate regulatory  
authorities.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 105The investigator(s) will noti fy Pfizer or its agents immediately  of any  regulatory  inspection 
notification in relation to the study . Furthermore, the investigator will cooperate with Pfizer 
or its agents to prepare the investigator site for the inspection and will allow Pfizer or its
agent, whenever feasible, to be present during the inspection.  The investigator site and 
investigator will promptly resolve an y discrepancies that are identified between the stud y 
data and the subject's medical records.
The investigator will promptly  provide copies of the inspection findings to Pfizer or its agent.  
Before response submission to the regulatory  authorities, the investigator will provide Pfizer 
or its agents with an opportunity  to review and comment on responses to any  such findings.
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits or inspections and that sufficient time is devoted to the 
process.
11.DATA HANDLING AND RECORD KEEPING
11.1. Case Report Forms/Electronic Data Record
As used in this protocol, the term CRF should be understood to refer to either a paper form or 
an electronic data record or both, depending on the data collection method used in this study .
A CRF is required and should be completed for each inc luded subject.  The completed 
original CRFs are the sole propert y of Pfizer and should not be made available in any form to 
third parties, except for authorized representatives of Pfizer or appropriate regulatory  
authorities, without written permission fro m Pfizer.
The investigator has ultimate responsibility  for the collection and reporting of all clinical, 
safet y
,and laboratory  data entered on the CRFs and any  other data collection forms (source 
documents) and ensuring th at they  are accurate, authentic /original, attributable, complete, 
consistent, legible, timely  (contemporaneous), enduring ,and available when required.  The 
CRFs must be signed b y the investigator or b y an authorized staff member to attest that the 
data contained on the CRFs aretrue. Any correcti ons to entries made in the CRFs or source 
documents must be dated, initialed ,and explained (if necessary ) and should not obscure the 
original entry .
In most cases, the source documents are the hospital or the ph ysician subject chart.  In these 
cases,data collected on the CRFs must match the data in those charts.
In some cases, the CRF may  also serve as the source document.  In these cases, a document 
should be available at the investigator site and at Pfizer that clearl y identifies those data th at 
will be recorded on the CRF, and for which the CRF will stand as the source document.
11.2. Record Retention
To enable evaluations and/or 
inspections/ audits from regulatory  authorities or Pfizer, the 
investigator agrees to keep records, including the identity of all participating subjects 
(sufficient information to link records, eg, CRFs and hospital records), all original signed 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 106informed consent /assent documents , copies of all CRFs, safet y reporting forms, source 
documents, and detailed records of treatment disposition, and adequate documentation of 
relevant correspondence ( eg,letters, meeting minutes, and telephone call reports).  The 
records should be retained by the investigator according to the ICH guidelines , according to 
local regulations, or as specified in the clinical study agreement (CSA) , whichever is longer.
If the investigator becomes unable for an y reason to continue to retain study records for the 
required period ( eg, retirement, reloc ation), Pfizer should be prospectivel y notified.  The 
study  records must be transferred to a designee acceptable to Pfizer , such as another 
investigator, another institution, or an independent third party  arranged by  Pfizer.
Investigator records must be ke pt for a minimum of 15 y ears after completion or 
discontinuation of the study
 or for longer if required by applicable local regulations.
The investigator must obtain Pfizer's written permission before disposing of an y records, 
even if retention requirement s have been met.
12.ETHICS
12.1. Institutional Review Board/Ethics Committee
It is the responsibility  of the investigator to have prospective approval of the study  protocol, 
protocol amendments, informed consent /assent documents , and other relevant documents, 
eg,recruitment advertisements, if applicable, from the I RB/EC.  All correspondence with the
IRB/EC should be retained in the investigator f ile.  Copies of IRB/EC approvals should be 
forwarded to Pfizer.
The only  circumstance in which an amendment may  be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In 
that event, the investigator must notify  the IRB/EC and Pfizer in writing im mediately  after 
the implementation.
12.2. Ethical Conduct of the Study
The study  will be conducted in accordance with the protocol, legal and regulatory  
requirements and the general principles set forth in the I nternational Ethical Guidelines for 
Biomedical Rese arch Involving Human Subjects (Council for International Organizations of 
Medical Sciences 2002), ICH Guideline for G ood Clinical Practice , and the Declaration of 
Helsinki .
12.3. Subject Information and Consent
All parties will ensure protection of subject perso nal data and will not include subject names 
or other identifiable data in any reports, publications, or other disclosures, except where
required b y law.
When study  data are compiled for transfer to Pfizer and other authorized parties, s ubject 
name s, addre sses, and other identifiable data will be replaced b y numerical code sbased on a 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 107numbering s ystem provided by  Pfizer in order to de -identify  study  subject s . The investigator
site will maintain a confidential list of subjects who participated in the study ,linking each 
subject’s numerical code to his or her actual identity .  In case of data transfer, Pfizer will 
maintain high standards of confidentialit y and protection of subjects’ personal data consistent 
with applicable privacy  laws .
The informed consent /assent document sand an y subject recruitment materials must be in 
compliance with ICH GCP, local regulatory  requirements, and legal requirements, including 
applicable privacy  laws .
The informed consent /assent document s used during the informed consent proc ess and any  
subject recruitment materials must be reviewed and approved by Pfizer , approved b y the 
IRB/EC before use , and avai lable for inspection.
The investigator must ensure that each study  subject ,or his or her parent(s) or legal guardian 
if a minor
,is fully  informed about the nature and objectives of the study and possible risks 
associated with participation.
Whenever consent is obtained from a subject’s parent(s) or legal guardian, the subject’s 
assent (affirmative agreement) must subsequently be o btained when the subject has the 
capacity  to provide assent, as determined by  the IRB/EC.  If the investigator determines that 
a subject’s decisional capacity  is so limited he/she cannot reasonabl y be cons ulted, then, as 
permitted by  the IRB/EC and consist ent with local regulatory  and legal requirements, the 
subject’s assent may  be waived with source documentation of the reason assent was not 
obtained.  If the stud y subject does not provide hisor herown consent, the source documents
must record why the su bject did not provide consent (eg , minor, decisionally  impaired adult), 
how the investigator determined that the person signing the consent was the subject’s legal ly 
acceptable representative, the consent signer’s relat
ionship to the study subject (eg , parent, 
spouse) , and that the subject’s assent was obtained or waived.  If assent is obtained verbally,
it must be documented in the source documents.
A study -specific assent form will be provided to pediatric subjects as required by  local 
regulations.  I t isto be understood as the adolescent's will to participate in a trial after having 
received age -appropriate information and is sometimes also referred to as "knowing 
agreement ."  If the stud y includes minor subjects who reach the age of majority  during the 
study , as recognized under local law, they  must reconsent as adults to remain in the study . If 
the enrollment of emancipated minors is permitted by  the study  age criteria, the IRB/EC , and 
local law, they  must provide documentation of legal status to give consent without the 
permission of a parent or legal guardian.
The investigator, or a person designated b y the investigator, will obtain written informed 
consent from each subject or parent(s) or legal guardian and the subject’s assent, when 
applicable ,before any  study -specific activity  is performe d, unless a waiver of informed 
consent has been granted by  an IRB/EC . The investigator will retain the original of each 
subject's signed consent /assent document .
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 10812.4. Reporting of Safety Issues and S erious Breaches of the Protocol or ICH GCP
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of any  new 
information that 
might influence the evaluation of the benefits and risks of the investigational 
product, Pfizer s hould be informed immediately .
In addition, the investigator will inform Pfizer immediately o f any urgent safet y measures 
taken b y the investigator to protect the study subjects against an y immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the investigator becomes aware of.
13.DEFINITION OF END OF TRIAL
13.1. End of Trial in a Member State 
End of 
trial in a Member State of the European Union is defined as the time at which it is 
deemed that a sufficient number of subjects have been recruited and completed the study  as 
stated in the regulatory  application (i e,clinical trial application [CTA ]) and ethics application 
in the Member State.  Poor recruitment (recruiting less than the anticipated number in the 
CTA) by  a Member State is not a reason for premature termination but is considered a 
normal conclusion to the study  in that Member State.
13.2. End of Trial in A llOther Participating Countries
End of trial in all other participating countries is defined as l ast subject last visit (LSLV).
14.SPONSOR DISCONTINUAT ION CRITERIA
Premature termination of this study  may  occur because of a regulatory  authority  decision, 
change in opinion of the IRB/EC , orinvestigational product safety  problems, or at the 
discretion of Pfizer.  In addition, Pfizer retains the right to discontinue dev elopment of
bivalent rL P2086, 
MenACWY -TT, and/or MenABCWY at an y time.
If a stud y is prematurel y terminated, Pfizer will promptly  notify  the investigator.  After 
notification, the investigator must contact all participating subjects and the hospital pharma cy 
(if applicable) immediately .  As directed b y Pfizer, all study  materials must be collected and 
all CRFs completed to the greatest extent possible.
15.PUBLICATION OF STUDY RESULTS
15.1. Communication of Results by Pfizer
Pfizer fulfills its commitment to publicly  disclose clinical trial results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/ or www.pfizer.com, and other public regis tries in accordance with 
applicable local laws/regulations.
In all cases, stud y results are reported b y Pfizer in an objective, accurate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the stud y was conducted.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 109www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer- sponsored 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
Pfizer product , regardless of the geographical location in which the study  is conducted.  US 
Basic Results are submitted for posting within 1 year of the primary  completion date (PCD) 
for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final subject was examined or received an intervention for 
the purposes of final collection of data for the primary  outcome, whether the clinical study  
concluded according to the pre specified protocol or was terminated.
EudraCT
Pfizer posts European Union ( EU)Basic Results on EudraCT for all Pfizer -sponsored 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts Public Disclosure Sy nopses (clinical study  report sy nopses in which any  data 
that could be used to identify  individual patients has been removed) on www.pfizer.com for 
Pfizer -sponsored interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov .
15.2. Publications by Investigators
Pfizer supports the exercise of academic freedom and has no objection to publication by  the 
principal i nvestigator (PI) of the results of the study based on information collected or 
generated b y the 
PI, whether or not the results are favorable to the Pfizer product.  However, 
to ensure aga inst inadvertent disclosure of confidential i nformation or unp rotected 
inventions, 
the investigator will provide Pfizer an opportunity  to review any  proposed 
publication or other t ype of disclosure of the results of the s tudy (collectively , “publication”) 
before it is submitted or otherwise disclosed.
The i nvestigato r will provide 
any publication to Pfizer at least 30 day s before it is submitted 
for publication or otherwise disclosed. If any patent action is required to protect intellectual 
propert y rights, the investigator agrees to delay  the disclosure for a period not to exceed an 
additional 60 day s.
The i nvestigator will, on request, remove an y previously  undisclosed confidential 
information bef ore disclosure, except for any  study-or Pfizer product -related information 
necessary  to the appropriate scientific prese ntation or understanding of the s tudy results.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 110If the study  is part of a multi centerstudy , the investigator agrees that the first publication is 
to be a joint publication covering all investigator sites, and that an y subsequent 
publications 
bythe PI willreference that primary  publication . However, if a joint manuscript has not 
been submitted for publication within 12 months of co mpletion or termination of the s tudy at 
all participating sites, the investigator is free to publish separatel y, subject to the other 
requirements of this s ection.
For all publications relating to the study, the i nstitution will comply  with recognized ethical 
standards concerning publications and authorship, including Section II -“Ethical 
Considerations in the Conduct and Report ing of Research” of the Uniform Requirements for 
Manuscripts Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, 
established by  the International Committee of Medical Journal Editors.
Publication of study  results is also provided for in the CSA between Pfizer and the 
institution.  I n this section entitled Publications by  Investigators, the defined terms shall have 
the meanings given to them in the CSA.
If there is an y conflict between the CSA and an y a
ttachments to it, the terms of the CSA 
control.  If there is an y conflict between this protocol and the CSA, this protocol will control 
as to any  issue regarding treatment of s tudy subjects, and the CSA will control as to all other 
issues.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 11116.REFERENCES
1.Rosenstein NE, Perkins BA, Stephen s DS, et al. Meningococcal disease. N Engl J Med.
2001; 344(18) :1378 - 88.
2.Harrison OB, Claus H, Jiang Y, et al. Description and nomenclature of 
Neisseria meningitidis capsule locus. Emerg Infect Dis . 2013; 19(4) :566- 73.
3.Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease 
epidemiology  in the United States, 1998- 2007: implications for prevention of 
meningococcal disease. Clin Infect Dis. 2010; 50(2) :184- 91.
4.Mandal S, Wu HM, MacNeil JR, et al. Prolonged university outbreak of meningococcal 
disease associated with a serogroup B strain rarel y seen in the United States. Clin Inf ect
Dis. 2013; 57(3):344-8.
5.European Centre for Disease Prevention and Control.  Surveillance report. Surveillance 
of invasive bacterial diseases in Europe, 2007. Stockholm, Sweden : ECDC; 2009. 
http://ecdc.europa.eu/en/publications/Publications/101011_SUR_Surveill ance_of_invasiv
e_bacterial_diseases_in_Europe_2007.pdf . Accessed 10 March 2015.
6.European Centre for Disease Prevention and Control. Surveillance report. Annual 
epidemiological report :reporting on 2011 surveillance data and 2012 epidemic 
intelligence data. Stockholm, Sweden : ECDC; 2013. 
http://ecdc.europa.eu/en/publications/_lay outs/forms/Publication_DispForm.aspx?L ist=4f
55ad51- 4aed -4d32-b960- af70113dbb90&ID=989 . Accessed 11 March 2016.
7. Centers for Disease Control and Prevention. Meningococcal disease. 
http://www.cdc.gov/meningococcal/surveillance/index.html .
Updated 05 August 2015. A ccessed 14 September 2016 .
8. Ce nters for Disease C ontrol and Prevention. Active Bacterial Core Surveillance (ABCs) 
report : Emerging Infections Program Network Neisseria meningitidis, 2014. 
http://www.cdc.gov/abcs/reports -findings/survreports/mening14.pdf.
Updated 25 April 2016. Accessed 09 May  2016.
9.
Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease: 
recommendations of the Advisory  Committee on Immunization Practices (ACI P). 
MMWR Recomm Rep . 2005; 54(RR- 7):1-21.
10.Cohn AC, MacNeil JR, Clark TA, et al . Prevent ion and control of m eningococcal disease. 
Recommendations of the Advisory  Committee on Immunization Practices (ACI P). 
MMWR Recomm Rep .2013; 62(RR- 2):1-28.
11.MacNeil JR, Rubin L , Folaranmi T, et al. Use of sero group B meningococcal vaccines in 
adolescents 
and young adults. Recommendations of the Advisory  Committee on 
Immunization Practices , 2015 . MMWR Morbid Mortal W kly Rep . 2015; 64(41):1171-6.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 11212.Folaranmi T, Rubin L, Martin SW, et al. Use of serogroup B meningococcal vaccines in 
persons aged 
10 years at in creased risk for sero group B meningococcal disease :
recommendations of the Advisory  Committee on Immunization Practices, 2015. 
MMWR Morbid Mortal Wkly Rep . 2015; 64(22):608 - 12.
13.European Centre for Disease Prevention and Control. Vaccine schedule. 
http://vaccine -schedule.ecdc.europa.eu/Pages/Scheduler.aspx . Accessed 16 September 
2016.
14.Public Health England. Continuing increase in meningococcal group W (MenW) disease 
in England. Health Protection Report; vol 9 ( 7).
https://www.gov.uk/government/uploads/sy stem/uploads/attachment_data/file/407865/hp
r0715_men
-w.pdf .Published 27 February  2015. Accessed 01 Febr uary 2016 and 09 May 
2016.
15.Public Health England. Introduction of 
meningococcal ACWY conjugate vaccination 
(MenACWY) [bipartite letter]. 
https://ww w.gov.uk/government/uploads/sy stem/uploads/attachment_data/file/437901/15
0622_ACWY_bipartite_letter.pdf.  Published 22 June 2015. Accessed 01 Feb ruary 2016.
16.Joint Committee on Vaccination and I mmunisation. JCVI  position statement on use of 
Bexseromeningo coccal B vaccine in the UK. 
https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/294245/JC
VI_Statement_on_MenB.pdf. Published 21 March 2014. Accessed 16 September 2016 .
17.Tzanakaki G, Kesanopoulos K, Yazdankhah SP, et al. Conventional and molecular 
investigation of meningococcal isolates in relation to two outbreaks in the area of Athens, 
Greece. Clin Microbiol Infect .2006; 12(10):1024 -6.
18.Stewart A, Coetzee N, Knapper E, et al. Public health action and mass chemoprophy laxis 
in response to a small meningococcal infection outbreak at a nursery  in the West 
Midlands, England. 
Perspect Public Health. 2013; 133(2):104-9.
19.Chatt C, Gajraj R, Hawker J, et al. Four -month outbreak of invasive meningococcal 
disease caused b y a rare serogroup B strain, identified through the use of molecular PorA 
subty ping, England, 2013. Euro Surveill .2014; 19(44) :20949 .
20. Acheson P, Barron R, Borrow R, et al. A cluster of four cases of meningococcal disease 
in a single nuclear family. Arch Dis Child .2012; 97(3):248 -9.
21.Caron F, du Chatelet IP, Leroy  JP, et al. From tailor -made to read y-to-wear 
meningococcal B vaccines: longitudinal study  of a clonal meningococcal B outbreak. 
Lancet Infect Dis. 2011; 11(6) :455- 63.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 11322.Abad R, L opez EL , Debbag R, et al . Group W meningococcal disease: global spread and 
current affect on the Southern Cone in Latin America. Epidemiol Infect
.2014;
142(12):2461-70.
23. Mathew S, Overturf GD. Complement and properidin deficiencies in meningococcal 
disease. Pediatr Infect Dis J . 2006;25(3):255 -6.
24.Schneider MC, Exley  RM, Chan H, et al. Functional significance of factor H binding to 
Neisseria meningitidis. J Immunol. 2006; 176(12):756 6-75.
25.
Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection –serum 
bactericidal antibody  activity . Vaccine . 2005; 23(17 -18):2222 -7.
26.Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for 
meningococcal C conjugate vac cine b y using efficacy  estimates from postlicensure 
surveillance in England. Clin Diagn Lab Immunol .2003; 10(5) :780- 6.
27.Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity  to the meningococcus. 
I. The role of humoral antibodies. J Exp Med .1969; 129(6):1307 -26.
28.Balmer P, Borrow R.Serologic correlates of protection for evaluating the response to 
meningococcal vaccines .Expert Rev Vaccines .2004; 3(1): 77-87 .
29.Cent ers for Disease Control and Prevention. Inadvertent misadministration of 
meningococcal conjugate vaccine –United States, June -August 2005. MMWR Morbid 
Mortal Wkly Rep . 2006; 55(37):1016
-7.
30.Bexsero prescribing information. 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/U
CM431447.pdf . Accessed 14 September 2016 .
31. Trumenba prescribing information. 
http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/U
CM421139.pdf . Accessed 14 September 2016 .
32.Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines 
containing outer membrane vesicles from Neisseria meningitidis . Vaccine .2009;
(27) (s uppl 2 ):B3- B12.
33.Sierra GV G, Campa HC, Varcacel NM, et al. Vaccine against group B 
Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.
1991;14(2):195 -207; discussion 208 -10.
34.de Moraes JC, Perkins BA, Camargo MC C, et al. 
Protective efficacy  of a serogroup B 
meningococcal vaccine in Sao Paulo, Brazil. Lancet . 1992; 340(8827):1074-8.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 11435.Milagres LG, Ramos SR, Sacchi CT, et al. Immune response of Brazilian children to a 
Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with 
efficacy . Infect Immun. 1994; 62(10):4419 -24.
36. Boslego J, Garcia J, Cruz C, et al ; and the National Committee for Meningococcal 
Disease . Efficacy , safety , and immunogenicit y of a meningococcal group B (15:P1.3) 
outer membrane protein vaccine in Iquique, Chile. Vaccine . 1995; 13(9):821 -9.
37.Bjune G, H
oiby EA, Gronnesby  JK, et al. Effect of outer membrane vesicle vaccine 
against group B menin gococcal disease in Norway. Lancet .1991; 338(8775):1093
-6.
38.O'Hallahan J, Lennon D, Oster P. The strategy  to control New Zealand's epidemic of 
group B meningococcal disease. Pediatr Infect Dis J .2004; 23(12 )(suppl):S293 -S298.
39.
Borrow R, Carlone GM, Rosens tein N, et al. Neisseria meningitidis group B correlates of 
protection and assay  standardization --International Meeting Report, Emory University, 
Atlanta, Georgia, United States, 16 -17 March 2005. Vaccine .2006; 24(24):5093 -107.
40.Frasch CE, Borrow R, Donnel ly J. Bactericidal antibody  is the immunologic surrogate of 
protection against meningococcal disease. Vaccine. 2009; 27(suppl 2):B112 -B116.
41.European Centre for Disease Prevention and Control. Surveillance of invasive bacterial 
diseases in Europe, 2012. Stockholm , Sweden : ECDC; 2015.
http://ecdc.europa.eu/en/publications/Report%20Assets/Sruv -IBD/IBD -surveillance -
IMD -2012.xlsx . Accessed 17 September 2016.
42.US F ood and D rug Administration, C enter for Biologics and E valuation and Research . 
Guidance for indust ry, toxicity  grading scale for healthy  adult and adolescent volunteers 
enrolled in preventive vaccine clinical trials. September 2007. 
http://www.fda.gov/cber/gdlns/toxvac.pdf. Accessed 29 May  2016.
43.Chan I SF, Zhang Z.  Test -based exact confidence intervals for the difference of two 
binomial proportions.  Biometrics
. 1999; 55:1202-9.
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 115Appendix 1.Abbreviations
This following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
AA Accelerated Approval
ACIP Advisory Committee on Immunization Practices
AE adverse event
AlPO 4 aluminum phosphate
ALT alanine aminotransferase
AST aspartate aminotransferase
bivalent rLP2086 bivalent recombinant lipoprotein 2086 vaccine (Trumenba)
CDC Centers for Disease Control and Prevention
CFR Code of Federal Regulations
CI confidence interval
CK creatine kinase
CRF case report form
CRM cross -reactive material
CSA clinical study agreement
CT clinical trial
CTA clinical trial application
DILI drug-induced liver injury
DTaP , dTaP diphtheria, tetanus, and acellular pertussis vaccine
DU dispensable unit
EC ethics committee
e-diary electronic diary
EDMC external data monitoring committee 
EDP exposure during pregnancy
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration (United States)
fHBP factor H binding protein
GCP Good Clinical Practice
GGT gamma -glutamyl transferase
GMT geometric mean titer
GSK GlaxoSmithKline
HBV hepatitis B virus
Hib Haemophilus influenzae type b 
HPV4 quadrivalent human papillomavirus vaccine
hSBA serum bactericidal assay using human complement
hSBA -MenA serum bactericidal assay using human complement to measure activity against 
Neisseria meningitidis group A 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 116Abbreviation Term
hSBA -MenA/C/W/Y serum bactericidal assay using human complement to measure activity against 
Neisseria meningitidis group A , group C, group W, and/or group Y
hSBA -MenC serum bactericidal assay using human complement to measure activity against 
Neisseria meningitidis group C 
hSBA -MenW serum bactericidal assay using human complement to measure activity against 
Neisseria meningitidis group W 
hSBA -MenY serum bactericidal assay using human complement to measure activity against 
Neisseria meningitidis group Y 
IB investigator’s brochure
ICD informed consent document
ICH International Co uncil for Harmonisation
ID identification
IMD invasive meningococcal disease
IND investigational new drug application
INR international normalized ratio
IP investigational product
IPV inactivated poliomyelitis virus
IRB institutional review board
IRC independent review committee 
IRT interactive response technology
ISC independent statistical center
ITT intent -to-treat
IUD intrauterine device
IVRS interactive voice response system
IWRS interactive Web -based response system
LCI lower limit of the confidence interval
LFT liver function test
LLOQ lower limit of quantitation
LOD limit of detection
LP2086 lipoprotein 2086
LSLV last subject last visit 
MCV4 quadrivalent meningococcal polysaccharide conjugate 
MedDRA Medical Dictionary for Regulatory Activities
MenA Neisseria meningitidis group A 
MenABCWY Neisseria meningitidis group A, B, C, W, and Y vaccine
MenACWY meningococcal groups A, C, W, and Y conjugate vaccine
MenA /C/W/Y Neisseria meningitidis group A , group C, group W, and/or group Y
MenACWY -CRM meningococcal group A, C, W -135, and Y conjugate vaccine ( Menveo )
MenACWY -TT meningococcal polysaccharide group sA, C, W -135, and Y tetanus toxoid conjugate 
vaccine ( Nimenrix )
MenB Neisseria meningitidis group B 
MenC Neisseria meningitidis group C 
PF-05212366 ( Neisseria meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine [Bivalent 
rLP2086 ; subfamily A and B; Ecoli])
B1971057
Final Protocol Amendment 2, 09 Ju ly 2019
PFIZER CONFIDENTIAL
Page 117Abbreviation Term
MenCYW -135 meningococcal group C, Y ,and W -135
MenW Neisseria meningitidis group W 
MenY Neisseria meningitidis group Y 
mITT modified intent -to-treat
MnB Neisseria meningitidis group B
N/A not applicable
OMV outer membrane vesicle
PAR postapproval requirement
PCD primary completion date
PI principal investigator
PRP-OMP polyribosylribitol phosphate oligosaccharide of Haemophilus influenzae type b 
conjugated to outer membrane protein
PT prothrombin time
rLP2086 recombinant lipoprotein 2086
RRI research -related injury
rSBA serum bactericidal assay using rabbit complement
rSBA -MenA serum bactericidal assay using rabbit complement to measure activity against 
Neisseria meningitidis group A
rSBA -MenC serum bactericidal assay using rabbit complement to measure activity against 
Neisseria meningitidis group C
rSBA -MenW serum bactericidal assay using rabbit complement to measure activity against 
Neisseria meningitidis group W
rSBA -MenY serum bactericidal assay using rabbit complement to measure activity against 
Neisseria meningitidis group Y
SAE serious adverse event
SAP statistical analysis plan
SBA serum bactericidal assay
SRM study reference manual
SRSD single reference safety document
TBili total bilirubin
Tdap tetanus, low -dose diphtheria, and low -dose acellular pertussis
ULN upper limit of normal
US United States
'RFXPHQW $SSURYDO 5HFRUG
'RFXPHQW 1DPH	


	
'RFXPHQW 7LWOH  !"#$%"&'()%&'"*&#+%,+&'#)-+%"&+
	./01%"* "(&%,%*(2*#(%,%$ %""*),(&2"21! "(&!*'&#*%(,%&1%  !"#$%"&'()%&'"*&#+%,+&'#)-+%"&+	./3#"&""$%"&-+%"&-"%4 0'5"1%+&1'(!%&(67	&#8/'%,(#)$%
6LJQHG %\ 'DWH*07 6LJQLQJ &DSDFLW\
	
2;2	<
<=/ )
>
	/2;2	@<=<
 )
>PPD
PPD